date generated: 2020-07-13

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##        heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate
## A2M                0.4967182           -0.27091788              0.6662719
## A4GALT             1.1055218            1.99263712              1.5792346
## AAAS               2.1498692            1.07279989              1.2886140
## AACS              -0.8274404           -0.00214706             -1.1333351
## AAED1              1.1657765           -1.15426628              0.9638579
## AAGAB             -1.5884609           -0.96778649              0.8245435
##        spleen_ctrl_vs_hifibre
## A2M                1.45975674
## A4GALT             1.70760621
## AAAS              -0.83461264
## AACS              -2.73557983
## AAED1              0.02403748
## AAGAB              0.33001838

Here are some metrics about the input data profile:

Profile metrics
Profile metrics
num_genes_in_profile 12665
duplicated_genes_present 0
num_profile_genes_in_sets 7247
num_profile_genes_not_in_sets 5418

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt

Gene sets metrics
Gene sets metrics
num_genesets 2400
num_genesets_excluded 1088
num_genesets_included 1312

Genes by sector
heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate spleen_ctrl_vs_hifibre Count
1 -1 -1 -1 -1 1554
2 1 -1 -1 -1 713
3 -1 1 -1 -1 536
4 1 1 -1 -1 1318
5 -1 -1 0 -1 1
6 -1 -1 1 -1 1009
7 1 -1 1 -1 374
8 -1 1 1 -1 338
9 1 1 1 -1 1018
10 1 -1 -1 0 1
11 -1 -1 -1 1 541
12 1 -1 -1 1 230
13 -1 1 -1 1 271
14 1 1 -1 1 655
15 -1 -1 1 1 1276
16 1 -1 1 1 475
17 1 0 1 1 1
18 -1 1 1 1 647
19 0 1 1 1 1
20 1 1 1 1 1706
Number of significant gene sets (FDR<0.05)= 609

Gene sets by sector


Gene sets by sector
s.heart_ctrl_vs_acetate s.heart_ctrl_vs_hifibre s.spleen_ctrl_vs_acetate s.spleen_ctrl_vs_hifibre Count
1 -1 -1 -1 -1 63
2 1 -1 -1 -1 20
3 -1 1 -1 -1 4
4 1 1 -1 -1 9
5 -1 -1 1 -1 47
6 1 -1 1 -1 52
7 -1 1 1 -1 7
8 1 1 1 -1 145
9 -1 -1 -1 1 25
10 -1 1 -1 1 14
11 1 1 -1 1 12
12 -1 -1 1 1 36
13 1 -1 1 1 7
14 -1 1 1 1 14
15 1 1 1 1 154

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

set setSize pMANOVA p.adjustMANOVA s.dist s.heart_ctrl_vs_acetate s.heart_ctrl_vs_hifibre s.spleen_ctrl_vs_acetate s.spleen_ctrl_vs_hifibre p.heart_ctrl_vs_acetate p.heart_ctrl_vs_hifibre p.spleen_ctrl_vs_acetate p.spleen_ctrl_vs_hifibre
Classical antibody-mediated complement activation 10 6.32e-09 4.74e-08 1.500 0.256 0.6840 0.896 0.9480 1.61e-01 1.78e-04 9.16e-07 2.05e-07
Unwinding of DNA 12 1.21e-13 1.89e-12 1.340 0.705 0.7050 0.864 -0.2310 2.32e-05 2.32e-05 2.19e-07 1.66e-01
Creation of C4 and C2 activators 11 7.68e-08 4.50e-07 1.320 0.265 0.7100 0.742 0.7940 1.28e-01 4.55e-05 2.02e-05 5.13e-06
Initial triggering of complement 18 3.07e-11 3.35e-10 1.270 0.349 0.6920 0.673 0.7470 1.03e-02 3.71e-07 7.58e-07 4.01e-08
Peptide chain elongation 55 3.62e-26 2.07e-24 1.140 0.604 0.5730 0.549 0.5570 9.17e-15 1.92e-13 1.95e-12 9.38e-13
Viral mRNA Translation 55 1.21e-25 6.60e-24 1.120 0.613 0.5450 0.523 0.5620 3.61e-15 2.61e-12 1.90e-11 5.45e-13
DNA strand elongation 32 5.30e-28 3.31e-26 1.120 0.542 0.5380 0.791 -0.2110 1.09e-07 1.41e-07 9.12e-15 3.94e-02
Selenocysteine synthesis 58 5.52e-25 2.90e-23 1.090 0.571 0.5550 0.508 0.5430 5.14e-14 2.72e-13 2.23e-11 8.89e-13
Eukaryotic Translation Termination 58 5.66e-24 2.32e-22 1.060 0.561 0.5060 0.524 0.5260 1.44e-13 2.60e-11 4.96e-12 4.11e-12
Eukaryotic Translation Elongation 59 9.44e-24 3.75e-22 1.050 0.544 0.5170 0.525 0.5150 4.99e-13 6.59e-12 3.07e-12 7.85e-12
FCGR activation 16 8.32e-07 4.21e-06 1.050 0.253 0.5050 0.544 0.6970 8.00e-02 4.65e-04 1.65e-04 1.36e-06
Processive synthesis on the lagging strand 15 4.64e-11 4.84e-10 1.030 0.493 0.5090 0.716 -0.2230 9.38e-04 6.50e-04 1.57e-06 1.34e-01
Activation of the pre-replicative complex 31 1.53e-23 5.27e-22 1.030 0.586 0.4810 0.613 -0.3250 1.66e-08 3.60e-06 3.44e-09 1.76e-03
SRP-dependent cotranslational protein targeting to membrane 76 5.08e-30 3.92e-28 1.030 0.481 0.4450 0.521 0.5940 4.44e-13 2.10e-11 4.03e-15 3.22e-19
Response of EIF2AK4 (GCN2) to amino acid deficiency 65 4.87e-24 2.06e-22 1.010 0.590 0.5530 0.440 0.4180 1.97e-16 1.31e-14 8.34e-10 5.69e-09
Formation of a pool of free 40S subunits 65 2.18e-24 9.85e-23 1.010 0.503 0.4680 0.544 0.4970 2.24e-12 6.76e-11 3.34e-14 4.18e-12
Removal of the Flap Intermediate 14 6.56e-10 5.90e-09 1.010 0.472 0.4810 0.714 -0.2160 2.23e-03 1.84e-03 3.71e-06 1.62e-01
Lagging Strand Synthesis 20 2.91e-14 4.84e-13 0.991 0.444 0.4360 0.746 -0.1980 5.95e-04 7.37e-04 7.54e-09 1.26e-01
Leading Strand Synthesis 14 7.29e-10 6.42e-09 0.984 0.407 0.3960 0.787 -0.1630 8.34e-03 1.03e-02 3.40e-07 2.90e-01
Polymerase switching 14 7.29e-10 6.42e-09 0.984 0.407 0.3960 0.787 -0.1630 8.34e-03 1.03e-02 3.40e-07 2.90e-01
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 60 9.57e-21 2.85e-19 0.969 0.511 0.4580 0.504 0.4620 7.36e-12 8.92e-10 1.50e-11 5.90e-10
Condensation of Prometaphase Chromosomes 11 1.54e-06 7.54e-06 0.953 0.531 0.5400 0.475 -0.3300 2.29e-03 1.92e-03 6.34e-03 5.83e-02
Mucopolysaccharidoses 11 2.12e-04 8.01e-04 0.952 -0.232 -0.0446 0.647 0.6560 1.83e-01 7.98e-01 2.01e-04 1.64e-04
G1/S-Specific Transcription 26 4.52e-18 1.10e-16 0.950 0.454 0.4420 0.637 -0.3090 6.18e-05 9.49e-05 1.85e-08 6.43e-03
Cholesterol biosynthesis 23 1.53e-07 8.41e-07 0.949 -0.333 -0.5080 -0.487 -0.5440 5.77e-03 2.46e-05 5.34e-05 6.35e-06
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 14 1.18e-07 6.68e-07 0.934 0.443 0.4350 0.693 -0.0805 4.11e-03 4.82e-03 7.08e-06 6.02e-01
L13a-mediated translational silencing of Ceruloplasmin expression 73 1.21e-23 4.69e-22 0.933 0.480 0.4290 0.508 0.4440 1.32e-12 2.46e-10 5.94e-14 5.31e-11
Interferon alpha/beta signaling 45 2.21e-14 3.73e-13 0.927 0.416 0.6190 0.345 0.4300 1.39e-06 6.72e-13 6.27e-05 6.11e-07
Polo-like kinase mediated events 15 3.64e-09 2.83e-08 0.916 0.518 0.3920 0.578 -0.2900 5.17e-04 8.61e-03 1.06e-04 5.20e-02
Condensation of Prophase Chromosomes 13 9.05e-08 5.19e-07 0.912 0.535 0.4260 0.470 -0.3780 8.37e-04 7.79e-03 3.37e-03 1.82e-02
GTP hydrolysis and joining of the 60S ribosomal subunit 75 5.04e-23 1.69e-21 0.911 0.473 0.4300 0.489 0.4270 1.38e-12 1.27e-10 2.51e-13 1.66e-10
Establishment of Sister Chromatid Cohesion 10 7.19e-05 2.86e-04 0.905 0.719 0.3460 0.049 -0.4240 8.17e-05 5.83e-02 7.88e-01 2.01e-02
PCNA-Dependent Long Patch Base Excision Repair 21 1.86e-11 2.14e-10 0.904 0.442 0.4060 0.663 -0.1310 4.51e-04 1.30e-03 1.46e-07 2.98e-01
Mitotic Telophase/Cytokinesis 12 3.06e-06 1.46e-05 0.902 0.676 0.3470 0.142 -0.4650 5.05e-05 3.73e-02 3.93e-01 5.31e-03
Selenoamino acid metabolism 70 1.38e-20 4.03e-19 0.902 0.468 0.4530 0.446 0.4350 1.25e-11 5.82e-11 1.07e-10 3.02e-10
Formation of the ternary complex, and subsequently, the 43S complex 39 1.83e-11 2.13e-10 0.893 0.439 0.4030 0.519 0.4160 2.13e-06 1.33e-05 2.05e-08 6.84e-06
G0 and Early G1 25 1.09e-14 1.91e-13 0.883 0.465 0.4330 0.496 -0.3600 5.73e-05 1.80e-04 1.77e-05 1.82e-03
Cap-dependent Translation Initiation 81 1.33e-23 4.73e-22 0.882 0.444 0.4060 0.504 0.4030 5.18e-12 2.81e-10 4.52e-15 3.59e-10
Eukaryotic Translation Initiation 81 1.33e-23 4.73e-22 0.882 0.444 0.4060 0.504 0.4030 5.18e-12 2.81e-10 4.52e-15 3.59e-10
HDMs demethylate histones 21 1.97e-06 9.56e-06 0.876 -0.174 -0.4100 -0.446 -0.6080 1.68e-01 1.14e-03 3.98e-04 1.40e-06
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 15 6.72e-08 3.95e-07 0.871 0.479 0.4020 0.558 -0.2380 1.31e-03 7.07e-03 1.84e-04 1.11e-01
LGI-ADAM interactions 11 1.67e-03 5.38e-03 0.864 -0.470 -0.6070 -0.391 -0.0678 6.97e-03 4.92e-04 2.49e-02 6.97e-01
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 14 4.10e-06 1.91e-05 0.855 0.393 0.4260 0.627 -0.0442 1.09e-02 5.76e-03 4.85e-05 7.75e-01
Trafficking and processing of endosomal TLR 11 1.89e-03 5.97e-03 0.853 0.216 0.1160 0.492 0.6530 2.15e-01 5.07e-01 4.72e-03 1.78e-04
Activation of ATR in response to replication stress 35 4.75e-17 9.74e-16 0.844 0.488 0.4090 0.499 -0.2390 5.85e-07 2.89e-05 3.21e-07 1.44e-02
Transcription of E2F targets under negative control by DREAM complex 18 4.75e-09 3.64e-08 0.825 0.410 0.4040 0.521 -0.2800 2.62e-03 2.98e-03 1.32e-04 3.95e-02
Termination of translesion DNA synthesis 29 2.03e-13 3.00e-12 0.822 0.409 0.4040 0.560 -0.1760 1.37e-04 1.64e-04 1.81e-07 1.01e-01
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 46 2.71e-11 2.98e-10 0.806 0.414 0.3620 0.482 0.3390 1.20e-06 2.23e-05 1.52e-08 7.00e-05
Presynaptic depolarization and calcium channel opening 11 9.75e-03 2.45e-02 0.800 -0.224 -0.2790 -0.565 -0.4390 1.98e-01 1.09e-01 1.17e-03 1.17e-02
Regulation of IFNA signaling 12 4.92e-03 1.38e-02 0.798 0.287 0.4820 0.279 0.4940 8.52e-02 3.83e-03 9.42e-02 3.02e-03


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.heart_ctrl_vs_acetate s.heart_ctrl_vs_hifibre s.spleen_ctrl_vs_acetate s.spleen_ctrl_vs_hifibre p.heart_ctrl_vs_acetate p.heart_ctrl_vs_hifibre p.spleen_ctrl_vs_acetate p.spleen_ctrl_vs_hifibre
Classical antibody-mediated complement activation 10 6.32e-09 4.74e-08 1.5000 0.256000 6.84e-01 0.896000 9.48e-01 1.61e-01 1.78e-04 9.16e-07 2.05e-07
Unwinding of DNA 12 1.21e-13 1.89e-12 1.3400 0.705000 7.05e-01 0.864000 -2.31e-01 2.32e-05 2.32e-05 2.19e-07 1.66e-01
Creation of C4 and C2 activators 11 7.68e-08 4.50e-07 1.3200 0.265000 7.10e-01 0.742000 7.94e-01 1.28e-01 4.55e-05 2.02e-05 5.13e-06
Initial triggering of complement 18 3.07e-11 3.35e-10 1.2700 0.349000 6.92e-01 0.673000 7.47e-01 1.03e-02 3.71e-07 7.58e-07 4.01e-08
Peptide chain elongation 55 3.62e-26 2.07e-24 1.1400 0.604000 5.73e-01 0.549000 5.57e-01 9.17e-15 1.92e-13 1.95e-12 9.38e-13
Viral mRNA Translation 55 1.21e-25 6.60e-24 1.1200 0.613000 5.45e-01 0.523000 5.62e-01 3.61e-15 2.61e-12 1.90e-11 5.45e-13
DNA strand elongation 32 5.30e-28 3.31e-26 1.1200 0.542000 5.38e-01 0.791000 -2.11e-01 1.09e-07 1.41e-07 9.12e-15 3.94e-02
Selenocysteine synthesis 58 5.52e-25 2.90e-23 1.0900 0.571000 5.55e-01 0.508000 5.43e-01 5.14e-14 2.72e-13 2.23e-11 8.89e-13
Eukaryotic Translation Termination 58 5.66e-24 2.32e-22 1.0600 0.561000 5.06e-01 0.524000 5.26e-01 1.44e-13 2.60e-11 4.96e-12 4.11e-12
Eukaryotic Translation Elongation 59 9.44e-24 3.75e-22 1.0500 0.544000 5.17e-01 0.525000 5.15e-01 4.99e-13 6.59e-12 3.07e-12 7.85e-12
FCGR activation 16 8.32e-07 4.21e-06 1.0500 0.253000 5.05e-01 0.544000 6.97e-01 8.00e-02 4.65e-04 1.65e-04 1.36e-06
Processive synthesis on the lagging strand 15 4.64e-11 4.84e-10 1.0300 0.493000 5.09e-01 0.716000 -2.23e-01 9.38e-04 6.50e-04 1.57e-06 1.34e-01
Activation of the pre-replicative complex 31 1.53e-23 5.27e-22 1.0300 0.586000 4.81e-01 0.613000 -3.25e-01 1.66e-08 3.60e-06 3.44e-09 1.76e-03
SRP-dependent cotranslational protein targeting to membrane 76 5.08e-30 3.92e-28 1.0300 0.481000 4.45e-01 0.521000 5.94e-01 4.44e-13 2.10e-11 4.03e-15 3.22e-19
Response of EIF2AK4 (GCN2) to amino acid deficiency 65 4.87e-24 2.06e-22 1.0100 0.590000 5.53e-01 0.440000 4.18e-01 1.97e-16 1.31e-14 8.34e-10 5.69e-09
Formation of a pool of free 40S subunits 65 2.18e-24 9.85e-23 1.0100 0.503000 4.68e-01 0.544000 4.97e-01 2.24e-12 6.76e-11 3.34e-14 4.18e-12
Removal of the Flap Intermediate 14 6.56e-10 5.90e-09 1.0100 0.472000 4.81e-01 0.714000 -2.16e-01 2.23e-03 1.84e-03 3.71e-06 1.62e-01
Lagging Strand Synthesis 20 2.91e-14 4.84e-13 0.9910 0.444000 4.36e-01 0.746000 -1.98e-01 5.95e-04 7.37e-04 7.54e-09 1.26e-01
Leading Strand Synthesis 14 7.29e-10 6.42e-09 0.9840 0.407000 3.96e-01 0.787000 -1.63e-01 8.34e-03 1.03e-02 3.40e-07 2.90e-01
Polymerase switching 14 7.29e-10 6.42e-09 0.9840 0.407000 3.96e-01 0.787000 -1.63e-01 8.34e-03 1.03e-02 3.40e-07 2.90e-01
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 60 9.57e-21 2.85e-19 0.9690 0.511000 4.58e-01 0.504000 4.62e-01 7.36e-12 8.92e-10 1.50e-11 5.90e-10
Condensation of Prometaphase Chromosomes 11 1.54e-06 7.54e-06 0.9530 0.531000 5.40e-01 0.475000 -3.30e-01 2.29e-03 1.92e-03 6.34e-03 5.83e-02
Mucopolysaccharidoses 11 2.12e-04 8.01e-04 0.9520 -0.232000 -4.46e-02 0.647000 6.56e-01 1.83e-01 7.98e-01 2.01e-04 1.64e-04
G1/S-Specific Transcription 26 4.52e-18 1.10e-16 0.9500 0.454000 4.42e-01 0.637000 -3.09e-01 6.18e-05 9.49e-05 1.85e-08 6.43e-03
Cholesterol biosynthesis 23 1.53e-07 8.41e-07 0.9490 -0.333000 -5.08e-01 -0.487000 -5.44e-01 5.77e-03 2.46e-05 5.34e-05 6.35e-06
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 14 1.18e-07 6.68e-07 0.9340 0.443000 4.35e-01 0.693000 -8.05e-02 4.11e-03 4.82e-03 7.08e-06 6.02e-01
L13a-mediated translational silencing of Ceruloplasmin expression 73 1.21e-23 4.69e-22 0.9330 0.480000 4.29e-01 0.508000 4.44e-01 1.32e-12 2.46e-10 5.94e-14 5.31e-11
Interferon alpha/beta signaling 45 2.21e-14 3.73e-13 0.9270 0.416000 6.19e-01 0.345000 4.30e-01 1.39e-06 6.72e-13 6.27e-05 6.11e-07
Polo-like kinase mediated events 15 3.64e-09 2.83e-08 0.9160 0.518000 3.92e-01 0.578000 -2.90e-01 5.17e-04 8.61e-03 1.06e-04 5.20e-02
Condensation of Prophase Chromosomes 13 9.05e-08 5.19e-07 0.9120 0.535000 4.26e-01 0.470000 -3.78e-01 8.37e-04 7.79e-03 3.37e-03 1.82e-02
GTP hydrolysis and joining of the 60S ribosomal subunit 75 5.04e-23 1.69e-21 0.9110 0.473000 4.30e-01 0.489000 4.27e-01 1.38e-12 1.27e-10 2.51e-13 1.66e-10
Establishment of Sister Chromatid Cohesion 10 7.19e-05 2.86e-04 0.9050 0.719000 3.46e-01 0.049000 -4.24e-01 8.17e-05 5.83e-02 7.88e-01 2.01e-02
PCNA-Dependent Long Patch Base Excision Repair 21 1.86e-11 2.14e-10 0.9040 0.442000 4.06e-01 0.663000 -1.31e-01 4.51e-04 1.30e-03 1.46e-07 2.98e-01
Mitotic Telophase/Cytokinesis 12 3.06e-06 1.46e-05 0.9020 0.676000 3.47e-01 0.142000 -4.65e-01 5.05e-05 3.73e-02 3.93e-01 5.31e-03
Selenoamino acid metabolism 70 1.38e-20 4.03e-19 0.9020 0.468000 4.53e-01 0.446000 4.35e-01 1.25e-11 5.82e-11 1.07e-10 3.02e-10
Formation of the ternary complex, and subsequently, the 43S complex 39 1.83e-11 2.13e-10 0.8930 0.439000 4.03e-01 0.519000 4.16e-01 2.13e-06 1.33e-05 2.05e-08 6.84e-06
G0 and Early G1 25 1.09e-14 1.91e-13 0.8830 0.465000 4.33e-01 0.496000 -3.60e-01 5.73e-05 1.80e-04 1.77e-05 1.82e-03
Cap-dependent Translation Initiation 81 1.33e-23 4.73e-22 0.8820 0.444000 4.06e-01 0.504000 4.03e-01 5.18e-12 2.81e-10 4.52e-15 3.59e-10
Eukaryotic Translation Initiation 81 1.33e-23 4.73e-22 0.8820 0.444000 4.06e-01 0.504000 4.03e-01 5.18e-12 2.81e-10 4.52e-15 3.59e-10
HDMs demethylate histones 21 1.97e-06 9.56e-06 0.8760 -0.174000 -4.10e-01 -0.446000 -6.08e-01 1.68e-01 1.14e-03 3.98e-04 1.40e-06
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 15 6.72e-08 3.95e-07 0.8710 0.479000 4.02e-01 0.558000 -2.38e-01 1.31e-03 7.07e-03 1.84e-04 1.11e-01
LGI-ADAM interactions 11 1.67e-03 5.38e-03 0.8640 -0.470000 -6.07e-01 -0.391000 -6.78e-02 6.97e-03 4.92e-04 2.49e-02 6.97e-01
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 14 4.10e-06 1.91e-05 0.8550 0.393000 4.26e-01 0.627000 -4.42e-02 1.09e-02 5.76e-03 4.85e-05 7.75e-01
Trafficking and processing of endosomal TLR 11 1.89e-03 5.97e-03 0.8530 0.216000 1.16e-01 0.492000 6.53e-01 2.15e-01 5.07e-01 4.72e-03 1.78e-04
Activation of ATR in response to replication stress 35 4.75e-17 9.74e-16 0.8440 0.488000 4.09e-01 0.499000 -2.39e-01 5.85e-07 2.89e-05 3.21e-07 1.44e-02
Transcription of E2F targets under negative control by DREAM complex 18 4.75e-09 3.64e-08 0.8250 0.410000 4.04e-01 0.521000 -2.80e-01 2.62e-03 2.98e-03 1.32e-04 3.95e-02
Termination of translesion DNA synthesis 29 2.03e-13 3.00e-12 0.8220 0.409000 4.04e-01 0.560000 -1.76e-01 1.37e-04 1.64e-04 1.81e-07 1.01e-01
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 46 2.71e-11 2.98e-10 0.8060 0.414000 3.62e-01 0.482000 3.39e-01 1.20e-06 2.23e-05 1.52e-08 7.00e-05
Presynaptic depolarization and calcium channel opening 11 9.75e-03 2.45e-02 0.8000 -0.224000 -2.79e-01 -0.565000 -4.39e-01 1.98e-01 1.09e-01 1.17e-03 1.17e-02
Regulation of IFNA signaling 12 4.92e-03 1.38e-02 0.7980 0.287000 4.82e-01 0.279000 4.94e-01 8.52e-02 3.83e-03 9.42e-02 3.02e-03
Mismatch Repair 15 2.83e-06 1.36e-05 0.7980 0.358000 3.81e-01 0.594000 -1.06e-01 1.65e-02 1.07e-02 6.89e-05 4.77e-01
Translation initiation complex formation 45 9.41e-11 9.73e-10 0.7970 0.402000 3.48e-01 0.478000 3.52e-01 3.02e-06 5.52e-05 2.96e-08 4.47e-05
Gap-filling DNA repair synthesis and ligation in GG-NER 23 2.78e-10 2.70e-09 0.7960 0.380000 3.53e-01 0.582000 -1.62e-01 1.63e-03 3.38e-03 1.38e-06 1.79e-01
Phosphorylation of CD3 and TCR zeta chains 11 1.39e-03 4.54e-03 0.7900 0.374000 6.30e-01 -0.295000 -1.66e-02 3.17e-02 2.95e-04 8.99e-02 9.24e-01
Ribosomal scanning and start codon recognition 46 1.11e-10 1.13e-09 0.7850 0.413000 3.55e-01 0.461000 3.29e-01 1.28e-06 3.20e-05 6.55e-08 1.13e-04
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 24 2.46e-10 2.41e-09 0.7830 0.379000 3.19e-01 0.592000 -1.34e-01 1.32e-03 6.86e-03 5.19e-07 2.58e-01
DNA Replication Pre-Initiation 77 6.37e-29 4.64e-27 0.7810 0.366000 3.53e-01 0.592000 -1.68e-02 2.79e-08 8.81e-08 2.55e-19 7.99e-01
Recognition of DNA damage by PCNA-containing replication complex 28 2.13e-12 2.72e-11 0.7750 0.459000 2.74e-01 0.528000 -1.91e-01 2.67e-05 1.22e-02 1.33e-06 8.08e-02
E2F mediated regulation of DNA replication 20 1.21e-09 1.02e-08 0.7730 0.408000 2.11e-01 0.587000 -2.03e-01 1.60e-03 1.03e-01 5.41e-06 1.17e-01
Phase 2 - plateau phase 16 5.28e-04 1.84e-03 0.7720 -0.247000 -2.85e-01 -0.597000 -3.13e-01 8.73e-02 4.83e-02 3.59e-05 3.03e-02
Inhibition of replication initiation of damaged DNA by RB1/E2F1 12 1.51e-06 7.47e-06 0.7700 0.286000 1.11e-01 0.663000 -2.42e-01 8.67e-02 5.04e-01 7.00e-05 1.46e-01
Orc1 removal from chromatin 63 9.26e-20 2.59e-18 0.7660 0.358000 3.59e-01 0.570000 7.18e-02 9.23e-07 8.48e-07 5.25e-15 3.25e-01
Striated Muscle Contraction 28 7.73e-09 5.66e-08 0.7600 -0.039100 1.88e-01 -0.615000 -4.03e-01 7.21e-01 8.54e-02 1.78e-08 2.23e-04
Assembly of the pre-replicative complex 61 1.62e-19 4.42e-18 0.7580 0.318000 3.31e-01 0.598000 7.61e-02 1.75e-05 7.94e-06 6.18e-16 3.05e-01
G1/S Transition 119 4.04e-44 7.58e-42 0.7580 0.378000 3.56e-01 0.547000 -7.12e-02 1.10e-12 2.01e-11 6.53e-25 1.81e-01
Cyclin A/B1/B2 associated events during G2/M transition 22 1.84e-08 1.23e-07 0.7550 0.514000 2.89e-01 0.434000 -1.81e-01 2.97e-05 1.88e-02 4.23e-04 1.42e-01
Cross-presentation of soluble exogenous antigens (endosomes) 45 3.39e-11 3.67e-10 0.7530 0.256000 3.02e-01 0.584000 2.65e-01 2.98e-03 4.64e-04 1.24e-11 2.13e-03
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 80 1.30e-16 2.50e-15 0.7520 0.444000 3.88e-01 0.364000 2.94e-01 7.02e-12 1.97e-09 1.94e-08 5.78e-06
Nonsense-Mediated Decay (NMD) 80 1.30e-16 2.50e-15 0.7520 0.444000 3.88e-01 0.364000 2.94e-01 7.02e-12 1.97e-09 1.94e-08 5.78e-06
EGR2 and SOX10-mediated initiation of Schwann cell myelination 21 3.61e-04 1.30e-03 0.7470 -0.312000 -3.43e-01 -0.424000 -4.05e-01 1.33e-02 6.57e-03 7.73e-04 1.31e-03
Regulation of expression of SLITs and ROBOs 120 7.26e-25 3.67e-23 0.7430 0.362000 3.53e-01 0.438000 3.23e-01 7.89e-12 2.48e-11 1.18e-16 1.03e-09
Telomere C-strand (Lagging Strand) Synthesis 33 1.27e-14 2.19e-13 0.7430 0.293000 3.52e-01 0.534000 -2.38e-01 3.59e-03 4.71e-04 1.12e-07 1.79e-02
Activation of gene expression by SREBF (SREBP) 41 1.86e-08 1.24e-07 0.7350 -0.174000 -3.31e-01 -0.404000 -4.87e-01 5.34e-02 2.43e-04 7.70e-06 6.95e-08
HSF1-dependent transactivation 31 3.91e-06 1.84e-05 0.7340 -0.495000 -4.62e-01 -0.103000 -2.64e-01 1.88e-06 8.63e-06 3.19e-01 1.11e-02
Synthesis of DNA 112 3.21e-38 3.83e-36 0.7260 0.352000 3.02e-01 0.557000 -3.64e-02 1.31e-10 3.35e-08 2.13e-24 5.07e-01
DNA Replication 119 1.41e-41 2.31e-39 0.7240 0.353000 2.99e-01 0.554000 -5.73e-02 3.21e-11 1.82e-08 1.62e-25 2.82e-01
tRNA processing in the mitochondrion 16 8.47e-04 2.87e-03 0.7210 0.105000 1.47e-01 -0.527000 -4.57e-01 4.67e-01 3.08e-01 2.61e-04 1.57e-03
Polymerase switching on the C-strand of the telomere 25 1.14e-09 9.70e-09 0.7180 0.290000 3.55e-01 0.521000 -1.86e-01 1.20e-02 2.14e-03 6.62e-06 1.08e-01
Mitotic G1 phase and G1/S transition 135 1.37e-44 3.37e-42 0.7160 0.381000 3.45e-01 0.490000 -9.15e-02 2.39e-14 4.50e-12 9.21e-23 6.72e-02
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 46 2.59e-11 2.88e-10 0.7070 0.199000 2.86e-01 0.584000 1.96e-01 1.99e-02 7.86e-04 7.44e-12 2.16e-02
p53-Independent DNA Damage Response 46 2.59e-11 2.88e-10 0.7070 0.199000 2.86e-01 0.584000 1.96e-01 1.99e-02 7.86e-04 7.44e-12 2.16e-02
p53-Independent G1/S DNA damage checkpoint 46 2.59e-11 2.88e-10 0.7070 0.199000 2.86e-01 0.584000 1.96e-01 1.99e-02 7.86e-04 7.44e-12 2.16e-02
CDC6 association with the ORC:origin complex 10 1.34e-03 4.39e-03 0.7070 0.450000 2.48e-01 0.449000 -1.83e-01 1.37e-02 1.74e-01 1.39e-02 3.16e-01
Metabolism of polyamines 52 7.76e-12 9.42e-11 0.7040 0.248000 2.97e-01 0.550000 2.08e-01 1.95e-03 2.14e-04 6.88e-12 9.41e-03
Deposition of new CENPA-containing nucleosomes at the centromere 22 1.27e-08 8.93e-08 0.7040 0.337000 2.24e-01 0.547000 -1.80e-01 6.30e-03 6.91e-02 8.84e-06 1.44e-01
Nucleosome assembly 22 1.27e-08 8.93e-08 0.7040 0.337000 2.24e-01 0.547000 -1.80e-01 6.30e-03 6.91e-02 8.84e-06 1.44e-01
CDT1 association with the CDC6:ORC:origin complex 52 4.35e-13 6.20e-12 0.7020 0.269000 2.70e-01 0.571000 1.49e-01 8.09e-04 7.73e-04 1.04e-12 6.37e-02
SCF(Skp2)-mediated degradation of p27/p21 52 4.45e-13 6.28e-12 0.7010 0.257000 3.32e-01 0.547000 1.23e-01 1.35e-03 3.45e-05 8.54e-12 1.25e-01
Processive synthesis on the C-strand of the telomere 19 4.70e-07 2.46e-06 0.6980 0.283000 4.17e-01 0.402000 -2.68e-01 3.30e-02 1.64e-03 2.42e-03 4.33e-02
Ubiquitin-dependent degradation of Cyclin D 46 4.82e-10 4.46e-09 0.6980 0.212000 2.69e-01 0.557000 2.44e-01 1.29e-02 1.59e-03 6.54e-11 4.26e-03
Regulation of activated PAK-2p34 by proteasome mediated degradation 44 1.03e-09 8.83e-09 0.6890 0.223000 2.71e-01 0.555000 2.11e-01 1.06e-02 1.88e-03 1.96e-10 1.54e-02
Glycogen storage diseases 11 2.71e-02 5.65e-02 0.6870 -0.431000 -5.13e-01 0.043500 1.41e-01 1.32e-02 3.20e-03 8.03e-01 4.18e-01
Regulation of Complement cascade 31 1.06e-05 4.75e-05 0.6860 0.239000 3.64e-01 0.254000 4.65e-01 2.12e-02 4.57e-04 1.45e-02 7.49e-06
Regulation of ornithine decarboxylase (ODC) 46 1.65e-10 1.64e-09 0.6800 0.222000 2.34e-01 0.569000 1.87e-01 9.23e-03 6.05e-03 2.47e-11 2.87e-02
Removal of the Flap Intermediate from the C-strand 17 1.23e-05 5.47e-05 0.6780 0.283000 4.36e-01 0.363000 -2.41e-01 4.37e-02 1.88e-03 9.65e-03 8.49e-02
Vif-mediated degradation of APOBEC3G 45 1.50e-09 1.23e-08 0.6780 0.221000 2.56e-01 0.547000 2.14e-01 1.02e-02 3.01e-03 2.21e-10 1.31e-02
Translesion synthesis by POLI 15 4.53e-05 1.88e-04 0.6760 0.321000 2.50e-01 0.520000 -1.46e-01 3.12e-02 9.38e-02 4.91e-04 3.28e-01
Negative regulation of NOTCH4 signaling 48 1.36e-09 1.13e-08 0.6760 0.257000 2.87e-01 0.511000 2.16e-01 2.07e-03 5.76e-04 9.01e-10 9.76e-03
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 35 1.23e-11 1.47e-10 0.6730 0.327000 3.01e-01 0.474000 -1.76e-01 8.22e-04 2.07e-03 1.21e-06 7.15e-02
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex 12 9.80e-03 2.46e-02 0.6720 0.401000 4.51e-01 0.283000 -9.10e-02 1.62e-02 6.85e-03 9.00e-02 5.85e-01
Laminin interactions 22 1.74e-05 7.60e-05 0.6720 -0.222000 -2.85e-02 -0.582000 -2.51e-01 7.14e-02 8.17e-01 2.27e-06 4.16e-02
S Phase 152 1.54e-44 3.37e-42 0.6720 0.366000 2.96e-01 0.474000 -7.21e-02 6.93e-15 3.16e-10 6.87e-24 1.26e-01
Generation of second messenger molecules 22 5.74e-06 2.65e-05 0.6720 0.238000 4.64e-01 -0.417000 -7.16e-02 5.37e-02 1.63e-04 7.12e-04 5.61e-01
Translesion synthesis by REV1 14 6.15e-05 2.47e-04 0.6710 0.329000 2.42e-01 0.490000 -2.05e-01 3.29e-02 1.17e-01 1.49e-03 1.84e-01
Hyaluronan uptake and degradation 11 4.06e-02 7.77e-02 0.6650 0.242000 2.03e-01 0.502000 3.02e-01 1.65e-01 2.44e-01 3.93e-03 8.31e-02
PI-3K cascade:FGFR2 12 7.19e-04 2.46e-03 0.6640 -0.012500 -5.60e-01 -0.269000 -2.35e-01 9.40e-01 7.91e-04 1.06e-01 1.58e-01
SCF-beta-TrCP mediated degradation of Emi1 49 3.53e-11 3.77e-10 0.6640 0.212000 2.45e-01 0.560000 1.51e-01 1.03e-02 3.02e-03 1.22e-11 6.78e-02
Extension of Telomeres 48 2.15e-17 4.56e-16 0.6620 0.262000 3.13e-01 0.462000 -2.40e-01 1.71e-03 1.75e-04 3.01e-08 4.02e-03
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 48 2.85e-08 1.81e-07 0.6610 0.285000 3.89e-01 0.183000 4.13e-01 6.46e-04 3.12e-06 2.86e-02 7.41e-07
DNA Damage Bypass 44 3.35e-14 5.49e-13 0.6600 0.375000 2.63e-01 0.436000 -1.91e-01 1.66e-05 2.57e-03 5.76e-07 2.87e-02
Translesion synthesis by POLK 15 8.51e-05 3.34e-04 0.6550 0.333000 2.69e-01 0.456000 -1.93e-01 2.54e-02 7.17e-02 2.25e-03 1.95e-01
ATF6 (ATF6-alpha) activates chaperone genes 10 9.19e-05 3.58e-04 0.6540 0.364000 -1.99e-01 0.502000 -6.00e-02 4.63e-02 2.77e-01 5.96e-03 7.43e-01
Heme biosynthesis 13 3.93e-05 1.65e-04 0.6520 -0.209000 -2.27e-01 0.472000 -3.28e-01 1.92e-01 1.56e-01 3.24e-03 4.09e-02
Common Pathway of Fibrin Clot Formation 10 1.58e-03 5.10e-03 0.6520 0.305000 2.34e-01 -0.274000 4.49e-01 9.47e-02 2.00e-01 1.33e-01 1.40e-02
Autodegradation of the E3 ubiquitin ligase COP1 46 1.97e-09 1.59e-08 0.6510 0.186000 2.39e-01 0.543000 1.92e-01 2.94e-02 5.06e-03 1.84e-10 2.40e-02
rRNA processing in the mitochondrion 17 3.25e-03 9.71e-03 0.6510 0.116000 6.34e-02 -0.407000 -4.90e-01 4.09e-01 6.51e-01 3.68e-03 4.64e-04
Defective CFTR causes cystic fibrosis 52 2.26e-09 1.78e-08 0.6500 0.197000 2.47e-01 0.506000 2.58e-01 1.38e-02 2.04e-03 2.80e-10 1.28e-03
Signaling by FGFR4 in disease 10 2.86e-02 5.88e-02 0.6480 0.147000 -1.65e-01 -0.351000 -4.98e-01 4.23e-01 3.66e-01 5.44e-02 6.36e-03
Attenuation phase 21 7.92e-04 2.70e-03 0.6460 -0.427000 -3.81e-01 0.008280 -2.99e-01 7.09e-04 2.52e-03 9.48e-01 1.76e-02
Influenza Viral RNA Transcription and Replication 96 1.91e-17 4.17e-16 0.6450 0.319000 2.44e-01 0.456000 2.16e-01 7.05e-08 3.71e-05 1.13e-14 2.57e-04
Vpu mediated degradation of CD4 46 4.91e-09 3.74e-08 0.6430 0.216000 2.52e-01 0.520000 1.79e-01 1.12e-02 3.18e-03 1.02e-09 3.55e-02
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 49 2.13e-09 1.70e-08 0.6400 0.211000 2.47e-01 0.517000 1.92e-01 1.08e-02 2.75e-03 3.75e-10 2.04e-02
cGMP effects 12 1.88e-04 7.17e-04 0.6390 -0.145000 9.65e-02 -0.610000 7.49e-02 3.83e-01 5.63e-01 2.51e-04 6.53e-01
Diseases of carbohydrate metabolism 27 5.72e-05 2.30e-04 0.6390 -0.269000 -2.18e-01 0.385000 3.74e-01 1.54e-02 5.05e-02 5.43e-04 7.72e-04
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 13 9.49e-03 2.40e-02 0.6380 -0.256000 -1.82e-01 0.505000 2.30e-01 1.10e-01 2.55e-01 1.60e-03 1.50e-01
Signaling by FGFR3 fusions in cancer 10 1.15e-02 2.80e-02 0.6380 0.334000 -7.98e-02 -0.293000 -4.51e-01 6.72e-02 6.62e-01 1.09e-01 1.36e-02
P2Y receptors 10 4.32e-02 8.18e-02 0.6370 0.416000 3.84e-01 -0.109000 2.71e-01 2.29e-02 3.54e-02 5.50e-01 1.37e-01
PD-1 signaling 10 2.15e-02 4.68e-02 0.6370 0.232000 4.61e-01 -0.351000 -1.26e-01 2.04e-01 1.16e-02 5.44e-02 4.90e-01
Cyclin E associated events during G1/S transition 75 2.27e-16 4.26e-15 0.6360 0.269000 3.02e-01 0.486000 6.39e-02 5.62e-05 6.10e-06 3.32e-13 3.39e-01
The role of GTSE1 in G2/M progression after G2 checkpoint 54 1.62e-11 1.90e-10 0.6360 0.196000 2.41e-01 0.538000 1.34e-01 1.28e-02 2.19e-03 7.85e-12 8.83e-02
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD 48 7.66e-09 5.65e-08 0.6340 0.164000 2.20e-01 0.524000 2.28e-01 4.96e-02 8.55e-03 3.35e-10 6.20e-03
G2/M Checkpoints 124 4.64e-31 3.81e-29 0.6320 0.314000 3.03e-01 0.455000 -4.95e-02 1.58e-09 6.09e-09 2.35e-18 3.42e-01
Complement cascade 34 3.42e-05 1.44e-04 0.6320 0.228000 3.54e-01 0.239000 4.05e-01 2.13e-02 3.53e-04 1.60e-02 4.33e-05
Cyclin A:Cdk2-associated events at S phase entry 77 2.70e-17 5.63e-16 0.6320 0.263000 3.01e-01 0.487000 4.20e-02 6.57e-05 5.18e-06 1.47e-13 5.25e-01
Switching of origins to a post-replicative state 83 2.08e-19 5.57e-18 0.6310 0.294000 2.48e-01 0.499000 3.38e-02 3.76e-06 9.49e-05 4.16e-15 5.95e-01
G beta:gamma signalling through BTK 13 7.16e-03 1.91e-02 0.6210 0.021800 1.57e-01 0.159000 5.79e-01 8.92e-01 3.29e-01 3.22e-01 3.02e-04
HDR through Homologous Recombination (HRR) 61 3.54e-19 9.10e-18 0.6180 0.288000 2.30e-01 0.454000 -2.02e-01 1.03e-04 1.94e-03 8.93e-10 6.30e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA 48 1.43e-09 1.18e-08 0.6170 0.154000 1.96e-01 0.542000 1.59e-01 6.60e-02 1.89e-02 8.40e-11 5.64e-02
Hh mutants abrogate ligand secretion 50 8.15e-09 5.91e-08 0.6160 0.156000 2.11e-01 0.514000 2.17e-01 5.62e-02 1.01e-02 3.29e-10 7.98e-03
Downregulation of SMAD2/3:SMAD4 transcriptional activity 20 4.00e-04 1.41e-03 0.6150 0.026800 -3.42e-01 -0.312000 -4.04e-01 8.36e-01 8.15e-03 1.58e-02 1.75e-03
Effects of PIP2 hydrolysis 22 1.42e-04 5.49e-04 0.6130 -0.347000 -5.45e-02 -0.388000 -3.19e-01 4.83e-03 6.58e-01 1.65e-03 9.63e-03
Regulation of Apoptosis 47 2.98e-08 1.87e-07 0.6120 0.184000 2.03e-01 0.509000 2.01e-01 2.94e-02 1.63e-02 1.58e-09 1.71e-02
Prostacyclin signalling through prostacyclin receptor 14 8.53e-03 2.19e-02 0.6100 0.031400 1.79e-01 0.188000 5.51e-01 8.39e-01 2.47e-01 2.24e-01 3.55e-04
Chromosome Maintenance 82 2.48e-24 1.09e-22 0.6090 0.252000 2.55e-01 0.464000 -1.66e-01 7.95e-05 6.53e-05 3.95e-13 9.54e-03
ER-Phagosome pathway 69 7.24e-10 6.42e-09 0.6080 0.200000 2.65e-01 0.423000 2.84e-01 4.19e-03 1.43e-04 1.22e-09 4.68e-05
Constitutive Signaling by NOTCH1 HD Domain Mutants 12 2.32e-04 8.69e-04 0.6060 -0.452000 1.24e-01 -0.323000 -2.07e-01 6.74e-03 4.57e-01 5.24e-02 2.15e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer 12 2.32e-04 8.69e-04 0.6060 -0.452000 1.24e-01 -0.323000 -2.07e-01 6.74e-03 4.57e-01 5.24e-02 2.15e-01
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 70 1.96e-14 3.34e-13 0.6040 0.249000 2.02e-01 0.505000 8.61e-02 3.27e-04 3.54e-03 2.69e-13 2.13e-01
Translesion Synthesis by POLH 16 1.36e-05 6.05e-05 0.6040 0.144000 6.89e-02 0.547000 -2.02e-01 3.20e-01 6.33e-01 1.52e-04 1.63e-01
Antigen processing-Cross presentation 83 4.46e-11 4.69e-10 0.6040 0.223000 2.83e-01 0.374000 3.07e-01 4.39e-04 8.53e-06 3.94e-09 1.34e-06
Signaling by Leptin 10 1.46e-01 2.19e-01 0.6010 -0.296000 -4.11e-01 -0.279000 -1.64e-01 1.05e-01 2.43e-02 1.27e-01 3.69e-01
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 24 1.43e-08 9.91e-08 0.6010 0.185000 1.21e-01 0.486000 -2.76e-01 1.17e-01 3.07e-01 3.79e-05 1.92e-02
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 67 3.01e-13 4.39e-12 0.6000 0.237000 1.97e-01 0.504000 1.05e-01 8.08e-04 5.42e-03 9.35e-13 1.39e-01
Collagen chain trimerization 32 3.87e-10 3.65e-09 0.6000 -0.455000 -7.76e-02 -0.348000 1.63e-01 8.50e-06 4.48e-01 6.71e-04 1.12e-01
Diseases associated with N-glycosylation of proteins 16 6.80e-03 1.83e-02 0.6000 -0.228000 -3.38e-01 0.358000 2.55e-01 1.15e-01 1.93e-02 1.32e-02 7.70e-02
FRS-mediated FGFR2 signaling 14 4.67e-03 1.33e-02 0.5980 -0.072000 -4.80e-01 -0.267000 -2.26e-01 6.41e-01 1.88e-03 8.32e-02 1.43e-01
APC/C:Cdc20 mediated degradation of mitotic proteins 69 9.73e-14 1.56e-12 0.5980 0.242000 1.97e-01 0.501000 9.39e-02 5.08e-04 4.70e-03 6.35e-13 1.78e-01
Formation of Fibrin Clot (Clotting Cascade) 17 3.31e-04 1.20e-03 0.5970 0.312000 2.07e-01 -0.090200 4.56e-01 2.60e-02 1.39e-01 5.20e-01 1.13e-03
FRS-mediated FGFR4 signaling 11 1.36e-02 3.22e-02 0.5960 -0.026400 -4.66e-01 -0.202000 -3.11e-01 8.80e-01 7.46e-03 2.46e-01 7.42e-02
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 66 1.01e-12 1.34e-11 0.5950 0.228000 1.88e-01 0.504000 1.14e-01 1.40e-03 8.46e-03 1.44e-12 1.11e-01
Regulation of cholesterol biosynthesis by SREBP (SREBF) 54 8.84e-08 5.09e-07 0.5940 -0.108000 -3.09e-01 -0.320000 -3.78e-01 1.69e-01 8.53e-05 4.70e-05 1.61e-06
Resolution of Sister Chromatid Cohesion 95 1.18e-32 1.03e-30 0.5920 0.308000 1.18e-01 0.375000 -3.18e-01 2.28e-07 4.76e-02 2.77e-10 8.77e-08
PI-3K cascade:FGFR3 10 4.22e-03 1.22e-02 0.5920 0.151000 -4.19e-01 -0.207000 -3.30e-01 4.08e-01 2.19e-02 2.57e-01 7.04e-02
TP53 Regulates Transcription of Death Receptors and Ligands 11 4.30e-02 8.15e-02 0.5900 -0.207000 -6.35e-02 -0.499000 -2.28e-01 2.35e-01 7.15e-01 4.15e-03 1.90e-01
Interferon gamma signaling 63 8.53e-10 7.41e-09 0.5890 0.247000 3.41e-01 0.098400 4.01e-01 7.10e-04 2.95e-06 1.77e-01 3.87e-08
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 10 1.58e-01 2.32e-01 0.5880 -0.233000 -3.01e-01 -0.385000 -2.31e-01 2.01e-01 9.96e-02 3.53e-02 2.06e-01
Retrograde neurotrophin signalling 13 2.10e-02 4.58e-02 0.5880 -0.278000 -1.66e-01 0.450000 1.94e-01 8.26e-02 2.99e-01 4.94e-03 2.25e-01
Signaling by FGFR3 in disease 14 5.54e-03 1.54e-02 0.5870 0.166000 -2.19e-01 -0.304000 -4.21e-01 2.83e-01 1.56e-01 4.89e-02 6.43e-03
Signaling by FGFR3 point mutants in cancer 14 5.54e-03 1.54e-02 0.5870 0.166000 -2.19e-01 -0.304000 -4.21e-01 2.83e-01 1.56e-01 4.89e-02 6.43e-03
Purine catabolism 16 7.58e-03 2.01e-02 0.5860 0.114000 2.32e-01 0.499000 1.65e-01 4.30e-01 1.09e-01 5.48e-04 2.54e-01
Homologous DNA Pairing and Strand Exchange 40 4.61e-12 5.65e-11 0.5850 0.250000 1.75e-01 0.450000 -2.16e-01 6.22e-03 5.60e-02 8.62e-07 1.79e-02
Regulation of pyruvate dehydrogenase (PDH) complex 15 1.11e-02 2.72e-02 0.5850 -0.021600 -3.48e-01 -0.302000 -3.60e-01 8.85e-01 1.96e-02 4.30e-02 1.59e-02
Presynaptic phase of homologous DNA pairing and strand exchange 37 2.43e-10 2.40e-09 0.5840 0.273000 2.04e-01 0.432000 -1.94e-01 4.02e-03 3.21e-02 5.40e-06 4.15e-02
Regulation of APC/C activators between G1/S and early anaphase 74 3.26e-15 5.93e-14 0.5840 0.243000 1.92e-01 0.492000 4.80e-02 3.06e-04 4.27e-03 2.50e-13 4.76e-01
Stabilization of p53 50 2.50e-08 1.61e-07 0.5830 0.204000 2.35e-01 0.473000 1.40e-01 1.25e-02 4.03e-03 7.51e-09 8.69e-02
APC/C-mediated degradation of cell cycle proteins 81 9.79e-18 2.22e-16 0.5830 0.245000 1.94e-01 0.492000 1.08e-02 1.40e-04 2.59e-03 2.00e-14 8.66e-01
Regulation of mitotic cell cycle 81 9.79e-18 2.22e-16 0.5830 0.245000 1.94e-01 0.492000 1.08e-02 1.40e-04 2.59e-03 2.00e-14 8.66e-01
Telomere Maintenance 62 1.05e-16 2.12e-15 0.5830 0.222000 2.63e-01 0.443000 -1.58e-01 2.49e-03 3.42e-04 1.70e-09 3.16e-02
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 10 3.34e-03 9.94e-03 0.5810 -0.201000 -1.88e-01 0.356000 -3.66e-01 2.72e-01 3.03e-01 5.10e-02 4.48e-02
Influenza Infection 112 3.44e-18 8.53e-17 0.5800 0.310000 2.04e-01 0.421000 1.49e-01 1.52e-08 2.03e-04 1.56e-14 6.55e-03
Translation 230 3.88e-33 3.63e-31 0.5780 0.139000 1.07e-01 0.453000 3.13e-01 3.08e-04 5.48e-03 2.95e-32 3.29e-16
Autodegradation of Cdh1 by Cdh1:APC/C 58 4.99e-10 4.58e-09 0.5740 0.164000 1.61e-01 0.505000 1.50e-01 3.14e-02 3.42e-02 3.00e-11 4.83e-02
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 89 1.26e-22 4.15e-21 0.5740 0.307000 2.29e-01 0.388000 -1.78e-01 5.64e-07 1.87e-04 2.49e-10 3.68e-03
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 68 8.86e-13 1.19e-11 0.5710 0.201000 1.60e-01 0.501000 9.54e-02 4.26e-03 2.24e-02 8.97e-13 1.74e-01
Resolution of D-Loop Structures 30 6.70e-09 4.97e-08 0.5690 0.225000 1.60e-01 0.436000 -2.40e-01 3.32e-02 1.29e-01 3.58e-05 2.31e-02
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 83 3.78e-28 2.48e-26 0.5680 0.243000 7.13e-02 0.397000 -3.18e-01 1.36e-04 2.62e-01 4.01e-10 5.82e-07
Amplification of signal from the kinetochores 83 3.78e-28 2.48e-26 0.5680 0.243000 7.13e-02 0.397000 -3.18e-01 1.36e-04 2.62e-01 4.01e-10 5.82e-07
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 20 9.04e-03 2.30e-02 0.5670 -0.012100 -1.35e-01 -0.323000 -4.46e-01 9.25e-01 2.95e-01 1.25e-02 5.48e-04
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 17 1.85e-05 8.02e-05 0.5660 0.082300 1.72e-01 0.472000 -2.47e-01 5.57e-01 2.20e-01 7.47e-04 7.77e-02
ABC transporter disorders 60 1.35e-08 9.40e-08 0.5660 0.148000 1.89e-01 0.464000 2.17e-01 4.73e-02 1.15e-02 5.09e-10 3.70e-03
CDK-mediated phosphorylation and removal of Cdc6 66 9.42e-12 1.13e-10 0.5650 0.208000 1.79e-01 0.484000 9.59e-02 3.49e-03 1.18e-02 1.03e-11 1.78e-01
Mitochondrial translation elongation 85 1.42e-13 2.17e-12 0.5650 -0.042900 -4.00e-02 0.499000 2.57e-01 4.94e-01 5.25e-01 1.74e-15 4.31e-05
Degradation of DVL 50 3.68e-08 2.26e-07 0.5640 0.170000 2.03e-01 0.480000 1.34e-01 3.82e-02 1.31e-02 4.47e-09 1.02e-01
Resolution of D-loop Structures through Holliday Junction Intermediates 29 2.49e-08 1.61e-07 0.5610 0.233000 1.42e-01 0.435000 -2.25e-01 2.97e-02 1.85e-01 4.95e-05 3.57e-02
Transport of Ribonucleoproteins into the Host Nucleus 27 4.12e-09 3.18e-08 0.5610 0.007080 -1.72e-01 0.313000 -4.33e-01 9.49e-01 1.23e-01 4.85e-03 9.99e-05
Mitochondrial translation termination 85 2.03e-13 3.00e-12 0.5610 -0.030300 -4.98e-02 0.494000 2.59e-01 6.29e-01 4.28e-01 3.50e-15 3.66e-05
Resolution of Abasic Sites (AP sites) 37 1.96e-07 1.06e-06 0.5610 0.183000 2.85e-01 0.447000 -1.46e-02 5.40e-02 2.76e-03 2.58e-06 8.78e-01
Nuclear import of Rev protein 28 8.15e-10 7.13e-09 0.5610 0.028300 -1.28e-01 0.378000 -3.92e-01 7.96e-01 2.42e-01 5.32e-04 3.27e-04
APC/C:Cdc20 mediated degradation of Securin 62 4.60e-10 4.31e-09 0.5600 0.196000 1.51e-01 0.480000 1.49e-01 7.81e-03 3.94e-02 6.33e-11 4.29e-02
ATF6 (ATF6-alpha) activates chaperones 12 3.26e-04 1.19e-03 0.5600 0.333000 -1.75e-01 0.414000 -2.03e-02 4.56e-02 2.93e-01 1.31e-02 9.03e-01
ADP signalling through P2Y purinoceptor 12 16 1.04e-02 2.57e-02 0.5590 0.147000 1.62e-01 0.129000 4.98e-01 3.09e-01 2.63e-01 3.70e-01 5.68e-04
Signaling by WNT in cancer 28 2.60e-03 7.96e-03 0.5580 -0.262000 -3.70e-01 -0.150000 -2.90e-01 1.66e-02 7.10e-04 1.70e-01 7.90e-03
Hedgehog ligand biogenesis 53 1.58e-07 8.67e-07 0.5570 0.115000 1.51e-01 0.474000 2.25e-01 1.49e-01 5.72e-02 2.48e-09 4.68e-03
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 25 2.34e-08 1.53e-07 0.5560 -0.009120 -1.50e-01 0.342000 -4.12e-01 9.37e-01 1.95e-01 3.10e-03 3.59e-04
Regulation of Glucokinase by Glucokinase Regulatory Protein 25 2.34e-08 1.53e-07 0.5560 -0.009120 -1.50e-01 0.342000 -4.12e-01 9.37e-01 1.95e-01 3.10e-03 3.59e-04
Synthesis, secretion, and deacylation of Ghrelin 10 1.37e-01 2.07e-01 0.5560 0.178000 1.44e-01 0.217000 4.58e-01 3.30e-01 4.31e-01 2.36e-01 1.21e-02
Mitochondrial translation initiation 85 1.32e-12 1.71e-11 0.5550 -0.045300 -4.45e-02 0.476000 2.76e-01 4.71e-01 4.79e-01 3.17e-14 1.08e-05
MASTL Facilitates Mitotic Progression 10 1.56e-02 3.62e-02 0.5550 0.369000 1.20e-01 0.373000 -1.35e-01 4.35e-02 5.12e-01 4.12e-02 4.61e-01
Degradation of cysteine and homocysteine 11 5.72e-03 1.58e-02 0.5540 -0.061700 -2.10e-01 0.501000 -9.07e-02 7.23e-01 2.29e-01 4.01e-03 6.02e-01
Degradation of GLI1 by the proteasome 53 4.78e-08 2.89e-07 0.5530 0.175000 1.67e-01 0.471000 1.58e-01 2.80e-02 3.61e-02 2.95e-09 4.69e-02
Interactions of Rev with host cellular proteins 31 1.14e-10 1.14e-09 0.5510 0.071200 -6.90e-02 0.389000 -3.78e-01 4.93e-01 5.06e-01 1.81e-04 2.72e-04
RUNX1 regulates transcription of genes involved in differentiation of HSCs 62 1.36e-08 9.41e-08 0.5510 0.165000 2.29e-01 0.439000 1.77e-01 2.52e-02 1.85e-03 2.26e-09 1.58e-02
Homology Directed Repair 95 1.33e-23 4.73e-22 0.5500 0.270000 1.98e-01 0.395000 -1.84e-01 5.40e-06 8.61e-04 3.03e-11 2.01e-03
Activated NTRK2 signals through FRS2 and FRS3 10 1.08e-01 1.70e-01 0.5490 -0.143000 -4.44e-01 -0.212000 -1.96e-01 4.32e-01 1.51e-02 2.46e-01 2.83e-01
CD28 dependent Vav1 pathway 12 9.51e-02 1.53e-01 0.5480 0.363000 3.63e-01 -0.086600 1.72e-01 2.96e-02 2.96e-02 6.03e-01 3.02e-01
Miscellaneous transport and binding events 18 7.14e-03 1.91e-02 0.5480 -0.201000 -4.31e-01 0.000852 -2.72e-01 1.41e-01 1.53e-03 9.95e-01 4.60e-02
NCAM1 interactions 26 1.92e-04 7.28e-04 0.5470 -0.432000 -2.32e-01 -0.229000 8.33e-02 1.36e-04 4.11e-02 4.36e-02 4.63e-01
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 30 1.89e-03 5.97e-03 0.5470 0.425000 3.36e-01 0.054500 4.58e-02 5.67e-05 1.43e-03 6.05e-01 6.64e-01
PI-3K cascade:FGFR1 11 7.65e-03 2.02e-02 0.5460 0.068400 -4.44e-01 -0.151000 -2.72e-01 6.95e-01 1.08e-02 3.86e-01 1.19e-01
Diseases associated with glycosylation precursor biosynthesis 18 6.19e-03 1.68e-02 0.5460 -0.214000 -7.67e-02 0.197000 4.55e-01 1.16e-01 5.73e-01 1.49e-01 8.27e-04
Signal regulatory protein family interactions 13 4.94e-02 9.09e-02 0.5450 0.019900 5.58e-03 0.246000 4.87e-01 9.01e-01 9.72e-01 1.25e-01 2.39e-03
Rev-mediated nuclear export of HIV RNA 30 4.67e-10 4.34e-09 0.5450 0.053200 -6.93e-02 0.391000 -3.69e-01 6.14e-01 5.11e-01 2.09e-04 4.66e-04
NEP/NS2 Interacts with the Cellular Export Machinery 27 6.41e-09 4.78e-08 0.5450 0.044600 -1.35e-01 0.345000 -3.97e-01 6.89e-01 2.25e-01 1.93e-03 3.57e-04
Glutamate binding, activation of AMPA receptors and synaptic plasticity 24 1.14e-02 2.77e-02 0.5450 -0.293000 -2.48e-01 -0.303000 -2.39e-01 1.29e-02 3.54e-02 1.02e-02 4.30e-02
Trafficking of AMPA receptors 24 1.14e-02 2.77e-02 0.5450 -0.293000 -2.48e-01 -0.303000 -2.39e-01 1.29e-02 3.54e-02 1.02e-02 4.30e-02
Degradation of GLI2 by the proteasome 52 8.20e-08 4.76e-07 0.5440 0.154000 1.65e-01 0.472000 1.51e-01 5.57e-02 4.03e-02 3.87e-09 6.05e-02
GLI3 is processed to GLI3R by the proteasome 52 1.67e-07 9.04e-07 0.5420 0.168000 1.67e-01 0.461000 1.60e-01 3.66e-02 3.70e-02 8.99e-09 4.63e-02
Pentose phosphate pathway 13 4.64e-02 8.68e-02 0.5420 0.125000 1.63e-01 0.477000 1.56e-01 4.37e-01 3.10e-01 2.91e-03 3.31e-01
Antimicrobial peptides 13 1.50e-02 3.49e-02 0.5400 0.138000 4.29e-01 -0.063200 2.90e-01 3.90e-01 7.35e-03 6.93e-01 7.00e-02
Export of Viral Ribonucleoproteins from Nucleus 28 1.02e-08 7.31e-08 0.5390 0.009770 -1.64e-01 0.298000 -4.18e-01 9.29e-01 1.32e-01 6.37e-03 1.29e-04
SUMOylation of DNA replication proteins 40 3.55e-12 4.43e-11 0.5360 0.186000 6.43e-02 0.383000 -3.20e-01 4.24e-02 4.82e-01 2.73e-05 4.70e-04
Regulation of necroptotic cell death 12 8.27e-03 2.17e-02 0.5360 0.088400 3.11e-01 -0.426000 4.07e-02 5.96e-01 6.20e-02 1.06e-02 8.07e-01
Cell Cycle Checkpoints 235 2.75e-55 1.20e-52 0.5360 0.275000 1.79e-01 0.394000 -1.56e-01 4.74e-13 2.37e-06 2.88e-25 3.92e-05
VLDLR internalisation and degradation 11 4.08e-02 7.80e-02 0.5360 0.008790 1.70e-01 0.499000 9.71e-02 9.60e-01 3.30e-01 4.20e-03 5.77e-01
NIK-->noncanonical NF-kB signaling 52 2.01e-07 1.08e-06 0.5320 0.164000 1.72e-01 0.455000 1.41e-01 4.05e-02 3.18e-02 1.40e-08 7.89e-02
Activation of Matrix Metalloproteinases 17 8.46e-03 2.19e-02 0.5310 -0.344000 -2.27e-01 0.023300 3.34e-01 1.42e-02 1.05e-01 8.68e-01 1.72e-02
Postmitotic nuclear pore complex (NPC) reformation 25 7.87e-08 4.59e-07 0.5290 0.061700 -1.21e-01 0.407000 -3.10e-01 5.94e-01 2.96e-01 4.30e-04 7.25e-03
Apoptotic factor-mediated response 13 2.69e-02 5.63e-02 0.5290 -0.125000 1.19e-01 0.464000 1.86e-01 4.37e-01 4.57e-01 3.77e-03 2.45e-01
Regulation of RUNX3 expression and activity 48 1.76e-06 8.59e-06 0.5240 0.163000 2.13e-01 0.430000 1.30e-01 5.06e-02 1.06e-02 2.49e-07 1.20e-01
Mitochondrial translation 91 1.12e-12 1.47e-11 0.5230 -0.053800 -7.07e-02 0.460000 2.34e-01 3.76e-01 2.44e-01 3.61e-14 1.19e-04
Pyruvate metabolism 26 1.51e-04 5.82e-04 0.5230 0.005260 -3.20e-01 -0.122000 -3.96e-01 9.63e-01 4.76e-03 2.83e-01 4.82e-04
Regulation of FZD by ubiquitination 13 1.84e-01 2.59e-01 0.5230 -0.305000 -3.15e-01 -0.227000 -1.71e-01 5.66e-02 4.93e-02 1.56e-01 2.85e-01
Vpr-mediated nuclear import of PICs 29 1.58e-08 1.09e-07 0.5220 -0.012600 -1.68e-01 0.346000 -3.54e-01 9.07e-01 1.18e-01 1.28e-03 9.72e-04
Interleukin-12 signaling 35 5.99e-04 2.07e-03 0.5220 0.428000 2.81e-01 0.052300 9.11e-02 1.21e-05 3.99e-03 5.92e-01 3.51e-01
Transport of the SLBP Dependant Mature mRNA 31 5.32e-09 4.01e-08 0.5220 -0.037500 -1.35e-01 0.310000 -3.96e-01 7.18e-01 1.93e-01 2.78e-03 1.36e-04
Synthesis of PE 11 1.68e-02 3.85e-02 0.5210 -0.433000 -9.82e-03 -0.250000 -1.45e-01 1.28e-02 9.55e-01 1.52e-01 4.06e-01
Dectin-1 mediated noncanonical NF-kB signaling 53 1.65e-07 9.00e-07 0.5200 0.148000 1.61e-01 0.455000 1.27e-01 6.29e-02 4.25e-02 1.04e-08 1.10e-01
Sulfur amino acid metabolism 20 2.15e-05 9.29e-05 0.5200 0.022900 -2.74e-01 0.424000 -1.23e-01 8.59e-01 3.42e-02 1.02e-03 3.40e-01
G1/S DNA Damage Checkpoints 60 5.10e-09 3.87e-08 0.5200 0.189000 2.38e-01 0.418000 5.23e-02 1.14e-02 1.45e-03 2.10e-08 4.84e-01
EML4 and NUDC in mitotic spindle formation 87 7.85e-25 3.81e-23 0.5180 0.223000 4.75e-02 0.366000 -2.88e-01 3.36e-04 4.45e-01 3.80e-09 3.43e-06
Formation of the beta-catenin:TCF transactivating complex 29 1.70e-03 5.44e-03 0.5170 -0.261000 -1.70e-01 -0.173000 -3.75e-01 1.51e-02 1.14e-01 1.06e-01 4.70e-04
Misspliced GSK3beta mutants stabilize beta-catenin 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
S33 mutants of beta-catenin aren't phosphorylated 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
S37 mutants of beta-catenin aren't phosphorylated 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
S45 mutants of beta-catenin aren't phosphorylated 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
T41 mutants of beta-catenin aren't phosphorylated 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex 14 1.90e-02 4.21e-02 0.5170 -0.046500 -3.08e-01 -0.059100 -4.08e-01 7.63e-01 4.58e-02 7.02e-01 8.16e-03
Transport of the SLBP independent Mature mRNA 30 2.92e-08 1.84e-07 0.5170 -0.059700 -1.62e-01 0.297000 -3.87e-01 5.72e-01 1.24e-01 4.93e-03 2.48e-04
Degradation of AXIN 49 1.53e-06 7.51e-06 0.5160 0.206000 1.78e-01 0.422000 1.18e-01 1.27e-02 3.09e-02 3.22e-07 1.52e-01
Prolactin receptor signaling 11 1.51e-01 2.23e-01 0.5160 -0.126000 -3.72e-01 -0.249000 -2.22e-01 4.70e-01 3.25e-02 1.53e-01 2.02e-01
Separation of Sister Chromatids 154 4.19e-35 4.23e-33 0.5150 0.253000 1.20e-01 0.412000 -1.32e-01 6.53e-08 1.01e-02 1.16e-18 4.81e-03
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 57 6.93e-07 3.54e-06 0.5150 0.198000 1.89e-01 0.407000 1.58e-01 9.84e-03 1.36e-02 1.10e-07 3.96e-02
Regulation of PTEN mRNA translation 11 2.09e-01 2.87e-01 0.5150 -0.145000 -2.03e-01 -0.387000 -2.30e-01 4.05e-01 2.44e-01 2.62e-02 1.87e-01
G beta:gamma signalling through PLC beta 15 1.65e-02 3.79e-02 0.5140 -0.083700 4.49e-02 0.122000 4.90e-01 5.75e-01 7.63e-01 4.12e-01 1.01e-03
Assembly of collagen fibrils and other multimeric structures 45 1.13e-10 1.14e-09 0.5140 -0.392000 -2.40e-02 -0.326000 5.67e-02 5.41e-06 7.80e-01 1.52e-04 5.11e-01
G beta:gamma signalling through CDC42 15 1.35e-02 3.21e-02 0.5140 0.006070 1.09e-01 0.077900 4.96e-01 9.68e-01 4.65e-01 6.02e-01 8.82e-04
FRS-mediated FGFR3 signaling 12 2.85e-02 5.87e-02 0.5130 0.054500 -3.49e-01 -0.215000 -3.04e-01 7.44e-01 3.62e-02 1.96e-01 6.86e-02
p53-Dependent G1 DNA Damage Response 58 3.23e-08 2.01e-07 0.5130 0.191000 2.27e-01 0.413000 6.70e-02 1.21e-02 2.82e-03 5.22e-08 3.78e-01
p53-Dependent G1/S DNA damage checkpoint 58 3.23e-08 2.01e-07 0.5130 0.191000 2.27e-01 0.413000 6.70e-02 1.21e-02 2.82e-03 5.22e-08 3.78e-01
NS1 Mediated Effects on Host Pathways 33 1.20e-09 1.01e-08 0.5130 0.065700 -8.44e-02 0.297000 -4.04e-01 5.14e-01 4.02e-01 3.16e-03 5.88e-05
Base Excision Repair 45 4.41e-08 2.69e-07 0.5120 0.172000 2.99e-01 0.373000 -6.58e-02 4.64e-02 5.23e-04 1.50e-05 4.45e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 19 7.68e-03 2.02e-02 0.5100 0.008000 -1.16e-02 -0.159000 -4.85e-01 9.52e-01 9.30e-01 2.29e-01 2.55e-04
STING mediated induction of host immune responses 12 9.63e-02 1.55e-01 0.5100 0.239000 4.36e-01 -0.101000 -5.19e-02 1.53e-01 8.87e-03 5.44e-01 7.56e-01
Purine salvage 12 1.60e-01 2.33e-01 0.5080 0.325000 2.36e-01 0.291000 1.09e-01 5.11e-02 1.56e-01 8.07e-02 5.14e-01
Initiation of Nuclear Envelope (NE) Reformation 19 2.13e-04 8.02e-04 0.5070 0.185000 2.34e-02 0.460000 -1.04e-01 1.62e-01 8.60e-01 5.19e-04 4.32e-01
Mitotic Spindle Checkpoint 100 1.92e-27 1.15e-25 0.5070 0.225000 3.37e-02 0.367000 -2.66e-01 1.05e-04 5.61e-01 2.35e-10 4.32e-06
Ion homeostasis 41 2.88e-04 1.05e-03 0.5060 -0.214000 -3.07e-01 -0.310000 -1.44e-01 1.80e-02 6.71e-04 6.08e-04 1.12e-01
Processing of DNA double-strand break ends 58 3.53e-11 3.77e-10 0.5050 0.280000 2.07e-01 0.322000 -1.73e-01 2.23e-04 6.56e-03 2.26e-05 2.25e-02
Cytosolic sulfonation of small molecules 15 8.22e-02 1.37e-01 0.5050 0.138000 3.18e-01 0.166000 3.27e-01 3.53e-01 3.28e-02 2.66e-01 2.84e-02
Thromboxane signalling through TP receptor 19 9.88e-03 2.47e-02 0.5040 -0.125000 5.45e-02 0.190000 4.47e-01 3.45e-01 6.81e-01 1.53e-01 7.47e-04
Downstream signaling of activated FGFR4 16 2.26e-02 4.88e-02 0.5040 0.021400 -2.80e-01 -0.213000 -3.60e-01 8.82e-01 5.23e-02 1.40e-01 1.26e-02
Downstream signaling of activated FGFR2 19 1.25e-02 3.01e-02 0.5040 -0.019700 -3.20e-01 -0.259000 -2.90e-01 8.82e-01 1.58e-02 5.04e-02 2.88e-02
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest 13 8.01e-03 2.10e-02 0.5030 0.171000 3.06e-01 0.217000 -2.88e-01 2.86e-01 5.60e-02 1.75e-01 7.20e-02
Transport of Mature mRNAs Derived from Intronless Transcripts 38 3.80e-10 3.61e-09 0.5030 -0.006950 -1.26e-01 0.257000 -4.13e-01 9.41e-01 1.81e-01 6.14e-03 1.04e-05
Meiotic recombination 22 4.40e-05 1.83e-04 0.5010 0.149000 1.29e-01 0.424000 -1.81e-01 2.26e-01 2.97e-01 5.81e-04 1.41e-01
ADP signalling through P2Y purinoceptor 1 20 5.14e-03 1.44e-02 0.5000 -0.030800 -5.09e-03 0.134000 4.81e-01 8.11e-01 9.69e-01 2.99e-01 1.98e-04
Elevation of cytosolic Ca2+ levels 12 3.34e-02 6.66e-02 0.5000 -0.387000 -7.88e-02 -0.302000 -5.06e-02 2.04e-02 6.36e-01 7.02e-02 7.61e-01
RORA activates gene expression 17 6.02e-02 1.07e-01 0.4980 -0.037200 -1.96e-01 -0.258000 -3.77e-01 7.91e-01 1.63e-01 6.60e-02 7.12e-03
Transport of Mature mRNA Derived from an Intronless Transcript 37 2.06e-09 1.66e-08 0.4970 -0.024100 -1.47e-01 0.244000 -4.06e-01 8.00e-01 1.21e-01 1.01e-02 1.91e-05
Detoxification of Reactive Oxygen Species 29 6.88e-03 1.85e-02 0.4960 0.103000 1.82e-01 0.369000 2.58e-01 3.35e-01 8.97e-02 5.90e-04 1.62e-02
Telomere C-strand synthesis initiation 12 2.02e-02 4.44e-02 0.4960 0.151000 3.59e-01 0.246000 -1.84e-01 3.65e-01 3.13e-02 1.40e-01 2.70e-01
HDR through Single Strand Annealing (SSA) 36 8.47e-08 4.89e-07 0.4950 0.215000 1.54e-01 0.366000 -2.05e-01 2.59e-02 1.10e-01 1.48e-04 3.34e-02
Interactions of Vpr with host cellular proteins 31 3.38e-08 2.09e-07 0.4950 -0.009950 -1.52e-01 0.324000 -3.42e-01 9.24e-01 1.43e-01 1.80e-03 9.86e-04
FOXO-mediated transcription of cell cycle genes 15 1.13e-01 1.76e-01 0.4950 -0.073700 -1.09e-01 -0.273000 -3.91e-01 6.21e-01 4.64e-01 6.70e-02 8.75e-03
Pyruvate metabolism and Citric Acid (TCA) cycle 50 6.50e-10 5.88e-09 0.4930 0.115000 -2.41e-01 -0.058600 -4.10e-01 1.61e-01 3.24e-03 4.74e-01 5.38e-07
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 17 2.04e-03 6.41e-03 0.4910 0.257000 -1.13e-01 0.232000 3.30e-01 6.71e-02 4.19e-01 9.77e-02 1.86e-02
Citric acid cycle (TCA cycle) 22 7.74e-05 3.07e-04 0.4900 0.207000 -1.32e-01 0.017000 -4.24e-01 9.34e-02 2.85e-01 8.90e-01 5.75e-04
CLEC7A (Dectin-1) induces NFAT activation 10 2.23e-01 3.02e-01 0.4880 0.130000 -8.80e-03 -0.393000 -2.57e-01 4.77e-01 9.62e-01 3.13e-02 1.59e-01
Glycogen synthesis 12 1.87e-01 2.62e-01 0.4870 -0.378000 -2.88e-01 -0.056000 8.60e-02 2.32e-02 8.36e-02 7.37e-01 6.06e-01
MET activates PTK2 signaling 17 1.30e-02 3.11e-02 0.4850 -0.207000 -4.55e-02 -0.426000 -9.34e-02 1.40e-01 7.45e-01 2.35e-03 5.05e-01
FRS-mediated FGFR1 signaling 13 3.88e-02 7.48e-02 0.4850 -0.008090 -3.76e-01 -0.167000 -2.56e-01 9.60e-01 1.89e-02 2.97e-01 1.10e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation 13 1.64e-01 2.37e-01 0.4840 -0.317000 -3.38e-01 0.090800 -1.07e-01 4.80e-02 3.49e-02 5.71e-01 5.04e-01
TRAF6-mediated induction of TAK1 complex within TLR4 complex 13 1.64e-01 2.37e-01 0.4840 -0.317000 -3.38e-01 0.090800 -1.07e-01 4.80e-02 3.49e-02 5.71e-01 5.04e-01
Nitric oxide stimulates guanylate cyclase 18 9.74e-04 3.25e-03 0.4810 -0.248000 -6.50e-04 -0.406000 6.40e-02 6.81e-02 9.96e-01 2.83e-03 6.38e-01
ATF4 activates genes in response to endoplasmic reticulum stress 24 4.77e-03 1.35e-02 0.4800 0.321000 2.82e-01 0.170000 -1.39e-01 6.46e-03 1.70e-02 1.49e-01 2.38e-01
PECAM1 interactions 11 4.71e-02 8.78e-02 0.4800 0.129000 3.26e-01 -0.313000 9.88e-02 4.58e-01 6.15e-02 7.26e-02 5.70e-01
Metabolism of porphyrins 21 2.78e-04 1.02e-03 0.4790 -0.080400 -7.19e-02 0.456000 -9.80e-02 5.24e-01 5.69e-01 2.99e-04 4.37e-01
G2/M DNA damage checkpoint 58 1.75e-09 1.43e-08 0.4790 0.265000 2.21e-01 0.293000 -1.55e-01 4.81e-04 3.65e-03 1.15e-04 4.15e-02
Mitochondrial iron-sulfur cluster biogenesis 12 1.43e-02 3.35e-02 0.4780 -0.210000 -1.86e-02 0.418000 -9.45e-02 2.08e-01 9.11e-01 1.22e-02 5.71e-01
InlB-mediated entry of Listeria monocytogenes into host cell 13 1.76e-01 2.50e-01 0.4770 -0.127000 -3.21e-01 -0.186000 -2.71e-01 4.26e-01 4.51e-02 2.45e-01 9.11e-02
Regulation of beta-cell development 20 7.56e-02 1.27e-01 0.4760 -0.120000 -1.68e-01 -0.325000 -2.80e-01 3.51e-01 1.93e-01 1.20e-02 3.00e-02
Activation of SMO 14 1.24e-01 1.90e-01 0.4760 -0.159000 -3.21e-02 0.305000 3.28e-01 3.04e-01 8.35e-01 4.79e-02 3.38e-02
Interleukin-12 family signaling 41 3.91e-04 1.39e-03 0.4760 0.399000 2.33e-01 0.039000 1.09e-01 1.01e-05 1.00e-02 6.66e-01 2.26e-01
AMER1 mutants destabilize the destruction complex 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
APC truncation mutants have impaired AXIN binding 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
AXIN missense mutants destabilize the destruction complex 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
AXIN mutants destabilize the destruction complex, activating WNT signaling 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
Truncations of AMER1 destabilize the destruction complex 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
truncated APC mutants destabilize the destruction complex 13 3.76e-02 7.29e-02 0.4740 0.009570 -2.79e-01 -0.056500 -3.80e-01 9.52e-01 8.19e-02 7.24e-01 1.78e-02
Nucleotide salvage 20 4.92e-02 9.09e-02 0.4740 0.211000 2.60e-01 0.316000 1.14e-01 1.03e-01 4.38e-02 1.46e-02 3.77e-01
Deadenylation of mRNA 24 3.51e-03 1.03e-02 0.4740 0.185000 8.72e-02 -0.122000 -4.10e-01 1.17e-01 4.60e-01 2.99e-01 5.14e-04
Collagen biosynthesis and modifying enzymes 50 1.04e-10 1.07e-09 0.4740 -0.359000 -2.69e-02 -0.155000 2.67e-01 1.15e-05 7.42e-01 5.88e-02 1.11e-03
Listeria monocytogenes entry into host cells 17 8.30e-02 1.38e-01 0.4740 -0.144000 -3.41e-01 -0.165000 -2.46e-01 3.05e-01 1.50e-02 2.40e-01 7.91e-02
RIPK1-mediated regulated necrosis 14 1.42e-02 3.34e-02 0.4730 0.109000 3.23e-01 -0.309000 1.10e-01 4.82e-01 3.66e-02 4.56e-02 4.75e-01
Regulated Necrosis 14 1.42e-02 3.34e-02 0.4730 0.109000 3.23e-01 -0.309000 1.10e-01 4.82e-01 3.66e-02 4.56e-02 4.75e-01
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 12 1.16e-01 1.81e-01 0.4720 0.142000 -4.12e-02 0.265000 3.61e-01 3.95e-01 8.05e-01 1.12e-01 3.04e-02
Downstream signaling of activated FGFR3 17 2.86e-02 5.88e-02 0.4720 0.075800 -2.09e-01 -0.222000 -3.52e-01 5.89e-01 1.36e-01 1.14e-01 1.20e-02
Signaling by ROBO receptors 162 7.97e-13 1.08e-11 0.4710 0.230000 2.38e-01 0.258000 2.15e-01 4.79e-07 1.88e-07 1.67e-08 2.37e-06
IRAK4 deficiency (TLR2/4) 11 1.17e-01 1.83e-01 0.4710 -0.052800 1.06e-01 0.115000 4.41e-01 7.62e-01 5.43e-01 5.10e-01 1.13e-02
Mitotic Metaphase and Anaphase 206 3.47e-41 5.06e-39 0.4710 0.202000 7.95e-02 0.400000 -1.20e-01 6.58e-07 4.99e-02 4.90e-23 3.00e-03
Processing of Intronless Pre-mRNAs 17 7.41e-03 1.97e-02 0.4700 0.158000 -4.53e-02 -0.037700 -4.38e-01 2.61e-01 7.46e-01 7.88e-01 1.75e-03
Glycogen metabolism 23 2.28e-02 4.92e-02 0.4690 -0.289000 -2.49e-01 -0.270000 -4.19e-02 1.65e-02 3.89e-02 2.52e-02 7.28e-01
Cell Cycle, Mitotic 457 2.46e-89 1.61e-86 0.4690 0.216000 1.40e-01 0.352000 -1.72e-01 3.46e-15 3.64e-07 9.41e-38 4.08e-10
Glucagon-type ligand receptors 16 1.71e-02 3.90e-02 0.4680 -0.169000 7.40e-02 0.100000 4.18e-01 2.43e-01 6.09e-01 4.88e-01 3.77e-03
CASP8 activity is inhibited 10 6.06e-02 1.07e-01 0.4670 0.063300 3.00e-01 -0.349000 4.56e-02 7.29e-01 1.00e-01 5.58e-02 8.03e-01
Dimerization of procaspase-8 10 6.06e-02 1.07e-01 0.4670 0.063300 3.00e-01 -0.349000 4.56e-02 7.29e-01 1.00e-01 5.58e-02 8.03e-01
Regulation by c-FLIP 10 6.06e-02 1.07e-01 0.4670 0.063300 3.00e-01 -0.349000 4.56e-02 7.29e-01 1.00e-01 5.58e-02 8.03e-01
Mitotic Anaphase 205 2.24e-40 2.94e-38 0.4670 0.199000 7.51e-02 0.398000 -1.18e-01 1.00e-06 6.46e-02 1.03e-22 3.60e-03
MyD88 deficiency (TLR2/4) 10 1.72e-01 2.46e-01 0.4650 -0.034400 1.11e-01 0.116000 4.35e-01 8.51e-01 5.42e-01 5.24e-01 1.73e-02
SUMOylation of SUMOylation proteins 29 8.56e-07 4.32e-06 0.4650 0.019900 -1.34e-01 0.276000 -3.49e-01 8.53e-01 2.12e-01 1.02e-02 1.16e-03
IRF3-mediated induction of type I IFN 10 2.10e-01 2.87e-01 0.4650 0.197000 4.14e-01 -0.032400 -6.46e-02 2.80e-01 2.33e-02 8.59e-01 7.24e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 33 8.72e-03 2.23e-02 0.4640 -0.168000 -1.32e-01 -0.302000 -2.80e-01 9.43e-02 1.89e-01 2.66e-03 5.45e-03
Nuclear Pore Complex (NPC) Disassembly 31 1.65e-07 9.00e-07 0.4630 0.071100 -9.67e-02 0.327000 -3.05e-01 4.93e-01 3.52e-01 1.65e-03 3.25e-03
FOXO-mediated transcription of cell death genes 14 4.66e-03 1.33e-02 0.4630 0.074200 -9.18e-02 0.161000 -4.18e-01 6.31e-01 5.52e-01 2.96e-01 6.83e-03
MECP2 regulates neuronal receptors and channels 12 1.63e-01 2.36e-01 0.4630 0.209000 2.82e-01 -0.283000 -1.05e-01 2.10e-01 9.05e-02 9.00e-02 5.28e-01
Transferrin endocytosis and recycling 24 2.06e-02 4.52e-02 0.4630 -0.218000 -2.00e-01 0.273000 2.28e-01 6.42e-02 8.99e-02 2.05e-02 5.34e-02
Regulation of MECP2 expression and activity 28 1.04e-02 2.57e-02 0.4630 -0.062100 -2.45e-01 -0.216000 -3.23e-01 5.70e-01 2.50e-02 4.85e-02 3.14e-03
Regulation of RAS by GAPs 60 3.25e-06 1.54e-05 0.4620 0.187000 2.31e-01 0.345000 7.96e-02 1.22e-02 2.01e-03 3.92e-06 2.87e-01
Metabolism of Angiotensinogen to Angiotensins 11 1.81e-01 2.56e-01 0.4620 -0.255000 -2.28e-01 0.071700 3.02e-01 1.43e-01 1.91e-01 6.81e-01 8.32e-02
Synthesis of Leukotrienes (LT) and Eoxins (EX) 14 1.27e-01 1.94e-01 0.4600 0.210000 2.65e-01 0.024800 3.12e-01 1.75e-01 8.65e-02 8.72e-01 4.34e-02
Acetylcholine regulates insulin secretion 10 2.58e-01 3.39e-01 0.4600 -0.388000 -2.19e-01 -0.075300 8.48e-02 3.36e-02 2.30e-01 6.80e-01 6.42e-01
Constitutive Signaling by EGFRvIII 15 1.64e-01 2.37e-01 0.4600 -0.128000 -1.81e-01 -0.188000 -3.57e-01 3.92e-01 2.26e-01 2.08e-01 1.68e-02
Signaling by EGFRvIII in Cancer 15 1.64e-01 2.37e-01 0.4600 -0.128000 -1.81e-01 -0.188000 -3.57e-01 3.92e-01 2.26e-01 2.08e-01 1.68e-02
Presynaptic function of Kainate receptors 16 2.74e-02 5.69e-02 0.4590 -0.033800 5.63e-02 0.074900 4.48e-01 8.15e-01 6.97e-01 6.04e-01 1.90e-03
SHC-mediated cascade:FGFR2 12 8.63e-02 1.42e-01 0.4590 0.022900 -3.20e-01 -0.231000 -2.33e-01 8.91e-01 5.50e-02 1.67e-01 1.62e-01
Transcriptional Regulation by E2F6 33 1.04e-04 4.03e-04 0.4590 0.328000 1.69e-01 0.243000 -1.23e-01 1.11e-03 9.28e-02 1.58e-02 2.21e-01
Asymmetric localization of PCP proteins 58 4.53e-06 2.11e-05 0.4580 -0.000948 7.43e-02 0.413000 1.83e-01 9.90e-01 3.28e-01 5.47e-08 1.57e-02
Protein methylation 11 2.28e-01 3.09e-01 0.4560 0.267000 1.40e-01 0.120000 3.20e-01 1.25e-01 4.20e-01 4.91e-01 6.60e-02
Disassembly of the destruction complex and recruitment of AXIN to the membrane 26 1.42e-02 3.34e-02 0.4560 -0.257000 -2.94e-01 0.025000 -2.34e-01 2.33e-02 9.55e-03 8.25e-01 3.87e-02
Viral Messenger RNA Synthesis 38 3.84e-08 2.35e-07 0.4560 -0.041400 -1.20e-01 0.380000 -2.17e-01 6.59e-01 1.99e-01 5.07e-05 2.09e-02
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 17 5.89e-03 1.62e-02 0.4550 0.193000 2.28e-01 0.217000 -2.65e-01 1.68e-01 1.03e-01 1.21e-01 5.86e-02
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 17 5.89e-03 1.62e-02 0.4550 0.193000 2.28e-01 0.217000 -2.65e-01 1.68e-01 1.03e-01 1.21e-01 5.86e-02
Metabolism of folate and pterines 15 3.98e-02 7.65e-02 0.4540 -0.234000 -1.61e-01 0.355000 -3.55e-03 1.17e-01 2.79e-01 1.74e-02 9.81e-01
EGFR downregulation 26 2.56e-02 5.41e-02 0.4540 -0.201000 -3.64e-01 -0.133000 -1.26e-01 7.65e-02 1.34e-03 2.39e-01 2.68e-01
VEGFR2 mediated cell proliferation 19 5.67e-02 1.02e-01 0.4530 -0.033600 4.93e-02 -0.353000 -2.78e-01 8.00e-01 7.10e-01 7.79e-03 3.59e-02
Long-term potentiation 16 1.26e-02 3.04e-02 0.4530 -0.147000 -8.33e-02 -0.417000 4.66e-02 3.09e-01 5.64e-01 3.84e-03 7.47e-01
EPHB-mediated forward signaling 32 2.12e-03 6.60e-03 0.4510 0.260000 2.15e-01 0.002650 3.01e-01 1.11e-02 3.57e-02 9.79e-01 3.26e-03
Gluconeogenesis 25 3.11e-02 6.30e-02 0.4510 -0.216000 -2.24e-01 -0.106000 -3.09e-01 6.20e-02 5.29e-02 3.58e-01 7.45e-03
DAG and IP3 signaling 38 7.00e-03 1.88e-02 0.4500 -0.175000 -2.44e-01 -0.271000 -1.96e-01 6.19e-02 9.21e-03 3.88e-03 3.65e-02
Ras activation upon Ca2+ influx through NMDA receptor 15 6.93e-02 1.20e-01 0.4480 -0.138000 -3.92e-02 -0.407000 -1.22e-01 3.53e-01 7.93e-01 6.40e-03 4.14e-01
PKA activation in glucagon signalling 15 1.21e-01 1.86e-01 0.4480 -0.222000 -3.75e-01 0.102000 1.95e-02 1.37e-01 1.19e-02 4.92e-01 8.96e-01
Nucleotide-like (purinergic) receptors 13 8.78e-02 1.44e-01 0.4480 0.256000 2.49e-01 -0.171000 2.09e-01 1.10e-01 1.20e-01 2.85e-01 1.93e-01
Signaling by FGFR2 IIIa TM 18 2.75e-02 5.71e-02 0.4470 -0.125000 -2.64e-01 0.326000 8.83e-02 3.59e-01 5.27e-02 1.66e-02 5.17e-01
Mitotic Prometaphase 175 2.71e-36 2.97e-34 0.4460 0.183000 7.35e-02 0.305000 -2.59e-01 3.27e-05 9.42e-02 3.62e-12 3.59e-09
TP53 Regulates Transcription of Cell Cycle Genes 46 1.02e-08 7.31e-08 0.4460 0.126000 1.57e-01 0.169000 -3.61e-01 1.41e-01 6.58e-02 4.73e-02 2.35e-05
G-protein activation 17 1.59e-02 3.67e-02 0.4460 0.013400 5.44e-02 0.017700 4.42e-01 9.24e-01 6.98e-01 8.99e-01 1.60e-03
Cell Cycle 570 1.80e-98 2.36e-95 0.4460 0.204000 1.43e-01 0.332000 -1.61e-01 1.34e-16 7.05e-09 2.24e-41 7.69e-11
Major pathway of rRNA processing in the nucleolus and cytosol 140 1.00e-09 8.64e-09 0.4460 0.265000 2.59e-01 0.189000 1.59e-01 6.22e-08 1.29e-07 1.19e-04 1.18e-03
activated TAK1 mediates p38 MAPK activation 18 4.35e-02 8.22e-02 0.4450 -0.130000 -3.71e-01 -0.032500 -2.06e-01 3.40e-01 6.38e-03 8.11e-01 1.31e-01
Cyclin D associated events in G1 41 2.21e-05 9.43e-05 0.4450 0.305000 1.88e-01 0.222000 -1.42e-01 7.19e-04 3.72e-02 1.40e-02 1.17e-01
G1 Phase 41 2.21e-05 9.43e-05 0.4450 0.305000 1.88e-01 0.222000 -1.42e-01 7.19e-04 3.72e-02 1.40e-02 1.17e-01
DNA Double-Strand Break Repair 122 4.73e-21 1.44e-19 0.4450 0.209000 1.46e-01 0.318000 -1.78e-01 6.72e-05 5.41e-03 1.46e-09 6.93e-04
Cytosolic iron-sulfur cluster assembly 11 2.09e-02 4.58e-02 0.4440 -0.239000 4.94e-03 0.171000 -3.33e-01 1.70e-01 9.77e-01 3.25e-01 5.60e-02
DNA Damage/Telomere Stress Induced Senescence 26 2.16e-05 9.29e-05 0.4430 0.062600 1.16e-01 0.216000 -3.64e-01 5.81e-01 3.08e-01 5.65e-02 1.32e-03
Plasma lipoprotein clearance 24 2.77e-02 5.73e-02 0.4430 -0.048200 1.22e-01 0.331000 2.64e-01 6.83e-01 3.03e-01 5.02e-03 2.51e-02
Receptor-type tyrosine-protein phosphatases 12 3.10e-02 6.28e-02 0.4430 -0.142000 -2.02e-01 -0.176000 3.23e-01 3.96e-01 2.25e-01 2.91e-01 5.26e-02
Unblocking of NMDA receptors, glutamate binding and activation 14 2.40e-02 5.13e-02 0.4420 -0.138000 -1.26e-01 -0.389000 9.73e-02 3.70e-01 4.13e-01 1.18e-02 5.29e-01
Norepinephrine Neurotransmitter Release Cycle 10 2.59e-01 3.39e-01 0.4420 -0.047600 -1.94e-02 -0.414000 -1.48e-01 7.95e-01 9.16e-01 2.35e-02 4.16e-01
Signaling by BMP 20 2.49e-03 7.68e-03 0.4420 0.016100 -3.19e-01 -0.305000 -2.88e-02 9.01e-01 1.37e-02 1.82e-02 8.24e-01
Collagen degradation 24 2.86e-03 8.66e-03 0.4400 -0.273000 -1.68e-01 -0.075000 2.92e-01 2.05e-02 1.54e-01 5.25e-01 1.32e-02
Nephrin family interactions 18 1.50e-02 3.49e-02 0.4400 0.067600 3.34e-01 -0.233000 -1.53e-01 6.20e-01 1.42e-02 8.76e-02 2.62e-01
Dual Incision in GG-NER 39 7.51e-06 3.43e-05 0.4400 0.179000 1.51e-01 0.359000 -9.69e-02 5.32e-02 1.03e-01 1.03e-04 2.95e-01
Serotonin Neurotransmitter Release Cycle 10 2.76e-01 3.58e-01 0.4400 -0.050200 -7.29e-02 -0.408000 -1.39e-01 7.83e-01 6.90e-01 2.56e-02 4.47e-01
Cardiac conduction 87 1.21e-07 6.81e-07 0.4390 -0.126000 -2.30e-01 -0.326000 -1.34e-01 4.19e-02 2.14e-04 1.52e-07 3.06e-02
Synthesis of PC 24 9.31e-03 2.36e-02 0.4390 -0.343000 -1.46e-01 -0.018100 -2.33e-01 3.67e-03 2.17e-01 8.78e-01 4.86e-02
CS/DS degradation 10 2.51e-01 3.31e-01 0.4390 -0.241000 -2.00e-02 0.209000 3.01e-01 1.86e-01 9.13e-01 2.53e-01 9.93e-02
Insulin processing 20 8.62e-02 1.42e-01 0.4390 -0.118000 -1.69e-01 -0.344000 -1.78e-01 3.62e-01 1.91e-01 7.74e-03 1.69e-01
Uptake and actions of bacterial toxins 24 8.93e-02 1.47e-01 0.4370 -0.218000 -2.44e-01 -0.230000 -1.76e-01 6.44e-02 3.86e-02 5.15e-02 1.35e-01
SUMOylation of ubiquitinylation proteins 33 9.24e-07 4.64e-06 0.4360 0.007930 -9.77e-02 0.248000 -3.45e-01 9.37e-01 3.32e-01 1.38e-02 6.02e-04
rRNA processing in the nucleus and cytosol 149 6.44e-10 5.87e-09 0.4360 0.260000 2.71e-01 0.174000 1.38e-01 4.85e-08 1.15e-08 2.58e-04 3.77e-03
Blood group systems biosynthesis 12 8.30e-02 1.38e-01 0.4360 -0.112000 -3.33e-01 0.256000 -3.30e-02 5.01e-01 4.60e-02 1.24e-01 8.43e-01
Transcriptional regulation by small RNAs 42 1.69e-08 1.15e-07 0.4360 -0.022800 -1.41e-01 0.311000 -2.70e-01 7.99e-01 1.14e-01 4.95e-04 2.50e-03
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway 11 8.36e-03 2.17e-02 0.4350 -0.165000 3.21e-01 -0.177000 1.67e-01 3.45e-01 6.54e-02 3.10e-01 3.38e-01
Phase 0 - rapid depolarisation 28 4.09e-03 1.18e-02 0.4350 -0.143000 -1.87e-01 -0.364000 -3.68e-02 1.92e-01 8.76e-02 8.59e-04 7.36e-01
SHC-mediated cascade:FGFR3 10 1.47e-01 2.19e-01 0.4340 0.194000 -1.31e-01 -0.161000 -3.28e-01 2.89e-01 4.73e-01 3.78e-01 7.26e-02
Biosynthesis of specialized proresolving mediators (SPMs) 13 1.16e-01 1.81e-01 0.4320 0.133000 3.09e-01 -0.045200 2.67e-01 4.07e-01 5.34e-02 7.78e-01 9.54e-02
Early Phase of HIV Life Cycle 13 1.77e-01 2.51e-01 0.4300 0.335000 2.18e-01 0.080700 -1.38e-01 3.66e-02 1.74e-01 6.15e-01 3.89e-01
Zinc transporters 13 2.99e-01 3.82e-01 0.4300 0.303000 2.83e-01 -0.104000 -4.79e-02 5.85e-02 7.70e-02 5.18e-01 7.65e-01
Telomere Extension By Telomerase 21 2.49e-03 7.68e-03 0.4300 0.140000 2.63e-01 0.178000 -2.54e-01 2.66e-01 3.72e-02 1.58e-01 4.39e-02
TNFR2 non-canonical NF-kB pathway 74 5.27e-06 2.44e-05 0.4290 0.088900 1.86e-01 0.335000 1.72e-01 1.86e-01 5.66e-03 6.45e-07 1.08e-02
Cytochrome c-mediated apoptotic response 10 2.38e-01 3.19e-01 0.4280 -0.172000 6.95e-04 0.368000 1.34e-01 3.48e-01 9.97e-01 4.38e-02 4.64e-01
Post-chaperonin tubulin folding pathway 17 4.61e-02 8.63e-02 0.4270 -0.179000 -9.24e-02 0.371000 6.54e-02 2.01e-01 5.10e-01 8.06e-03 6.41e-01
Abortive elongation of HIV-1 transcript in the absence of Tat 22 3.65e-03 1.07e-02 0.4270 -0.160000 -1.35e-01 0.366000 -6.59e-02 1.93e-01 2.72e-01 2.93e-03 5.93e-01
Cargo concentration in the ER 22 1.99e-02 4.40e-02 0.4270 -0.009110 -1.74e-01 0.251000 2.98e-01 9.41e-01 1.59e-01 4.15e-02 1.55e-02
Nucleobase catabolism 30 3.65e-02 7.14e-02 0.4260 0.121000 1.45e-01 0.297000 2.40e-01 2.50e-01 1.69e-01 4.88e-03 2.29e-02
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 17 1.60e-01 2.33e-01 0.4260 -0.155000 -1.86e-01 -0.132000 -3.25e-01 2.70e-01 1.84e-01 3.48e-01 2.04e-02
Signaling by Ligand-Responsive EGFR Variants in Cancer 17 1.60e-01 2.33e-01 0.4260 -0.155000 -1.86e-01 -0.132000 -3.25e-01 2.70e-01 1.84e-01 3.48e-01 2.04e-02
Voltage gated Potassium channels 20 6.02e-02 1.07e-01 0.4250 -0.296000 -1.61e-01 -0.253000 -6.04e-02 2.22e-02 2.12e-01 5.05e-02 6.40e-01
Glutamate and glutamine metabolism 11 2.80e-01 3.62e-01 0.4240 -0.072200 6.17e-02 0.368000 1.88e-01 6.79e-01 7.23e-01 3.45e-02 2.81e-01
Synthesis of IP2, IP, and Ins in the cytosol 13 1.19e-01 1.85e-01 0.4240 -0.165000 -3.50e-01 -0.145000 9.47e-02 3.02e-01 2.89e-02 3.66e-01 5.54e-01
Budding and maturation of HIV virion 23 3.15e-02 6.36e-02 0.4240 -0.008770 -1.19e-01 0.271000 3.03e-01 9.42e-01 3.23e-01 2.43e-02 1.20e-02
Regulation of PTEN stability and activity 62 3.88e-06 1.83e-05 0.4230 0.135000 1.21e-01 0.374000 8.17e-02 6.64e-02 9.92e-02 3.70e-07 2.66e-01
Metal ion SLC transporters 21 1.07e-01 1.68e-01 0.4230 0.338000 2.20e-01 0.078900 1.01e-01 7.42e-03 8.10e-02 5.31e-01 4.21e-01
Glycogen breakdown (glycogenolysis) 14 2.21e-01 3.01e-01 0.4220 -0.134000 -1.23e-01 -0.350000 -1.50e-01 3.87e-01 4.25e-01 2.34e-02 3.32e-01
Late endosomal microautophagy 25 2.58e-02 5.44e-02 0.4220 -0.071600 -1.36e-01 0.329000 2.14e-01 5.36e-01 2.38e-01 4.42e-03 6.41e-02
PERK regulates gene expression 28 9.50e-03 2.40e-02 0.4220 0.303000 2.21e-01 0.169000 -9.35e-02 5.59e-03 4.29e-02 1.23e-01 3.92e-01
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 1.95e-01 2.71e-01 0.4210 -0.025000 -2.41e-01 -0.065400 -3.38e-01 8.86e-01 1.67e-01 7.07e-01 5.22e-02
Energy dependent regulation of mTOR by LKB1-AMPK 28 1.63e-02 3.74e-02 0.4200 -0.169000 -3.38e-01 -0.003120 -1.83e-01 1.23e-01 1.99e-03 9.77e-01 9.33e-02
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 17 3.81e-02 7.37e-02 0.4190 -0.056600 -3.78e-01 -0.115000 -1.27e-01 6.87e-01 6.96e-03 4.11e-01 3.65e-01
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 36 8.75e-04 2.96e-03 0.4190 -0.105000 -2.64e-01 -0.002590 -3.07e-01 2.76e-01 6.12e-03 9.79e-01 1.44e-03
Defects in vitamin and cofactor metabolism 19 1.75e-01 2.50e-01 0.4180 -0.177000 -2.96e-01 -0.138000 -1.93e-01 1.82e-01 2.57e-02 2.98e-01 1.45e-01
MicroRNA (miRNA) biogenesis 23 1.61e-02 3.72e-02 0.4180 -0.207000 -1.78e-01 0.316000 1.42e-02 8.54e-02 1.40e-01 8.70e-03 9.06e-01
Collagen formation 70 3.99e-12 4.94e-11 0.4180 -0.322000 -1.54e-02 -0.191000 1.84e-01 3.14e-06 8.24e-01 5.74e-03 7.79e-03
Defects in cobalamin (B12) metabolism 11 2.93e-01 3.76e-01 0.4170 -0.149000 -3.69e-01 -0.046300 -1.18e-01 3.93e-01 3.42e-02 7.90e-01 4.99e-01
RET signaling 32 4.76e-02 8.87e-02 0.4160 -0.235000 -2.26e-01 -0.185000 -1.82e-01 2.14e-02 2.71e-02 7.09e-02 7.52e-02
Metabolism of amino acids and derivatives 242 1.57e-17 3.48e-16 0.4160 0.206000 1.64e-01 0.286000 1.47e-01 3.53e-08 1.16e-05 1.96e-14 8.36e-05
TRAF6 mediated IRF7 activation 15 1.53e-01 2.26e-01 0.4130 0.188000 3.16e-01 -0.090000 -1.65e-01 2.08e-01 3.39e-02 5.46e-01 2.68e-01
Regulation of RUNX2 expression and activity 63 4.61e-05 1.90e-04 0.4130 0.175000 1.15e-01 0.329000 1.37e-01 1.64e-02 1.16e-01 6.39e-06 5.98e-02
PKMTs methylate histone lysines 37 1.39e-03 4.52e-03 0.4130 0.018700 -6.10e-02 -0.119000 -3.90e-01 8.44e-01 5.21e-01 2.12e-01 3.99e-05
Plasma lipoprotein assembly 10 4.13e-01 4.96e-01 0.4130 0.004120 -5.62e-02 0.272000 3.06e-01 9.82e-01 7.58e-01 1.37e-01 9.41e-02
Interferon Signaling 145 1.68e-08 1.15e-07 0.4120 0.216000 2.35e-01 0.188000 1.80e-01 7.13e-06 1.09e-06 9.74e-05 1.82e-04
Host Interactions of HIV factors 112 7.54e-14 1.22e-12 0.4120 0.131000 1.36e-01 0.365000 -3.17e-02 1.65e-02 1.33e-02 2.64e-11 5.63e-01
CaMK IV-mediated phosphorylation of CREB 10 3.53e-01 4.38e-01 0.4110 0.032800 -5.80e-02 -0.374000 -1.56e-01 8.58e-01 7.51e-01 4.04e-02 3.92e-01
UCH proteinases 78 6.40e-08 3.78e-07 0.4110 0.145000 1.77e-01 0.341000 1.75e-02 2.67e-02 6.87e-03 1.99e-07 7.90e-01
Activation of RAC1 12 1.57e-01 2.30e-01 0.4110 0.226000 -1.55e-02 -0.313000 -1.41e-01 1.76e-01 9.26e-01 6.06e-02 3.99e-01
Signaling by NTRK3 (TRKC) 17 1.76e-01 2.50e-01 0.4110 -0.049800 -7.71e-02 -0.348000 -1.97e-01 7.22e-01 5.82e-01 1.29e-02 1.59e-01
Thrombin signalling through proteinase activated receptors (PARs) 25 2.11e-02 4.61e-02 0.4100 -0.112000 2.69e-02 0.155000 3.62e-01 3.33e-01 8.16e-01 1.80e-01 1.72e-03
Negative regulation of FGFR2 signaling 21 1.51e-02 3.52e-02 0.4090 -0.084800 -3.94e-01 -0.033300 -6.46e-02 5.01e-01 1.78e-03 7.92e-01 6.09e-01
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 23 6.41e-02 1.12e-01 0.4090 -0.063000 -8.52e-02 -0.356000 -1.73e-01 6.01e-01 4.80e-01 3.16e-03 1.52e-01
Glucose metabolism 74 8.83e-09 6.37e-08 0.4090 -0.137000 -2.29e-01 0.099400 -2.94e-01 4.24e-02 6.77e-04 1.40e-01 1.23e-05
HSF1 activation 23 1.73e-02 3.95e-02 0.4090 -0.211000 -2.10e-01 0.089600 -2.66e-01 8.06e-02 8.12e-02 4.57e-01 2.71e-02
Non-integrin membrane-ECM interactions 39 4.81e-05 1.97e-04 0.4090 -0.195000 -2.56e-02 -0.358000 3.90e-04 3.48e-02 7.83e-01 1.10e-04 9.97e-01
CaM pathway 32 2.97e-02 6.08e-02 0.4080 -0.149000 -2.70e-01 -0.226000 -1.42e-01 1.45e-01 8.15e-03 2.73e-02 1.64e-01
Calmodulin induced events 32 2.97e-02 6.08e-02 0.4080 -0.149000 -2.70e-01 -0.226000 -1.42e-01 1.45e-01 8.15e-03 2.73e-02 1.64e-01
Meiotic synapsis 27 3.40e-03 1.01e-02 0.4080 0.193000 2.48e-01 0.116000 -2.32e-01 8.29e-02 2.55e-02 2.99e-01 3.71e-02
Signaling by NOTCH4 74 3.98e-05 1.66e-04 0.4060 0.137000 1.90e-01 0.299000 1.42e-01 4.23e-02 4.67e-03 8.56e-06 3.43e-02
Platelet calcium homeostasis 22 3.08e-02 6.26e-02 0.4050 -0.265000 -1.13e-01 -0.282000 -3.67e-02 3.14e-02 3.59e-01 2.21e-02 7.66e-01
Cellular response to heat stress 86 1.83e-08 1.23e-07 0.4040 -0.164000 -2.34e-01 0.050300 -2.82e-01 8.72e-03 1.81e-04 4.21e-01 6.37e-06
DAP12 signaling 25 5.89e-02 1.05e-01 0.4040 0.220000 3.33e-01 -0.055800 -2.31e-02 5.68e-02 3.96e-03 6.29e-01 8.42e-01
Endosomal Sorting Complex Required For Transport (ESCRT) 26 2.61e-02 5.49e-02 0.4030 0.011500 -1.04e-01 0.251000 2.97e-01 9.19e-01 3.59e-01 2.69e-02 8.77e-03
Regulation of TP53 Activity through Methylation 14 1.72e-01 2.46e-01 0.4030 -0.167000 -8.06e-02 -0.093400 -3.45e-01 2.81e-01 6.02e-01 5.45e-01 2.54e-02
M Phase 322 5.85e-50 1.92e-47 0.4010 0.158000 7.02e-02 0.330000 -1.49e-01 1.30e-06 3.13e-02 3.29e-24 4.92e-06
Cellular response to hypoxia 64 5.07e-05 2.07e-04 0.4010 0.123000 1.30e-01 0.340000 1.15e-01 9.01e-02 7.31e-02 2.61e-06 1.12e-01
Synthesis of PIPs at the early endosome membrane 16 1.88e-01 2.63e-01 0.4000 0.021100 3.88e-02 -0.345000 -1.97e-01 8.84e-01 7.88e-01 1.67e-02 1.73e-01
RHO GTPases Activate Formins 109 5.89e-18 1.41e-16 0.4000 0.155000 6.86e-02 0.273000 -2.38e-01 5.13e-03 2.17e-01 9.09e-07 1.85e-05
ERBB2 Regulates Cell Motility 12 3.04e-01 3.86e-01 0.3990 -0.329000 -1.88e-01 -0.020000 1.23e-01 4.85e-02 2.59e-01 9.04e-01 4.62e-01
Assembly and cell surface presentation of NMDA receptors 15 3.87e-02 7.48e-02 0.3990 -0.092200 -2.13e-01 -0.303000 1.17e-01 5.37e-01 1.54e-01 4.24e-02 4.32e-01
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 14 9.23e-02 1.51e-01 0.3980 -0.223000 8.02e-04 0.060900 3.24e-01 1.48e-01 9.96e-01 6.93e-01 3.59e-02
Metabolism of non-coding RNA 48 2.86e-08 1.81e-07 0.3980 0.071100 -7.70e-02 0.338000 -1.81e-01 3.94e-01 3.57e-01 5.09e-05 3.00e-02
snRNP Assembly 48 2.86e-08 1.81e-07 0.3980 0.071100 -7.70e-02 0.338000 -1.81e-01 3.94e-01 3.57e-01 5.09e-05 3.00e-02
Cobalamin (Cbl, vitamin B12) transport and metabolism 12 3.77e-01 4.63e-01 0.3970 -0.149000 -3.23e-01 -0.112000 -1.36e-01 3.71e-01 5.26e-02 5.00e-01 4.15e-01
Signal amplification 27 1.28e-02 3.07e-02 0.3960 0.042200 3.20e-02 0.092400 3.82e-01 7.05e-01 7.73e-01 4.06e-01 5.97e-04
Nuclear Envelope (NE) Reassembly 64 3.43e-10 3.31e-09 0.3960 0.033500 -8.59e-02 0.364000 -1.27e-01 6.43e-01 2.35e-01 4.89e-07 7.93e-02
Beta-catenin phosphorylation cascade 16 9.42e-02 1.53e-01 0.3960 -0.079700 -2.36e-01 0.002350 -3.07e-01 5.81e-01 1.02e-01 9.87e-01 3.35e-02
ABC-family proteins mediated transport 84 2.65e-06 1.28e-05 0.3960 0.092100 8.16e-02 0.345000 1.48e-01 1.45e-01 1.97e-01 4.53e-08 1.90e-02
Interleukin-10 signaling 24 4.95e-02 9.09e-02 0.3960 0.165000 8.94e-02 0.122000 3.26e-01 1.61e-01 4.48e-01 2.99e-01 5.73e-03
Signaling by ERBB2 ECD mutants 15 2.58e-01 3.38e-01 0.3950 -0.157000 -1.25e-01 -0.130000 -3.14e-01 2.91e-01 4.02e-01 3.83e-01 3.54e-02
Negative regulation of NMDA receptor-mediated neuronal transmission 16 6.57e-02 1.15e-01 0.3940 -0.206000 -1.72e-01 -0.269000 1.06e-01 1.54e-01 2.34e-01 6.27e-02 4.65e-01
p130Cas linkage to MAPK signaling for integrins 12 4.93e-02 9.09e-02 0.3920 0.082800 8.31e-02 -0.293000 2.32e-01 6.20e-01 6.18e-01 7.88e-02 1.63e-01
Synaptic adhesion-like molecules 15 7.13e-02 1.22e-01 0.3910 -0.116000 -2.02e-01 -0.013500 3.14e-01 4.36e-01 1.76e-01 9.28e-01 3.51e-02
Circadian Clock 63 1.76e-05 7.64e-05 0.3910 0.090500 -1.45e-01 -0.211000 -2.82e-01 2.14e-01 4.65e-02 3.81e-03 1.11e-04
Gap-filling DNA repair synthesis and ligation in TC-NER 61 5.59e-07 2.89e-06 0.3910 0.156000 1.40e-01 0.323000 -6.91e-02 3.49e-02 5.90e-02 1.30e-05 3.51e-01
Meiosis 47 3.98e-06 1.86e-05 0.3900 0.152000 1.86e-01 0.235000 -1.97e-01 7.16e-02 2.72e-02 5.32e-03 1.93e-02
Nuclear Envelope Breakdown 48 4.47e-08 2.71e-07 0.3900 0.023500 -3.97e-02 0.309000 -2.34e-01 7.79e-01 6.35e-01 2.18e-04 5.15e-03
GRB2:SOS provides linkage to MAPK signaling for Integrins 12 4.38e-02 8.26e-02 0.3900 0.067200 8.36e-03 -0.324000 2.05e-01 6.87e-01 9.60e-01 5.17e-02 2.19e-01
FCERI mediated Ca+2 mobilization 27 2.87e-02 5.89e-02 0.3890 0.138000 1.45e-01 -0.312000 -1.17e-01 2.14e-01 1.94e-01 4.97e-03 2.92e-01
Negative regulation of FGFR4 signaling 18 3.05e-02 6.21e-02 0.3890 -0.059000 -3.71e-01 0.045600 -8.96e-02 6.65e-01 6.45e-03 7.38e-01 5.11e-01
Cleavage of the damaged purine 11 9.38e-02 1.52e-01 0.3890 0.043500 3.32e-01 0.099300 -1.70e-01 8.03e-01 5.65e-02 5.69e-01 3.28e-01
Depurination 11 9.38e-02 1.52e-01 0.3890 0.043500 3.32e-01 0.099300 -1.70e-01 8.03e-01 5.65e-02 5.69e-01 3.28e-01
Recognition and association of DNA glycosylase with site containing an affected purine 11 9.38e-02 1.52e-01 0.3890 0.043500 3.32e-01 0.099300 -1.70e-01 8.03e-01 5.65e-02 5.69e-01 3.28e-01
Transcriptional activation of mitochondrial biogenesis 50 3.25e-03 9.71e-03 0.3880 -0.009440 -1.33e-01 -0.232000 -2.80e-01 9.08e-01 1.03e-01 4.53e-03 6.09e-04
Pre-NOTCH Processing in Golgi 16 1.52e-01 2.24e-01 0.3880 -0.333000 -1.44e-01 0.135000 2.16e-02 2.12e-02 3.20e-01 3.49e-01 8.81e-01
PKA activation 16 1.19e-01 1.85e-01 0.3880 -0.136000 -3.53e-01 0.058200 5.98e-02 3.47e-01 1.45e-02 6.87e-01 6.79e-01
Hyaluronan metabolism 14 3.69e-01 4.55e-01 0.3870 0.061700 8.87e-02 0.306000 2.10e-01 6.90e-01 5.66e-01 4.74e-02 1.74e-01
Free fatty acids regulate insulin secretion 10 5.76e-01 6.36e-01 0.3850 -0.290000 -2.51e-01 -0.029400 2.21e-02 1.12e-01 1.69e-01 8.72e-01 9.04e-01
Uptake and function of anthrax toxins 11 3.92e-01 4.77e-01 0.3840 -0.168000 -3.45e-01 -0.014100 -1.24e-02 3.35e-01 4.74e-02 9.36e-01 9.43e-01
Phosphorylation of the APC/C 20 5.94e-03 1.62e-02 0.3840 0.241000 -2.30e-02 0.290000 -7.16e-02 6.24e-02 8.58e-01 2.50e-02 5.79e-01
Glycolysis 58 4.77e-07 2.49e-06 0.3840 -0.086300 -1.97e-01 0.128000 -2.91e-01 2.56e-01 9.50e-03 9.25e-02 1.26e-04
Translation of Replicase and Assembly of the Replication Transcription Complex 11 2.91e-01 3.74e-01 0.3830 0.049500 -1.17e-01 0.309000 1.88e-01 7.76e-01 5.02e-01 7.62e-02 2.79e-01
Inactivation of APC/C via direct inhibition of the APC/C complex 21 4.54e-03 1.30e-02 0.3820 0.187000 -4.03e-02 0.323000 -7.13e-02 1.38e-01 7.49e-01 1.04e-02 5.72e-01
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 21 4.54e-03 1.30e-02 0.3820 0.187000 -4.03e-02 0.323000 -7.13e-02 1.38e-01 7.49e-01 1.04e-02 5.72e-01
Activation of G protein gated Potassium channels 18 2.34e-02 5.03e-02 0.3820 0.059400 1.07e-01 -0.094000 3.50e-01 6.63e-01 4.32e-01 4.90e-01 1.03e-02
G protein gated Potassium channels 18 2.34e-02 5.03e-02 0.3820 0.059400 1.07e-01 -0.094000 3.50e-01 6.63e-01 4.32e-01 4.90e-01 1.03e-02
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 18 2.34e-02 5.03e-02 0.3820 0.059400 1.07e-01 -0.094000 3.50e-01 6.63e-01 4.32e-01 4.90e-01 1.03e-02
Activation of NF-kappaB in B cells 61 2.80e-05 1.19e-04 0.3820 0.130000 1.47e-01 0.326000 2.89e-02 8.05e-02 4.74e-02 1.05e-05 6.97e-01
APC-Cdc20 mediated degradation of Nek2A 24 2.01e-03 6.33e-03 0.3810 0.170000 -2.14e-02 0.329000 -8.98e-02 1.51e-01 8.56e-01 5.29e-03 4.47e-01
Nucleobase biosynthesis 15 7.22e-02 1.23e-01 0.3810 0.006170 4.36e-02 0.378000 -1.73e-02 9.67e-01 7.70e-01 1.12e-02 9.08e-01
Carnitine metabolism 12 2.55e-01 3.36e-01 0.3810 -0.237000 -1.87e-02 -0.223000 -1.97e-01 1.55e-01 9.11e-01 1.82e-01 2.37e-01
Disorders of developmental biology 11 1.50e-01 2.23e-01 0.3800 0.128000 -1.95e-01 -0.079600 -2.90e-01 4.63e-01 2.62e-01 6.48e-01 9.63e-02
Loss of function of MECP2 in Rett syndrome 11 1.50e-01 2.23e-01 0.3800 0.128000 -1.95e-01 -0.079600 -2.90e-01 4.63e-01 2.62e-01 6.48e-01 9.63e-02
Pervasive developmental disorders 11 1.50e-01 2.23e-01 0.3800 0.128000 -1.95e-01 -0.079600 -2.90e-01 4.63e-01 2.62e-01 6.48e-01 9.63e-02
LDL clearance 15 2.73e-01 3.55e-01 0.3790 -0.061200 2.79e-02 0.322000 1.89e-01 6.82e-01 8.52e-01 3.08e-02 2.06e-01
Role of phospholipids in phagocytosis 27 2.50e-02 5.31e-02 0.3790 0.007680 2.54e-01 0.216000 1.80e-01 9.45e-01 2.22e-02 5.23e-02 1.06e-01
Activation of the AP-1 family of transcription factors 10 2.39e-01 3.19e-01 0.3790 0.034600 -2.90e-01 -0.108000 -2.16e-01 8.50e-01 1.12e-01 5.55e-01 2.37e-01
FGFR2 mutant receptor activation 21 6.87e-02 1.19e-01 0.3780 -0.146000 -3.00e-01 0.176000 2.54e-02 2.47e-01 1.73e-02 1.62e-01 8.40e-01
Hedgehog 'on' state 75 8.77e-05 3.43e-04 0.3780 0.092600 9.50e-02 0.317000 1.59e-01 1.66e-01 1.55e-01 2.15e-06 1.74e-02
TNFs bind their physiological receptors 11 4.02e-01 4.85e-01 0.3780 -0.039700 1.31e-01 0.172000 3.07e-01 8.20e-01 4.51e-01 3.24e-01 7.76e-02
Mitotic G2-G2/M phases 175 1.47e-21 4.71e-20 0.3780 0.129000 9.22e-02 0.330000 -9.13e-02 3.31e-03 3.60e-02 5.27e-14 3.78e-02
G2/M Transition 173 4.56e-21 1.42e-19 0.3770 0.131000 9.37e-02 0.328000 -8.99e-02 3.02e-03 3.41e-02 1.02e-13 4.20e-02
Translation of structural proteins 26 5.83e-02 1.05e-01 0.3760 -0.171000 -1.82e-01 0.259000 1.10e-01 1.30e-01 1.09e-01 2.25e-02 3.33e-01
rRNA processing 166 2.39e-08 1.55e-07 0.3760 0.245000 2.51e-01 0.114000 7.31e-02 5.35e-08 2.75e-08 1.14e-02 1.05e-01
Prolonged ERK activation events 13 1.91e-01 2.67e-01 0.3750 0.006430 -2.81e-01 -0.137000 -2.08e-01 9.68e-01 7.95e-02 3.94e-01 1.95e-01
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 75 3.01e-07 1.59e-06 0.3750 0.140000 8.79e-02 0.336000 2.22e-05 3.62e-02 1.89e-01 4.89e-07 1.00e+00
Post NMDA receptor activation events 51 1.10e-02 2.71e-02 0.3750 -0.151000 -2.11e-01 -0.218000 -1.59e-01 6.20e-02 9.05e-03 7.17e-03 4.97e-02
Signaling by cytosolic FGFR1 fusion mutants 18 2.42e-01 3.21e-01 0.3740 -0.034000 -1.80e-01 -0.248000 -2.13e-01 8.03e-01 1.87e-01 6.86e-02 1.18e-01
Surfactant metabolism 14 2.33e-01 3.13e-01 0.3740 -0.064100 -7.60e-02 0.123000 3.39e-01 6.78e-01 6.23e-01 4.24e-01 2.81e-02
FCGR3A-mediated phagocytosis 61 4.60e-04 1.61e-03 0.3740 0.159000 2.57e-01 0.016400 2.20e-01 3.23e-02 5.17e-04 8.25e-01 3.00e-03
Leishmania phagocytosis 61 4.60e-04 1.61e-03 0.3740 0.159000 2.57e-01 0.016400 2.20e-01 3.23e-02 5.17e-04 8.25e-01 3.00e-03
Parasite infection 61 4.60e-04 1.61e-03 0.3740 0.159000 2.57e-01 0.016400 2.20e-01 3.23e-02 5.17e-04 8.25e-01 3.00e-03
Phase II - Conjugation of compounds 66 4.92e-04 1.72e-03 0.3740 0.276000 1.47e-01 0.142000 1.48e-01 1.06e-04 3.88e-02 4.68e-02 3.82e-02
PI3K events in ERBB2 signaling 13 3.78e-01 4.63e-01 0.3740 -0.248000 -2.41e-01 -0.131000 5.33e-02 1.21e-01 1.33e-01 4.14e-01 7.39e-01
Inwardly rectifying K+ channels 20 2.61e-02 5.49e-02 0.3730 0.088600 1.03e-01 -0.061700 3.42e-01 4.93e-01 4.25e-01 6.33e-01 8.10e-03
TRAF3-dependent IRF activation pathway 13 2.06e-01 2.82e-01 0.3730 0.117000 3.20e-01 -0.055700 -1.42e-01 4.63e-01 4.61e-02 7.28e-01 3.76e-01
Signaling by ERBB2 TMD/JMD mutants 18 2.30e-01 3.10e-01 0.3730 -0.300000 -1.62e-01 -0.128000 -8.13e-02 2.78e-02 2.34e-01 3.49e-01 5.51e-01
Signaling by NODAL 13 1.18e-01 1.84e-01 0.3730 -0.039800 -3.16e-01 0.179000 7.16e-02 8.04e-01 4.83e-02 2.63e-01 6.55e-01
Golgi Cisternae Pericentriolar Stack Reorganization 14 1.03e-01 1.63e-01 0.3730 0.177000 -1.17e-02 0.327000 2.36e-02 2.51e-01 9.40e-01 3.43e-02 8.78e-01
Constitutive Signaling by AKT1 E17K in Cancer 25 2.40e-02 5.13e-02 0.3720 -0.039600 -2.00e-01 -0.021500 -3.11e-01 7.32e-01 8.42e-02 8.53e-01 7.10e-03
Processing of SMDT1 15 2.12e-01 2.91e-01 0.3720 0.103000 -2.37e-02 0.318000 1.62e-01 4.89e-01 8.74e-01 3.32e-02 2.78e-01
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 39 3.02e-03 9.06e-03 0.3720 0.090200 -8.48e-02 -0.126000 -3.27e-01 3.30e-01 3.60e-01 1.73e-01 4.11e-04
Nicotinamide salvaging 13 4.20e-01 5.02e-01 0.3710 0.174000 2.79e-01 0.021200 1.69e-01 2.76e-01 8.12e-02 8.95e-01 2.92e-01
Triglyceride catabolism 15 1.93e-01 2.69e-01 0.3700 0.029300 2.33e-02 -0.104000 -3.54e-01 8.44e-01 8.76e-01 4.85e-01 1.78e-02
YAP1- and WWTR1 (TAZ)-stimulated gene expression 13 5.22e-01 5.92e-01 0.3700 -0.221000 -2.72e-01 -0.092100 -7.60e-02 1.68e-01 8.96e-02 5.65e-01 6.35e-01
Integrin cell surface interactions 51 1.35e-07 7.53e-07 0.3700 -0.074000 1.40e-01 -0.312000 1.22e-01 3.61e-01 8.47e-02 1.19e-04 1.33e-01
Notch-HLH transcription pathway 25 1.59e-01 2.33e-01 0.3700 -0.087700 -1.19e-01 -0.270000 -2.05e-01 4.48e-01 3.02e-01 1.95e-02 7.63e-02
BMAL1:CLOCK,NPAS2 activates circadian gene expression 24 2.76e-02 5.71e-02 0.3700 0.131000 -1.23e-01 -0.276000 -1.68e-01 2.68e-01 2.97e-01 1.92e-02 1.55e-01
CRMPs in Sema3A signaling 15 2.55e-02 5.41e-02 0.3690 -0.118000 8.43e-02 -0.312000 1.33e-01 4.28e-01 5.72e-01 3.63e-02 3.73e-01
Ca-dependent events 34 3.16e-02 6.36e-02 0.3690 -0.113000 -2.65e-01 -0.203000 -1.11e-01 2.57e-01 7.57e-03 4.10e-02 2.63e-01
Regulation of HSF1-mediated heat shock response 69 1.02e-07 5.79e-07 0.3680 -0.098400 -1.91e-01 0.141000 -2.64e-01 1.58e-01 6.25e-03 4.24e-02 1.51e-04
Regulation of TLR by endogenous ligand 10 9.90e-02 1.58e-01 0.3680 -0.156000 1.09e-01 -0.168000 2.67e-01 3.92e-01 5.51e-01 3.58e-01 1.44e-01
GRB2 events in ERBB2 signaling 13 4.28e-01 5.09e-01 0.3680 -0.247000 -2.07e-01 -0.177000 -1.69e-02 1.23e-01 1.96e-01 2.70e-01 9.16e-01
HCMV Late Events 47 1.20e-05 5.37e-05 0.3680 0.002430 -1.18e-01 0.345000 -4.70e-02 9.77e-01 1.60e-01 4.28e-05 5.77e-01
Scavenging by Class A Receptors 13 1.71e-01 2.45e-01 0.3680 -0.139000 2.08e-02 0.038000 3.38e-01 3.84e-01 8.97e-01 8.13e-01 3.50e-02
IRE1alpha activates chaperones 49 1.27e-03 4.21e-03 0.3680 -0.137000 -2.17e-01 0.248000 9.03e-02 9.80e-02 8.79e-03 2.66e-03 2.74e-01
Gene Silencing by RNA 59 1.04e-07 5.93e-07 0.3680 -0.086500 -1.39e-01 0.252000 -2.12e-01 2.51e-01 6.56e-02 8.18e-04 4.93e-03
tRNA Aminoacylation 24 6.72e-02 1.17e-01 0.3680 -0.148000 -1.66e-01 0.280000 8.35e-02 2.08e-01 1.59e-01 1.75e-02 4.79e-01
Glyoxylate metabolism and glycine degradation 24 8.44e-02 1.39e-01 0.3670 -0.051000 -1.77e-01 -0.102000 -3.01e-01 6.66e-01 1.33e-01 3.87e-01 1.07e-02
Metabolism of nucleotides 85 2.76e-05 1.18e-04 0.3670 0.101000 1.06e-01 0.309000 1.33e-01 1.08e-01 9.29e-02 8.33e-07 3.40e-02
Interleukin-35 Signalling 10 2.00e-01 2.76e-01 0.3660 0.315000 3.97e-02 -0.157000 9.25e-02 8.45e-02 8.28e-01 3.91e-01 6.13e-01
ROS and RNS production in phagocytes 28 6.69e-02 1.16e-01 0.3660 -0.000192 1.62e-01 0.191000 2.67e-01 9.99e-01 1.38e-01 7.98e-02 1.47e-02
Regulation of TP53 Degradation 32 5.73e-04 1.98e-03 0.3660 0.143000 -5.86e-02 0.051500 -3.28e-01 1.63e-01 5.67e-01 6.14e-01 1.34e-03
Assembly Of The HIV Virion 13 3.44e-01 4.29e-01 0.3660 -0.157000 -1.95e-01 0.250000 9.16e-02 3.27e-01 2.23e-01 1.18e-01 5.67e-01
Lewis blood group biosynthesis 10 1.46e-01 2.18e-01 0.3660 0.025500 -3.22e-01 0.158000 6.53e-02 8.89e-01 7.77e-02 3.86e-01 7.21e-01
Muscle contraction 143 3.48e-10 3.34e-09 0.3660 -0.133000 -6.20e-02 -0.316000 -1.11e-01 6.28e-03 2.02e-01 7.30e-11 2.22e-02
Metabolism of steroid hormones 18 5.46e-02 9.89e-02 0.3650 0.081200 3.69e-02 -0.010400 3.54e-01 5.51e-01 7.86e-01 9.39e-01 9.28e-03
Syndecan interactions 19 9.70e-03 2.45e-02 0.3650 -0.079800 -8.09e-03 -0.305000 1.84e-01 5.47e-01 9.51e-01 2.14e-02 1.66e-01
CREB1 phosphorylation through the activation of Adenylate Cyclase 10 2.84e-01 3.66e-01 0.3640 -0.070000 -3.31e-01 0.121000 6.13e-02 7.02e-01 7.01e-02 5.07e-01 7.37e-01
G beta:gamma signalling through PI3Kgamma 20 9.35e-02 1.52e-01 0.3630 0.071300 1.49e-01 0.031500 3.22e-01 5.81e-01 2.50e-01 8.07e-01 1.26e-02
Mitotic Prophase 77 4.24e-11 4.49e-10 0.3630 0.078100 -2.45e-02 0.302000 -1.85e-01 2.37e-01 7.11e-01 4.83e-06 5.13e-03
Transcriptional regulation of pluripotent stem cells 14 3.07e-02 6.24e-02 0.3620 0.038100 -3.22e-01 -0.121000 1.05e-01 8.05e-01 3.69e-02 4.31e-01 4.98e-01
Degradation of beta-catenin by the destruction complex 75 3.30e-06 1.56e-05 0.3610 0.111000 1.03e-01 0.327000 2.52e-02 9.60e-02 1.25e-01 9.84e-07 7.07e-01
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 24 2.22e-01 3.02e-01 0.3610 -0.234000 -2.27e-01 -0.057000 -1.44e-01 4.76e-02 5.42e-02 6.29e-01 2.22e-01
Pausing and recovery of Tat-mediated HIV elongation 26 3.00e-03 8.99e-03 0.3610 -0.073900 -7.75e-03 0.339000 -9.75e-02 5.14e-01 9.45e-01 2.76e-03 3.90e-01
Tat-mediated HIV elongation arrest and recovery 26 3.00e-03 8.99e-03 0.3610 -0.073900 -7.75e-03 0.339000 -9.75e-02 5.14e-01 9.45e-01 2.76e-03 3.90e-01
GPVI-mediated activation cascade 30 7.64e-03 2.02e-02 0.3600 0.092600 3.19e-01 -0.125000 6.11e-02 3.80e-01 2.49e-03 2.37e-01 5.63e-01
PCP/CE pathway 85 3.20e-06 1.53e-05 0.3600 -0.043200 6.25e-02 0.331000 1.19e-01 4.92e-01 3.20e-01 1.35e-07 5.92e-02
Regulation of TNFR1 signaling 27 3.33e-02 6.65e-02 0.3600 0.075500 2.27e-01 -0.224000 -1.48e-01 4.97e-01 4.10e-02 4.45e-02 1.82e-01
Interleukin-2 signaling 11 4.58e-01 5.33e-01 0.3600 0.025100 6.18e-02 -0.315000 -1.60e-01 8.86e-01 7.23e-01 7.06e-02 3.57e-01
Methylation 11 1.22e-01 1.88e-01 0.3600 0.263000 -1.73e-02 0.223000 -9.97e-02 1.31e-01 9.21e-01 2.00e-01 5.67e-01
SHC-mediated cascade:FGFR1 11 2.43e-01 3.22e-01 0.3590 0.107000 -1.83e-01 -0.109000 -2.69e-01 5.39e-01 2.94e-01 5.32e-01 1.22e-01
EPHA-mediated growth cone collapse 14 7.22e-02 1.23e-01 0.3590 0.011800 3.00e-01 -0.139000 1.39e-01 9.39e-01 5.20e-02 3.66e-01 3.68e-01
Diseases of programmed cell death 20 7.58e-03 2.01e-02 0.3590 -0.019300 1.13e-01 0.301000 -1.59e-01 8.81e-01 3.81e-01 2.00e-02 2.17e-01
TICAM1, RIP1-mediated IKK complex recruitment 16 3.41e-01 4.25e-01 0.3580 0.023700 -5.57e-02 -0.289000 -2.03e-01 8.70e-01 7.00e-01 4.55e-02 1.59e-01
Interleukin-7 signaling 20 1.63e-01 2.36e-01 0.3580 -0.104000 1.73e-02 -0.258000 -2.25e-01 4.19e-01 8.94e-01 4.58e-02 8.15e-02
PLC beta mediated events 47 8.53e-03 2.19e-02 0.3580 -0.117000 -2.34e-01 -0.225000 -9.47e-02 1.64e-01 5.49e-03 7.58e-03 2.62e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 11 3.09e-01 3.91e-01 0.3570 0.098400 3.34e-01 -0.073500 -3.51e-02 5.72e-01 5.54e-02 6.73e-01 8.40e-01
Calnexin/calreticulin cycle 23 2.65e-02 5.55e-02 0.3570 -0.049000 -2.85e-01 0.186000 9.66e-02 6.84e-01 1.82e-02 1.22e-01 4.23e-01
Activation of kainate receptors upon glutamate binding 23 4.02e-02 7.71e-02 0.3570 0.001540 4.22e-02 0.035100 3.53e-01 9.90e-01 7.26e-01 7.71e-01 3.42e-03
Dual incision in TC-NER 62 8.67e-06 3.94e-05 0.3570 0.140000 1.19e-01 0.302000 -4.91e-02 5.75e-02 1.07e-01 3.90e-05 5.04e-01
HCMV Early Events 53 1.44e-07 7.99e-07 0.3570 0.056100 -8.64e-02 0.221000 -2.61e-01 4.81e-01 2.77e-01 5.43e-03 1.04e-03
Rap1 signalling 15 3.03e-01 3.86e-01 0.3570 -0.097600 -1.49e-03 -0.297000 -1.72e-01 5.13e-01 9.92e-01 4.68e-02 2.48e-01
Membrane binding and targetting of GAG proteins 11 5.12e-01 5.82e-01 0.3560 -0.187000 -2.27e-01 0.183000 8.10e-02 2.82e-01 1.92e-01 2.94e-01 6.42e-01
Synthesis And Processing Of GAG, GAGPOL Polyproteins 11 5.12e-01 5.82e-01 0.3560 -0.187000 -2.27e-01 0.183000 8.10e-02 2.82e-01 1.92e-01 2.94e-01 6.42e-01
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 13 4.89e-01 5.62e-01 0.3550 -0.034000 -8.20e-02 -0.285000 -1.92e-01 8.32e-01 6.09e-01 7.49e-02 2.31e-01
Mitochondrial tRNA aminoacylation 18 2.13e-01 2.91e-01 0.3550 -0.141000 -2.15e-01 0.221000 1.05e-01 3.01e-01 1.15e-01 1.05e-01 4.39e-01
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 31 1.08e-02 2.67e-02 0.3540 -0.044900 -2.36e-01 0.220000 1.39e-01 6.66e-01 2.33e-02 3.40e-02 1.79e-01
Triglyceride metabolism 23 6.29e-02 1.11e-01 0.3540 -0.053300 6.87e-02 -0.143000 -3.12e-01 6.58e-01 5.69e-01 2.34e-01 9.70e-03
Response of EIF2AK1 (HRI) to heme deficiency 14 8.72e-02 1.43e-01 0.3540 0.107000 1.66e-01 0.212000 -2.03e-01 4.89e-01 2.82e-01 1.70e-01 1.89e-01
Cell recruitment (pro-inflammatory response) 19 9.90e-02 1.58e-01 0.3540 -0.055200 1.81e-01 0.113000 2.76e-01 6.77e-01 1.71e-01 3.94e-01 3.72e-02
Purinergic signaling in leishmaniasis infection 19 9.90e-02 1.58e-01 0.3540 -0.055200 1.81e-01 0.113000 2.76e-01 6.77e-01 1.71e-01 3.94e-01 3.72e-02
Signaling by EGFR 45 4.37e-02 8.25e-02 0.3530 -0.151000 -1.74e-01 -0.178000 -2.00e-01 7.94e-02 4.39e-02 3.86e-02 2.04e-02
DAP12 interactions 28 9.88e-02 1.58e-01 0.3530 0.184000 2.90e-01 -0.034200 7.25e-02 9.21e-02 7.86e-03 7.54e-01 5.07e-01
APC/C:Cdc20 mediated degradation of Cyclin B 22 9.84e-03 2.46e-02 0.3530 0.187000 -2.93e-02 0.291000 -6.25e-02 1.29e-01 8.12e-01 1.81e-02 6.12e-01
Mitochondrial protein import 59 5.12e-05 2.08e-04 0.3530 0.026400 6.02e-02 0.345000 3.14e-02 7.26e-01 4.24e-01 4.56e-06 6.77e-01
IRS-mediated signalling 33 3.40e-02 6.73e-02 0.3520 -0.011400 -1.93e-01 -0.149000 -2.53e-01 9.10e-01 5.48e-02 1.38e-01 1.19e-02
Transport of bile salts and organic acids, metal ions and amine compounds 49 1.04e-02 2.57e-02 0.3520 0.295000 1.86e-01 -0.014700 4.49e-02 3.57e-04 2.45e-02 8.59e-01 5.87e-01
Synthesis of very long-chain fatty acyl-CoAs 13 3.80e-01 4.65e-01 0.3520 -0.081500 -1.29e-01 -0.075800 -3.08e-01 6.11e-01 4.19e-01 6.36e-01 5.49e-02
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 68 2.34e-04 8.72e-04 0.3510 -0.108000 -1.96e-01 0.176000 2.05e-01 1.22e-01 5.31e-03 1.20e-02 3.42e-03
Chondroitin sulfate biosynthesis 15 8.29e-02 1.38e-01 0.3510 -0.146000 1.61e-01 0.061000 2.69e-01 3.29e-01 2.80e-01 6.83e-01 7.16e-02
Arachidonic acid metabolism 36 1.77e-02 3.99e-02 0.3500 0.142000 2.47e-01 -0.031600 2.01e-01 1.41e-01 1.02e-02 7.43e-01 3.70e-02
TNFR1-induced NFkappaB signaling pathway 24 5.34e-02 9.73e-02 0.3500 0.014200 1.78e-01 -0.193000 -2.31e-01 9.04e-01 1.31e-01 1.01e-01 5.05e-02
RHO GTPases Activate NADPH Oxidases 19 2.49e-01 3.29e-01 0.3500 0.186000 2.85e-01 -0.071700 4.36e-02 1.61e-01 3.18e-02 5.88e-01 7.42e-01
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 32 6.38e-02 1.12e-01 0.3500 0.240000 2.07e-01 -0.148000 -2.15e-02 1.91e-02 4.32e-02 1.48e-01 8.33e-01
Regulation of TP53 Activity through Phosphorylation 86 2.45e-11 2.79e-10 0.3500 0.108000 2.93e-02 0.216000 -2.52e-01 8.50e-02 6.39e-01 5.44e-04 5.64e-05
Stimuli-sensing channels 51 1.59e-02 3.67e-02 0.3490 -0.248000 -1.82e-01 -0.147000 -7.12e-02 2.20e-03 2.46e-02 6.89e-02 3.79e-01
Synthesis of PA 24 2.57e-01 3.38e-01 0.3480 -0.184000 -1.83e-01 -0.117000 -2.01e-01 1.19e-01 1.22e-01 3.21e-01 8.84e-02
Signaling by PDGF 47 3.94e-03 1.14e-02 0.3480 -0.191000 -1.05e-01 -0.266000 -5.60e-02 2.36e-02 2.12e-01 1.64e-03 5.07e-01
Regulation of mRNA stability by proteins that bind AU-rich elements 80 9.95e-06 4.49e-05 0.3480 0.105000 1.30e-01 0.303000 3.43e-02 1.04e-01 4.53e-02 2.82e-06 5.96e-01
Sialic acid metabolism 25 8.39e-02 1.39e-01 0.3480 -0.117000 -2.07e-01 0.232000 1.03e-01 3.12e-01 7.38e-02 4.46e-02 3.75e-01
Incretin synthesis, secretion, and inactivation 10 2.14e-01 2.92e-01 0.3470 -0.000790 1.55e-01 -0.130000 2.82e-01 9.97e-01 3.97e-01 4.76e-01 1.23e-01
RHO GTPases activate KTN1 10 2.33e-01 3.13e-01 0.3460 -0.126000 5.88e-03 -0.082400 3.12e-01 4.92e-01 9.74e-01 6.52e-01 8.75e-02
Regulation of FOXO transcriptional activity by acetylation 10 2.29e-01 3.09e-01 0.3460 0.043200 -1.12e-03 0.089700 -3.31e-01 8.13e-01 9.95e-01 6.23e-01 6.97e-02
Formation of the cornified envelope 15 3.90e-01 4.76e-01 0.3460 -0.117000 -2.37e-01 -0.207000 -8.40e-02 4.33e-01 1.12e-01 1.66e-01 5.73e-01
AURKA Activation by TPX2 71 2.34e-09 1.84e-08 0.3460 0.044900 1.83e-02 0.270000 -2.10e-01 5.14e-01 7.90e-01 8.61e-05 2.19e-03
Plasma lipoprotein assembly, remodeling, and clearance 47 1.36e-02 3.22e-02 0.3450 -0.074400 3.12e-02 0.246000 2.29e-01 3.78e-01 7.12e-01 3.55e-03 6.76e-03
NF-kB is activated and signals survival 11 5.01e-01 5.75e-01 0.3450 -0.292000 -1.58e-01 0.052800 -7.64e-02 9.33e-02 3.64e-01 7.62e-01 6.61e-01
Transcriptional regulation of granulopoiesis 26 3.52e-02 6.93e-02 0.3450 0.086400 2.49e-01 0.222000 -1.32e-02 4.46e-01 2.81e-02 4.97e-02 9.08e-01
Signaling by Erythropoietin 24 1.82e-01 2.57e-01 0.3450 -0.005220 -1.86e-02 -0.194000 -2.85e-01 9.65e-01 8.75e-01 1.01e-01 1.58e-02
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models 19 1.30e-02 3.11e-02 0.3440 -0.019400 9.59e-02 0.269000 -1.92e-01 8.84e-01 4.70e-01 4.26e-02 1.48e-01
Neurodegenerative Diseases 19 1.30e-02 3.11e-02 0.3440 -0.019400 9.59e-02 0.269000 -1.92e-01 8.84e-01 4.70e-01 4.26e-02 1.48e-01
XBP1(S) activates chaperone genes 47 4.30e-03 1.24e-02 0.3440 -0.129000 -1.87e-01 0.247000 7.75e-02 1.26e-01 2.66e-02 3.46e-03 3.58e-01
Smooth Muscle Contraction 34 8.37e-05 3.30e-04 0.3430 -0.122000 2.45e-01 -0.057800 1.99e-01 2.19e-01 1.34e-02 5.60e-01 4.48e-02
Class B/2 (Secretin family receptors) 42 8.65e-03 2.22e-02 0.3430 -0.160000 -6.66e-02 0.105000 2.76e-01 7.23e-02 4.56e-01 2.40e-01 1.98e-03
NOTCH4 Activation and Transmission of Signal to the Nucleus 11 2.42e-01 3.21e-01 0.3420 0.000467 3.07e-01 0.017500 1.50e-01 9.98e-01 7.76e-02 9.20e-01 3.89e-01
COPII-mediated vesicle transport 58 2.51e-03 7.70e-03 0.3420 -0.156000 -2.23e-01 0.177000 1.07e-01 3.98e-02 3.41e-03 1.97e-02 1.58e-01
Depolymerisation of the Nuclear Lamina 15 4.79e-02 8.91e-02 0.3410 0.019600 1.56e-01 0.205000 -2.23e-01 8.96e-01 2.97e-01 1.69e-01 1.34e-01
SUMOylation of transcription cofactors 39 2.73e-02 5.69e-02 0.3410 0.021100 -8.50e-02 -0.153000 -2.92e-01 8.20e-01 3.58e-01 9.75e-02 1.63e-03
Negative regulation of MET activity 19 3.12e-01 3.93e-01 0.3410 -0.106000 -2.53e-01 -0.138000 -1.48e-01 4.22e-01 5.68e-02 2.99e-01 2.64e-01
ECM proteoglycans 40 1.36e-03 4.46e-03 0.3400 -0.092300 -1.36e-02 -0.327000 3.81e-03 3.13e-01 8.82e-01 3.49e-04 9.67e-01
Transport of inorganic cations/anions and amino acids/oligopeptides 65 5.15e-03 1.44e-02 0.3400 -0.099300 -1.78e-01 -0.227000 -1.49e-01 1.67e-01 1.32e-02 1.53e-03 3.76e-02
tRNA processing in the nucleus 51 1.03e-05 4.61e-05 0.3390 -0.055100 -5.01e-02 0.309000 -1.19e-01 4.96e-01 5.36e-01 1.38e-04 1.40e-01
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 25 1.72e-03 5.50e-03 0.3390 0.114000 -1.47e-01 0.196000 -2.06e-01 3.26e-01 2.03e-01 9.07e-02 7.51e-02
Aberrant regulation of mitotic exit in cancer due to RB1 defects 20 1.33e-02 3.16e-02 0.3390 0.081500 -1.48e-01 0.279000 -9.30e-02 5.28e-01 2.51e-01 3.09e-02 4.72e-01
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 11 6.39e-01 6.90e-01 0.3390 -0.054000 -5.20e-02 -0.249000 -2.17e-01 7.57e-01 7.65e-01 1.53e-01 2.12e-01
Regulation of innate immune responses to cytosolic DNA 11 5.19e-01 5.89e-01 0.3390 0.113000 2.97e-01 0.072100 9.34e-02 5.15e-01 8.84e-02 6.79e-01 5.92e-01
Synthesis of IP3 and IP4 in the cytosol 21 5.43e-02 9.86e-02 0.3390 -0.331000 -5.68e-02 -0.032700 3.38e-02 8.74e-03 6.52e-01 7.96e-01 7.89e-01
Cristae formation 11 2.99e-01 3.82e-01 0.3380 0.187000 3.29e-02 0.279000 -1.12e-02 2.82e-01 8.50e-01 1.09e-01 9.49e-01
SUMOylation of RNA binding proteins 41 8.28e-05 3.27e-04 0.3380 0.002790 -1.44e-01 0.169000 -2.55e-01 9.75e-01 1.10e-01 6.18e-02 4.82e-03
Integration of energy metabolism 85 2.03e-03 6.38e-03 0.3380 -0.178000 -2.24e-01 -0.109000 -1.43e-01 4.68e-03 3.61e-04 8.20e-02 2.31e-02
PI3K Cascade 29 7.08e-02 1.22e-01 0.3380 -0.039500 -2.27e-01 -0.120000 -2.15e-01 7.13e-01 3.43e-02 2.63e-01 4.47e-02
Signaling by FGFR1 in disease 31 4.88e-02 9.04e-02 0.3370 0.036700 -1.64e-01 -0.203000 -2.10e-01 7.24e-01 1.13e-01 5.09e-02 4.27e-02
FOXO-mediated transcription 52 5.24e-03 1.46e-02 0.3370 0.027800 -4.20e-02 -0.138000 -3.03e-01 7.29e-01 6.01e-01 8.47e-02 1.58e-04
Negative regulation of FGFR1 signaling 20 5.64e-02 1.02e-01 0.3370 -0.043900 -3.22e-01 0.043600 -7.60e-02 7.34e-01 1.27e-02 7.36e-01 5.56e-01
Aquaporin-mediated transport 34 4.51e-02 8.47e-02 0.3370 -0.148000 -2.16e-01 0.108000 1.81e-01 1.34e-01 2.92e-02 2.75e-01 6.78e-02
PIWI-interacting RNA (piRNA) biogenesis 16 2.82e-01 3.64e-01 0.3360 -0.003440 6.46e-03 0.320000 1.04e-01 9.81e-01 9.64e-01 2.67e-02 4.73e-01
Regulation of TP53 Activity through Association with Co-factors 12 5.14e-01 5.84e-01 0.3360 -0.113000 -2.73e-01 -0.138000 -8.23e-02 4.99e-01 1.02e-01 4.07e-01 6.22e-01
Netrin-1 signaling 41 2.18e-02 4.74e-02 0.3360 -0.013900 -1.19e-01 -0.284000 -1.33e-01 8.78e-01 1.87e-01 1.65e-03 1.41e-01
Regulation of IFNG signaling 13 2.30e-01 3.09e-01 0.3360 0.190000 9.50e-02 -0.077100 2.48e-01 2.36e-01 5.53e-01 6.31e-01 1.21e-01
Asparagine N-linked glycosylation 247 7.65e-15 1.36e-13 0.3350 -0.113000 -2.14e-01 0.166000 1.62e-01 2.27e-03 7.63e-09 7.68e-06 1.27e-05
Fanconi Anemia Pathway 31 2.05e-03 6.42e-03 0.3350 0.034900 5.92e-02 0.307000 -1.16e-01 7.37e-01 5.68e-01 3.10e-03 2.66e-01
DNA Repair 266 1.70e-24 7.98e-23 0.3350 0.140000 1.25e-01 0.259000 -1.01e-01 9.35e-05 4.89e-04 4.55e-13 4.81e-03
Inflammasomes 19 4.70e-03 1.33e-02 0.3350 -0.150000 2.82e-01 -0.056300 8.26e-02 2.59e-01 3.33e-02 6.71e-01 5.33e-01
Assembly of active LPL and LIPC lipase complexes 11 6.07e-01 6.62e-01 0.3350 -0.272000 -1.82e-01 0.018200 6.92e-02 1.19e-01 2.97e-01 9.17e-01 6.91e-01
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) 11 5.75e-01 6.36e-01 0.3340 0.217000 1.25e-01 -0.135000 -1.76e-01 2.14e-01 4.71e-01 4.39e-01 3.13e-01
Gap junction trafficking 13 5.27e-01 5.95e-01 0.3340 -0.061400 -5.04e-02 0.241000 2.17e-01 7.02e-01 7.53e-01 1.32e-01 1.76e-01
HS-GAG degradation 19 7.95e-02 1.33e-01 0.3340 -0.200000 5.97e-03 0.019500 2.67e-01 1.32e-01 9.64e-01 8.83e-01 4.43e-02
Cleavage of the damaged pyrimidine 16 9.52e-02 1.53e-01 0.3340 0.016400 3.18e-01 0.100000 6.63e-03 9.09e-01 2.78e-02 4.87e-01 9.63e-01
Depyrimidination 16 9.52e-02 1.53e-01 0.3340 0.016400 3.18e-01 0.100000 6.63e-03 9.09e-01 2.78e-02 4.87e-01 9.63e-01
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 16 9.52e-02 1.53e-01 0.3340 0.016400 3.18e-01 0.100000 6.63e-03 9.09e-01 2.78e-02 4.87e-01 9.63e-01
RUNX3 regulates NOTCH signaling 14 4.82e-01 5.56e-01 0.3330 -0.089800 -7.81e-02 -0.278000 -1.41e-01 5.61e-01 6.13e-01 7.20e-02 3.61e-01
Ca2+ pathway 51 3.54e-03 1.04e-02 0.3330 -0.197000 -1.26e-01 -0.237000 -1.66e-02 1.52e-02 1.19e-01 3.43e-03 8.38e-01
Formation of tubulin folding intermediates by CCT/TriC 19 2.44e-02 5.20e-02 0.3320 0.024900 -1.29e-01 0.180000 -2.46e-01 8.51e-01 3.30e-01 1.75e-01 6.33e-02
Purine ribonucleoside monophosphate biosynthesis 12 2.89e-01 3.71e-01 0.3320 0.030000 1.31e-01 0.303000 -9.69e-03 8.57e-01 4.33e-01 6.88e-02 9.54e-01
Signaling by EGFR in Cancer 20 3.92e-01 4.77e-01 0.3310 -0.177000 -1.95e-01 -0.080300 -1.84e-01 1.70e-01 1.31e-01 5.34e-01 1.55e-01
Selective autophagy 52 1.53e-02 3.55e-02 0.3310 -0.195000 -2.47e-01 0.042300 -9.41e-02 1.53e-02 2.06e-03 5.98e-01 2.41e-01
Formation of the Early Elongation Complex 32 2.24e-02 4.86e-02 0.3310 -0.147000 -1.11e-01 0.275000 1.12e-02 1.51e-01 2.78e-01 7.08e-03 9.13e-01
Formation of the HIV-1 Early Elongation Complex 32 2.24e-02 4.86e-02 0.3310 -0.147000 -1.11e-01 0.275000 1.12e-02 1.51e-01 2.78e-01 7.08e-03 9.13e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation 14 4.33e-01 5.13e-01 0.3310 -0.002700 -1.48e-01 -0.253000 -1.53e-01 9.86e-01 3.38e-01 1.01e-01 3.21e-01
TRP channels 12 1.97e-01 2.73e-01 0.3310 0.034000 2.30e-01 -0.159000 1.73e-01 8.38e-01 1.67e-01 3.40e-01 2.99e-01
Glycosphingolipid metabolism 33 2.63e-02 5.51e-02 0.3300 -0.141000 5.52e-02 0.142000 2.57e-01 1.62e-01 5.84e-01 1.59e-01 1.07e-02
Diseases of DNA repair 10 4.24e-01 5.05e-01 0.3300 -0.105000 7.60e-02 0.293000 7.82e-02 5.64e-01 6.77e-01 1.09e-01 6.69e-01
KSRP (KHSRP) binds and destabilizes mRNA 16 4.47e-01 5.24e-01 0.3290 0.259000 1.94e-01 0.034200 -5.02e-02 7.33e-02 1.79e-01 8.13e-01 7.28e-01
Global Genome Nucleotide Excision Repair (GG-NER) 80 8.17e-06 3.72e-05 0.3290 0.159000 8.90e-02 0.274000 -8.15e-03 1.39e-02 1.69e-01 2.35e-05 9.00e-01
Hedgehog 'off' state 90 4.05e-05 1.69e-04 0.3290 0.042400 3.91e-03 0.301000 1.25e-01 4.88e-01 9.49e-01 8.10e-07 4.00e-02
Dopamine Neurotransmitter Release Cycle 13 2.00e-01 2.76e-01 0.3290 0.064600 -5.50e-02 -0.317000 2.06e-02 6.87e-01 7.31e-01 4.78e-02 8.98e-01
Deactivation of the beta-catenin transactivating complex 34 1.33e-01 2.02e-01 0.3290 -0.149000 -1.36e-01 -0.132000 -2.23e-01 1.33e-01 1.70e-01 1.82e-01 2.45e-02
Plasma lipoprotein remodeling 15 3.18e-01 3.99e-01 0.3280 -0.143000 5.41e-02 0.190000 2.20e-01 3.38e-01 7.17e-01 2.03e-01 1.40e-01
NRAGE signals death through JNK 54 5.85e-03 1.61e-02 0.3280 -0.248000 -1.41e-01 -0.162000 -1.57e-02 1.66e-03 7.29e-02 3.91e-02 8.42e-01
Neutrophil degranulation 353 2.25e-15 4.16e-14 0.3280 0.073500 1.34e-01 0.149000 2.49e-01 1.84e-02 1.79e-05 1.70e-06 1.22e-15
SUMO E3 ligases SUMOylate target proteins 143 3.36e-13 4.85e-12 0.3280 0.143000 3.77e-02 0.053200 -2.88e-01 3.25e-03 4.37e-01 2.73e-01 3.02e-09
HIV elongation arrest and recovery 28 3.47e-03 1.02e-02 0.3280 -0.036200 1.48e-02 0.293000 -1.41e-01 7.40e-01 8.92e-01 7.27e-03 1.98e-01
Pausing and recovery of HIV elongation 28 3.47e-03 1.02e-02 0.3280 -0.036200 1.48e-02 0.293000 -1.41e-01 7.40e-01 8.92e-01 7.27e-03 1.98e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 13 4.37e-01 5.15e-01 0.3270 -0.292000 -1.31e-01 -0.011000 6.79e-02 6.84e-02 4.12e-01 9.45e-01 6.72e-01
Defective EXT2 causes exostoses 2 13 4.37e-01 5.15e-01 0.3270 -0.292000 -1.31e-01 -0.011000 6.79e-02 6.84e-02 4.12e-01 9.45e-01 6.72e-01
NOTCH1 Intracellular Domain Regulates Transcription 43 6.60e-02 1.15e-01 0.3270 -0.075700 -1.57e-01 -0.208000 -1.83e-01 3.91e-01 7.54e-02 1.81e-02 3.85e-02
Recruitment of NuMA to mitotic centrosomes 79 2.17e-09 1.73e-08 0.3260 0.011900 -1.94e-02 0.250000 -2.09e-01 8.55e-01 7.66e-01 1.27e-04 1.35e-03
Loss of Nlp from mitotic centrosomes 68 5.14e-08 3.08e-07 0.3260 0.011100 -1.46e-02 0.253000 -2.04e-01 8.74e-01 8.35e-01 3.17e-04 3.58e-03
Loss of proteins required for interphase microtubule organization from the centrosome 68 5.14e-08 3.08e-07 0.3260 0.011100 -1.46e-02 0.253000 -2.04e-01 8.74e-01 8.35e-01 3.17e-04 3.58e-03
Vasopressin regulates renal water homeostasis via Aquaporins 32 5.29e-02 9.65e-02 0.3260 -0.100000 -1.84e-01 0.123000 2.17e-01 3.26e-01 7.17e-02 2.28e-01 3.41e-02
Regulation of TP53 Expression and Degradation 33 2.83e-03 8.57e-03 0.3260 0.116000 -7.20e-02 0.042300 -2.93e-01 2.51e-01 4.74e-01 6.74e-01 3.63e-03
Regulation of KIT signaling 16 2.27e-01 3.07e-01 0.3250 0.120000 1.68e-01 -0.251000 1.39e-02 4.05e-01 2.46e-01 8.21e-02 9.23e-01
G-protein mediated events 48 2.00e-02 4.43e-02 0.3250 -0.109000 -2.13e-01 -0.206000 -7.74e-02 1.91e-01 1.09e-02 1.35e-02 3.54e-01
Erythropoietin activates RAS 13 4.20e-01 5.02e-01 0.3250 0.065400 -3.15e-02 -0.105000 -2.99e-01 6.83e-01 8.44e-01 5.14e-01 6.20e-02
Activation of BAD and translocation to mitochondria 14 6.18e-01 6.72e-01 0.3250 0.224000 2.26e-01 0.035800 5.54e-02 1.47e-01 1.43e-01 8.16e-01 7.20e-01
FCERI mediated NF-kB activation 72 1.78e-04 6.82e-04 0.3240 0.143000 1.12e-01 0.268000 2.02e-02 3.56e-02 1.02e-01 8.59e-05 7.68e-01
mRNA decay by 3' to 5' exoribonuclease 15 5.65e-01 6.28e-01 0.3240 0.127000 1.52e-01 0.215000 1.40e-01 3.95e-01 3.07e-01 1.50e-01 3.48e-01
Killing mechanisms 10 6.57e-01 7.05e-01 0.3240 -0.237000 -1.47e-01 0.098200 1.32e-01 1.94e-01 4.22e-01 5.91e-01 4.70e-01
WNT5:FZD7-mediated leishmania damping 10 6.57e-01 7.05e-01 0.3240 -0.237000 -1.47e-01 0.098200 1.32e-01 1.94e-01 4.22e-01 5.91e-01 4.70e-01
Regulation of localization of FOXO transcription factors 11 3.38e-01 4.22e-01 0.3240 0.126000 1.82e-02 0.011200 -2.98e-01 4.69e-01 9.17e-01 9.49e-01 8.73e-02
Downstream signaling of activated FGFR1 21 1.22e-01 1.88e-01 0.3240 0.045900 -1.96e-01 -0.138000 -2.12e-01 7.16e-01 1.19e-01 2.74e-01 9.24e-02
IL-6-type cytokine receptor ligand interactions 12 2.70e-01 3.51e-01 0.3230 0.245000 7.09e-02 -0.112000 1.64e-01 1.41e-01 6.71e-01 5.01e-01 3.27e-01
Mitochondrial biogenesis 69 1.31e-03 4.33e-03 0.3230 0.010700 -1.31e-01 -0.144000 -2.58e-01 8.78e-01 6.10e-02 3.82e-02 2.14e-04
Reduction of cytosolic Ca++ levels 10 5.63e-01 6.27e-01 0.3230 -0.119000 -1.54e-01 -0.258000 -1.98e-02 5.15e-01 3.99e-01 1.58e-01 9.13e-01
SUMOylation 149 1.28e-13 1.98e-12 0.3230 0.143000 3.51e-02 0.060300 -2.81e-01 2.58e-03 4.61e-01 2.05e-01 3.36e-09
RHO GTPases Activate WASPs and WAVEs 35 4.19e-02 7.97e-02 0.3230 0.208000 1.83e-01 -0.086500 1.42e-01 3.33e-02 6.09e-02 3.76e-01 1.46e-01
Ovarian tumor domain proteases 34 7.26e-02 1.23e-01 0.3230 0.051800 4.72e-02 -0.159000 -2.72e-01 6.01e-01 6.34e-01 1.08e-01 6.07e-03
Aberrant regulation of mitotic cell cycle due to RB1 defects 36 9.47e-04 3.18e-03 0.3220 0.143000 3.56e-02 0.237000 -1.61e-01 1.38e-01 7.12e-01 1.38e-02 9.55e-02
Diseases of mitotic cell cycle 36 9.47e-04 3.18e-03 0.3220 0.143000 3.56e-02 0.237000 -1.61e-01 1.38e-01 7.12e-01 1.38e-02 9.55e-02
Signaling by ERBB2 KD Mutants 21 4.01e-01 4.85e-01 0.3220 -0.203000 -1.52e-01 -0.146000 -1.35e-01 1.07e-01 2.28e-01 2.48e-01 2.84e-01
Gastrin-CREB signalling pathway via PKC and MAPK 16 4.81e-01 5.56e-01 0.3210 -0.199000 -1.08e-01 -0.166000 -1.56e-01 1.67e-01 4.56e-01 2.49e-01 2.81e-01
Adherens junctions interactions 14 5.62e-01 6.27e-01 0.3210 -0.154000 -2.00e-01 -0.187000 -6.61e-02 3.19e-01 1.95e-01 2.26e-01 6.68e-01
Olfactory Signaling Pathway 12 3.68e-01 4.54e-01 0.3210 -0.101000 -2.46e-02 0.302000 3.25e-02 5.46e-01 8.83e-01 7.01e-02 8.46e-01
Binding and Uptake of Ligands by Scavenger Receptors 30 6.02e-02 1.07e-01 0.3200 -0.171000 4.22e-04 0.135000 2.35e-01 1.06e-01 9.97e-01 2.02e-01 2.58e-02
SUMOylation of DNA damage response and repair proteins 66 3.07e-07 1.62e-06 0.3200 0.120000 1.71e-03 0.178000 -2.38e-01 9.35e-02 9.81e-01 1.24e-02 8.49e-04
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 15 9.75e-02 1.56e-01 0.3200 0.062400 1.13e-01 0.161000 -2.44e-01 6.76e-01 4.49e-01 2.80e-01 1.02e-01
Branched-chain amino acid catabolism 21 6.98e-02 1.20e-01 0.3190 0.085900 -2.02e-01 -0.184000 -1.41e-01 4.96e-01 1.10e-01 1.45e-01 2.62e-01
Negative regulation of FGFR3 signaling 19 6.76e-02 1.17e-01 0.3180 -0.006180 -3.02e-01 0.024200 -9.67e-02 9.63e-01 2.26e-02 8.55e-01 4.66e-01
Downstream TCR signaling 78 2.03e-04 7.69e-04 0.3180 0.183000 1.61e-01 0.202000 -2.72e-02 5.15e-03 1.41e-02 2.07e-03 6.78e-01
Glutamate Neurotransmitter Release Cycle 16 4.32e-01 5.13e-01 0.3180 -0.024400 1.01e-02 -0.271000 -1.64e-01 8.66e-01 9.44e-01 6.11e-02 2.55e-01
Maturation of nucleoprotein 10 5.35e-01 6.01e-01 0.3170 0.095800 2.16e-01 -0.038000 2.07e-01 6.00e-01 2.36e-01 8.35e-01 2.56e-01
Ub-specific processing proteases 165 1.20e-09 1.01e-08 0.3170 0.215000 1.46e-01 0.016500 -1.81e-01 2.06e-06 1.25e-03 7.15e-01 6.42e-05
SARS-CoV-1 Infection 41 1.31e-02 3.13e-02 0.3170 -0.043800 -1.34e-01 0.269000 9.00e-02 6.28e-01 1.38e-01 2.89e-03 3.19e-01
TCR signaling 99 2.82e-04 1.03e-03 0.3160 0.195000 2.33e-01 0.081900 -3.01e-02 8.14e-04 6.24e-05 1.60e-01 6.06e-01
WNT5A-dependent internalization of FZD4 15 2.42e-01 3.21e-01 0.3160 -0.264000 -8.46e-02 0.132000 -7.44e-02 7.67e-02 5.71e-01 3.75e-01 6.18e-01
Constitutive Signaling by Overexpressed ERBB2 10 5.55e-01 6.21e-01 0.3160 -0.023800 -7.60e-02 -0.054500 -3.00e-01 8.96e-01 6.77e-01 7.65e-01 1.00e-01
Biosynthesis of DHA-derived SPMs 11 3.60e-01 4.47e-01 0.3150 0.071500 2.22e-01 -0.128000 1.69e-01 6.82e-01 2.02e-01 4.64e-01 3.32e-01
Regulation of PLK1 Activity at G2/M Transition 84 2.51e-09 1.96e-08 0.3150 0.026200 -3.64e-02 0.230000 -2.10e-01 6.78e-01 5.65e-01 2.65e-04 9.02e-04
Processing of Capped Intronless Pre-mRNA 26 1.74e-02 3.95e-02 0.3140 0.136000 3.78e-02 0.107000 -2.59e-01 2.31e-01 7.39e-01 3.44e-01 2.23e-02
Glutathione conjugation 28 3.89e-02 7.49e-02 0.3140 0.181000 -2.77e-02 0.226000 1.18e-01 9.79e-02 8.00e-01 3.86e-02 2.81e-01
PKA-mediated phosphorylation of CREB 18 1.34e-01 2.04e-01 0.3130 -0.052500 -3.09e-01 -0.007790 1.04e-02 7.00e-01 2.34e-02 9.54e-01 9.39e-01
HSP90 chaperone cycle for steroid hormone receptors (SHR) 33 7.48e-02 1.26e-01 0.3130 -0.123000 -1.94e-01 -0.000264 -2.13e-01 2.23e-01 5.37e-02 9.98e-01 3.42e-02
Synthesis of substrates in N-glycan biosythesis 54 9.88e-03 2.47e-02 0.3120 -0.086300 -1.46e-01 0.161000 2.07e-01 2.73e-01 6.34e-02 4.13e-02 8.58e-03
Iron uptake and transport 48 1.78e-02 4.01e-02 0.3110 0.010300 -7.74e-02 0.227000 1.98e-01 9.02e-01 3.54e-01 6.51e-03 1.78e-02
SUMOylation of chromatin organization proteins 49 8.70e-05 3.41e-04 0.3110 0.021700 -1.45e-01 0.123000 -2.44e-01 7.93e-01 7.87e-02 1.36e-01 3.11e-03
Base-Excision Repair, AP Site Formation 18 6.99e-02 1.20e-01 0.3100 -0.029600 2.88e-01 0.107000 3.16e-02 8.28e-01 3.47e-02 4.30e-01 8.17e-01
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 27 7.44e-02 1.25e-01 0.3100 0.092000 1.05e-01 -0.041400 -2.73e-01 4.08e-01 3.44e-01 7.10e-01 1.40e-02
MAPK6/MAPK4 signaling 77 1.48e-04 5.72e-04 0.3100 0.041900 9.85e-02 0.287000 4.54e-02 5.26e-01 1.35e-01 1.36e-05 4.92e-01
ER to Golgi Anterograde Transport 120 1.76e-05 7.64e-05 0.3090 -0.146000 -2.05e-01 0.148000 1.03e-01 5.88e-03 1.09e-04 5.20e-03 5.18e-02
Amine ligand-binding receptors 12 3.64e-01 4.49e-01 0.3090 0.113000 -1.50e-01 -0.155000 -1.91e-01 4.99e-01 3.70e-01 3.54e-01 2.52e-01
Signaling by FGFR4 28 5.87e-02 1.05e-01 0.3090 -0.005530 -2.26e-01 -0.058400 -2.02e-01 9.60e-01 3.88e-02 5.93e-01 6.39e-02
Signaling by Hippo 19 1.85e-01 2.60e-01 0.3090 -0.052000 -2.71e-01 -0.133000 -3.80e-02 6.95e-01 4.08e-02 3.16e-01 7.74e-01
Glucagon signaling in metabolic regulation 25 1.45e-01 2.18e-01 0.3080 -0.071100 -1.37e-01 0.111000 2.43e-01 5.39e-01 2.35e-01 3.36e-01 3.58e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus 18 1.12e-02 2.76e-02 0.3080 -0.203000 2.12e-01 -0.086700 3.32e-02 1.36e-01 1.19e-01 5.24e-01 8.07e-01
Ion transport by P-type ATPases 36 4.22e-02 8.02e-02 0.3070 -0.152000 -1.63e-01 -0.209000 2.65e-02 1.14e-01 9.09e-02 2.97e-02 7.83e-01
DCC mediated attractive signaling 13 3.92e-01 4.77e-01 0.3070 0.136000 1.64e-01 -0.216000 4.65e-02 3.95e-01 3.07e-01 1.77e-01 7.72e-01
Tie2 Signaling 16 4.05e-01 4.88e-01 0.3070 0.045000 -1.29e-01 -0.173000 -2.13e-01 7.55e-01 3.72e-01 2.32e-01 1.40e-01
Downstream signaling events of B Cell Receptor (BCR) 73 3.80e-04 1.36e-03 0.3070 0.153000 1.45e-01 0.221000 -2.49e-02 2.36e-02 3.22e-02 1.12e-03 7.13e-01
Centrosome maturation 80 2.07e-08 1.36e-07 0.3060 0.005620 -5.50e-03 0.228000 -2.04e-01 9.31e-01 9.32e-01 4.21e-04 1.61e-03
Recruitment of mitotic centrosome proteins and complexes 80 2.07e-08 1.36e-07 0.3060 0.005620 -5.50e-03 0.228000 -2.04e-01 9.31e-01 9.32e-01 4.21e-04 1.61e-03
NCAM signaling for neurite out-growth 46 3.36e-02 6.66e-02 0.3060 -0.233000 -1.47e-01 -0.134000 4.59e-03 6.40e-03 8.52e-02 1.16e-01 9.57e-01
NGF-stimulated transcription 34 1.40e-01 2.10e-01 0.3060 -0.160000 -2.49e-01 -0.075600 -7.26e-03 1.07e-01 1.19e-02 4.46e-01 9.42e-01
GRB2 events in EGFR signaling 10 7.64e-01 8.04e-01 0.3060 -0.201000 -2.19e-01 -0.070300 6.26e-03 2.71e-01 2.30e-01 7.00e-01 9.73e-01
Other interleukin signaling 19 2.70e-01 3.51e-01 0.3060 0.060800 2.15e-01 0.028900 2.06e-01 6.46e-01 1.05e-01 8.27e-01 1.19e-01
Trafficking of GluR2-containing AMPA receptors 13 4.76e-01 5.52e-01 0.3050 -0.261000 -1.01e-01 -0.016100 -1.21e-01 1.04e-01 5.30e-01 9.20e-01 4.49e-01
SHC1 events in ERBB2 signaling 19 4.03e-01 4.86e-01 0.3050 -0.207000 -1.23e-01 -0.175000 -6.45e-02 1.18e-01 3.52e-01 1.87e-01 6.26e-01
Spry regulation of FGF signaling 14 4.22e-01 5.03e-01 0.3050 -0.114000 -2.58e-01 0.115000 -8.49e-03 4.62e-01 9.51e-02 4.55e-01 9.56e-01
Antiviral mechanism by IFN-stimulated genes 70 1.54e-05 6.74e-05 0.3040 0.158000 7.93e-02 0.220000 -1.13e-01 2.22e-02 2.52e-01 1.45e-03 1.03e-01
CD28 co-stimulation 32 1.51e-01 2.23e-01 0.3040 0.230000 1.46e-01 -0.111000 -7.74e-02 2.45e-02 1.53e-01 2.76e-01 4.49e-01
Reproduction 55 7.57e-04 2.59e-03 0.3040 0.131000 1.83e-01 0.147000 -1.42e-01 9.19e-02 1.91e-02 5.92e-02 6.97e-02
MTOR signalling 39 8.75e-03 2.23e-02 0.3040 -0.066900 -2.42e-01 0.094900 -1.42e-01 4.70e-01 9.07e-03 3.05e-01 1.24e-01
Transport of Mature Transcript to Cytoplasm 74 7.98e-07 4.06e-06 0.3030 0.086400 7.91e-02 0.151000 -2.36e-01 1.99e-01 2.40e-01 2.52e-02 4.56e-04
Chemokine receptors bind chemokines 26 5.86e-02 1.05e-01 0.3030 0.120000 1.47e-01 -0.113000 2.08e-01 2.89e-01 1.96e-01 3.19e-01 6.65e-02
Cell junction organization 50 4.81e-03 1.36e-02 0.3030 -0.161000 -5.23e-02 -0.250000 -2.92e-02 4.91e-02 5.23e-01 2.28e-03 7.21e-01
Activation of NMDA receptors and postsynaptic events 58 1.90e-02 4.21e-02 0.3020 -0.098800 -1.86e-01 -0.200000 -8.47e-02 1.94e-01 1.45e-02 8.44e-03 2.65e-01
Extracellular matrix organization 218 2.13e-19 5.59e-18 0.3020 -0.200000 -2.60e-02 -0.184000 1.30e-01 4.15e-07 5.09e-01 3.02e-06 1.01e-03
Sealing of the nuclear envelope (NE) by ESCRT-III 22 2.57e-01 3.38e-01 0.3010 -0.138000 -1.18e-01 0.230000 7.17e-02 2.62e-01 3.40e-01 6.23e-02 5.60e-01
Downstream signal transduction 28 2.84e-01 3.66e-01 0.3010 -0.033900 -4.89e-02 -0.217000 -2.00e-01 7.56e-01 6.54e-01 4.73e-02 6.67e-02
The NLRP3 inflammasome 14 1.20e-01 1.86e-01 0.3000 -0.165000 1.88e-01 0.069200 1.50e-01 2.85e-01 2.24e-01 6.54e-01 3.30e-01
Regulation of actin dynamics for phagocytic cup formation 63 1.68e-02 3.84e-02 0.3000 0.138000 2.06e-01 0.033800 1.66e-01 5.93e-02 4.76e-03 6.43e-01 2.32e-02
Chondroitin sulfate/dermatan sulfate metabolism 41 6.35e-03 1.72e-02 0.3000 -0.131000 9.36e-02 0.073800 2.42e-01 1.46e-01 3.00e-01 4.14e-01 7.47e-03
Signaling by FGFR2 in disease 31 4.88e-02 9.04e-02 0.2990 -0.051700 -2.57e-01 0.006100 -1.44e-01 6.18e-01 1.34e-02 9.53e-01 1.66e-01
TNF signaling 37 5.60e-02 1.01e-01 0.2990 0.038100 1.36e-01 -0.218000 -1.48e-01 6.88e-01 1.54e-01 2.17e-02 1.20e-01
Signaling by KIT in disease 20 3.91e-01 4.76e-01 0.2980 0.109000 5.35e-02 -0.221000 -1.60e-01 3.97e-01 6.79e-01 8.76e-02 2.17e-01
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants 20 3.91e-01 4.76e-01 0.2980 0.109000 5.35e-02 -0.221000 -1.60e-01 3.97e-01 6.79e-01 8.76e-02 2.17e-01
FCGR3A-mediated IL10 synthesis 39 1.25e-01 1.92e-01 0.2980 0.013100 8.09e-02 0.167000 2.33e-01 8.87e-01 3.82e-01 7.14e-02 1.19e-02
Gap junction trafficking and regulation 15 5.28e-01 5.95e-01 0.2970 -0.038700 -8.70e-02 0.203000 1.95e-01 7.95e-01 5.60e-01 1.73e-01 1.91e-01
Peptide ligand-binding receptors 62 3.99e-04 1.41e-03 0.2970 0.021700 1.40e-01 -0.023200 2.60e-01 7.68e-01 5.61e-02 7.53e-01 4.05e-04
Regulated proteolysis of p75NTR 11 6.77e-01 7.23e-01 0.2970 -0.131000 -1.73e-01 0.126000 1.58e-01 4.51e-01 3.21e-01 4.70e-01 3.63e-01
Regulation of TP53 Activity through Acetylation 29 1.29e-02 3.10e-02 0.2970 -0.033400 1.20e-02 0.091000 -2.80e-01 7.56e-01 9.11e-01 3.96e-01 9.07e-03
Molecules associated with elastic fibres 27 5.37e-02 9.77e-02 0.2970 -0.002580 -3.40e-02 -0.294000 1.16e-02 9.82e-01 7.60e-01 8.13e-03 9.17e-01
Elastic fibre formation 37 1.24e-02 3.01e-02 0.2960 -0.112000 -8.42e-02 -0.254000 5.77e-02 2.37e-01 3.76e-01 7.43e-03 5.44e-01
HIV Infection 204 1.18e-13 1.87e-12 0.2950 0.067600 3.55e-02 0.285000 -1.02e-02 9.72e-02 3.84e-01 2.64e-12 8.03e-01
RNA Polymerase III Chain Elongation 18 5.36e-01 6.03e-01 0.2950 0.010600 6.16e-02 0.201000 2.07e-01 9.38e-01 6.51e-01 1.41e-01 1.29e-01
Nucleotide Excision Repair 105 1.19e-06 5.91e-06 0.2950 0.125000 8.19e-02 0.252000 -3.26e-02 2.69e-02 1.48e-01 8.52e-06 5.65e-01
Deubiquitination 238 7.27e-13 9.93e-12 0.2950 0.184000 1.15e-01 0.002960 -1.99e-01 1.11e-06 2.24e-03 9.37e-01 1.36e-07
Interconversion of nucleotide di- and triphosphates 24 1.89e-01 2.65e-01 0.2950 0.073700 2.90e-02 0.275000 6.92e-02 5.32e-01 8.06e-01 1.97e-02 5.57e-01
Signaling by ERBB2 in Cancer 22 4.86e-01 5.60e-01 0.2940 -0.167000 -1.36e-01 -0.150000 -1.31e-01 1.74e-01 2.69e-01 2.23e-01 2.86e-01
HCMV Infection 73 2.18e-06 1.06e-05 0.2940 0.045400 -8.78e-02 0.265000 -7.83e-02 5.02e-01 1.95e-01 8.97e-05 2.48e-01
Costimulation by the CD28 family 55 4.00e-02 7.68e-02 0.2940 0.214000 1.68e-01 -0.080900 -7.42e-02 5.98e-03 3.11e-02 3.00e-01 3.42e-01
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 20 5.06e-02 9.28e-02 0.2930 0.079400 -1.29e-01 0.240000 -7.17e-02 5.39e-01 3.19e-01 6.28e-02 5.79e-01
Insulin receptor recycling 19 4.38e-01 5.15e-01 0.2920 -0.112000 -6.36e-02 0.154000 2.12e-01 3.98e-01 6.31e-01 2.44e-01 1.09e-01
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 18 4.22e-01 5.03e-01 0.2920 0.093800 1.05e-01 0.247000 6.95e-02 4.91e-01 4.43e-01 6.99e-02 6.10e-01
Ion channel transport 103 8.87e-04 2.99e-03 0.2920 -0.208000 -1.72e-01 -0.110000 4.21e-03 2.63e-04 2.62e-03 5.35e-02 9.41e-01
PRC2 methylates histones and DNA 14 3.38e-01 4.22e-01 0.2920 0.257000 4.37e-02 0.002720 -1.30e-01 9.54e-02 7.77e-01 9.86e-01 4.00e-01
Regulation of insulin secretion 58 5.28e-02 9.65e-02 0.2910 -0.160000 -1.74e-01 -0.156000 -7.05e-02 3.56e-02 2.20e-02 4.07e-02 3.54e-01
Insulin receptor signalling cascade 38 7.42e-02 1.25e-01 0.2910 -0.003040 -1.57e-01 -0.116000 -2.16e-01 9.74e-01 9.33e-02 2.18e-01 2.11e-02
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 11 4.17e-01 5.00e-01 0.2900 -0.005910 2.00e-02 0.287000 -3.62e-02 9.73e-01 9.09e-01 9.98e-02 8.35e-01
Frs2-mediated activation 11 4.19e-01 5.01e-01 0.2890 0.005880 -2.58e-01 -0.031700 -1.27e-01 9.73e-01 1.38e-01 8.56e-01 4.67e-01
MET activates RAP1 and RAC1 11 3.07e-01 3.89e-01 0.2890 0.116000 -1.28e-01 0.056800 2.24e-01 5.07e-01 4.63e-01 7.45e-01 1.98e-01
Interleukin-17 signaling 63 9.75e-03 2.45e-02 0.2890 -0.049000 -2.12e-01 -0.111000 -1.54e-01 5.02e-01 3.67e-03 1.29e-01 3.46e-02
RHO GTPases activate PAKs 21 1.00e-01 1.60e-01 0.2880 0.027000 2.32e-01 -0.160000 5.27e-02 8.31e-01 6.60e-02 2.04e-01 6.76e-01
Protein-protein interactions at synapses 55 9.96e-04 3.31e-03 0.2880 -0.123000 -1.35e-01 -0.183000 1.26e-01 1.14e-01 8.45e-02 1.89e-02 1.06e-01
G-protein beta:gamma signalling 27 7.53e-02 1.27e-01 0.2870 0.035400 1.03e-01 -0.031300 2.64e-01 7.50e-01 3.53e-01 7.78e-01 1.78e-02
Oncogene Induced Senescence 29 3.34e-02 6.66e-02 0.2860 -0.047300 4.63e-02 0.009180 -2.79e-01 6.60e-01 6.66e-01 9.32e-01 9.46e-03
Inactivation, recovery and regulation of the phototransduction cascade 19 5.72e-01 6.33e-01 0.2860 -0.180000 -1.62e-01 -0.136000 -6.72e-02 1.74e-01 2.22e-01 3.04e-01 6.12e-01
The phototransduction cascade 19 5.72e-01 6.33e-01 0.2860 -0.180000 -1.62e-01 -0.136000 -6.72e-02 1.74e-01 2.22e-01 3.04e-01 6.12e-01
Transcriptional regulation by RUNX2 106 6.61e-04 2.27e-03 0.2860 0.110000 5.89e-02 0.224000 1.26e-01 5.17e-02 2.95e-01 6.92e-05 2.48e-02
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 38 1.06e-01 1.67e-01 0.2860 -0.004990 -1.35e-01 -0.124000 -2.19e-01 9.58e-01 1.50e-01 1.87e-01 1.96e-02
Transcriptional Regulation by MECP2 46 1.31e-01 2.00e-01 0.2850 -0.069600 -1.44e-01 -0.162000 -1.72e-01 4.15e-01 9.13e-02 5.77e-02 4.38e-02
Signaling by FGFR3 29 7.81e-02 1.31e-01 0.2850 0.027300 -1.86e-01 -0.068900 -2.03e-01 7.99e-01 8.37e-02 5.21e-01 5.84e-02
Transport to the Golgi and subsequent modification 145 6.08e-06 2.79e-05 0.2850 -0.117000 -1.94e-01 0.126000 1.18e-01 1.54e-02 5.67e-05 9.07e-03 1.42e-02
Regulation of TP53 Activity 147 6.80e-13 9.39e-12 0.2850 0.057300 -2.05e-02 0.142000 -2.39e-01 2.31e-01 6.69e-01 3.13e-03 5.69e-07
ISG15 antiviral mechanism 62 3.00e-05 1.27e-04 0.2840 0.112000 1.37e-02 0.210000 -1.56e-01 1.29e-01 8.52e-01 4.28e-03 3.44e-02
IRS-related events triggered by IGF1R 36 9.35e-02 1.52e-01 0.2840 -0.000180 -1.68e-01 -0.118000 -1.97e-01 9.99e-01 8.20e-02 2.21e-01 4.14e-02
Inhibition of DNA recombination at telomere 20 2.57e-01 3.38e-01 0.2840 0.063000 1.69e-01 0.219000 2.70e-03 6.26e-01 1.91e-01 8.95e-02 9.83e-01
The role of Nef in HIV-1 replication and disease pathogenesis 25 2.02e-01 2.78e-01 0.2830 0.079700 2.51e-01 0.101000 2.88e-02 4.91e-01 3.01e-02 3.83e-01 8.03e-01
EPH-ephrin mediated repulsion of cells 41 6.70e-02 1.16e-01 0.2820 -0.085200 4.88e-02 0.138000 2.26e-01 3.46e-01 5.89e-01 1.27e-01 1.22e-02
Negative regulation of MAPK pathway 40 5.22e-02 9.55e-02 0.2820 -0.047900 -1.54e-01 -0.028600 -2.30e-01 6.01e-01 9.28e-02 7.55e-01 1.18e-02
Nonhomologous End-Joining (NHEJ) 33 6.11e-02 1.08e-01 0.2810 0.213000 9.42e-02 0.132000 -8.38e-02 3.41e-02 3.49e-01 1.90e-01 4.05e-01
RNA Polymerase III Transcription Termination 23 4.97e-01 5.70e-01 0.2810 0.063900 1.06e-01 0.170000 1.86e-01 5.96e-01 3.81e-01 1.59e-01 1.22e-01
NOD1/2 Signaling Pathway 29 2.83e-01 3.66e-01 0.2810 -0.065600 -3.53e-02 -0.229000 -1.44e-01 5.41e-01 7.42e-01 3.31e-02 1.78e-01
Transport of Mature mRNA derived from an Intron-Containing Transcript 65 5.13e-05 2.08e-04 0.2800 0.082800 9.60e-02 0.153000 -1.98e-01 2.49e-01 1.81e-01 3.34e-02 5.83e-03
mRNA 3'-end processing 52 2.01e-02 4.44e-02 0.2800 0.150000 1.70e-01 0.002940 -1.64e-01 6.19e-02 3.39e-02 9.71e-01 4.05e-02
Tight junction interactions 10 4.77e-01 5.52e-01 0.2800 -0.038900 -1.27e-01 -0.234000 7.71e-02 8.31e-01 4.88e-01 2.00e-01 6.73e-01
SUMOylation of transcription factors 15 6.02e-01 6.59e-01 0.2800 0.079200 -1.77e-02 -0.199000 -1.79e-01 5.96e-01 9.06e-01 1.83e-01 2.29e-01
RAF activation 34 1.32e-01 2.02e-01 0.2790 -0.006150 -1.57e-01 -0.105000 -2.05e-01 9.51e-01 1.14e-01 2.89e-01 3.86e-02
Metabolism of nitric oxide: NOS3 activation and regulation 15 5.48e-01 6.14e-01 0.2780 0.149000 1.55e-01 -0.023500 1.75e-01 3.19e-01 2.99e-01 8.75e-01 2.41e-01
Formation of HIV-1 elongation complex containing HIV-1 Tat 38 1.75e-02 3.95e-02 0.2770 -0.105000 -6.07e-02 0.245000 -4.88e-02 2.62e-01 5.18e-01 9.10e-03 6.03e-01
HIV Transcription Elongation 38 1.75e-02 3.95e-02 0.2770 -0.105000 -6.07e-02 0.245000 -4.88e-02 2.62e-01 5.18e-01 9.10e-03 6.03e-01
Tat-mediated elongation of the HIV-1 transcript 38 1.75e-02 3.95e-02 0.2770 -0.105000 -6.07e-02 0.245000 -4.88e-02 2.62e-01 5.18e-01 9.10e-03 6.03e-01
Signaling by PDGFRA extracellular domain mutants 12 4.55e-01 5.31e-01 0.2770 0.202000 8.09e-03 -0.015700 -1.89e-01 2.27e-01 9.61e-01 9.25e-01 2.58e-01
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 12 4.55e-01 5.31e-01 0.2770 0.202000 8.09e-03 -0.015700 -1.89e-01 2.27e-01 9.61e-01 9.25e-01 2.58e-01
Amino acid transport across the plasma membrane 21 1.90e-01 2.66e-01 0.2760 0.057000 -1.67e-01 -0.076300 -1.99e-01 6.52e-01 1.85e-01 5.45e-01 1.15e-01
Late Phase of HIV Life Cycle 120 1.24e-08 8.79e-08 0.2760 -0.018000 -9.65e-02 0.247000 -7.57e-02 7.34e-01 6.85e-02 3.10e-06 1.53e-01
Fcgamma receptor (FCGR) dependent phagocytosis 86 3.47e-03 1.02e-02 0.2760 0.091800 2.08e-01 0.040700 1.51e-01 1.42e-01 8.48e-04 5.15e-01 1.58e-02
Receptor Mediated Mitophagy 11 6.78e-01 7.23e-01 0.2750 -0.105000 -2.33e-01 0.035800 -9.62e-02 5.46e-01 1.81e-01 8.37e-01 5.81e-01
Biotin transport and metabolism 11 8.28e-01 8.58e-01 0.2750 -0.112000 -1.42e-01 -0.119000 -1.69e-01 5.20e-01 4.15e-01 4.93e-01 3.33e-01
Formation of TC-NER Pre-Incision Complex 50 2.53e-02 5.35e-02 0.2740 0.041700 -2.96e-02 0.253000 9.25e-02 6.10e-01 7.18e-01 1.97e-03 2.58e-01
TGF-beta receptor signaling activates SMADs 29 2.04e-02 4.47e-02 0.2740 0.063800 -2.36e-01 -0.024500 -1.22e-01 5.52e-01 2.82e-02 8.19e-01 2.55e-01
Downregulation of TGF-beta receptor signaling 24 3.54e-02 6.96e-02 0.2740 0.085800 -2.27e-01 -0.017100 -1.25e-01 4.67e-01 5.39e-02 8.85e-01 2.89e-01
Activated NOTCH1 Transmits Signal to the Nucleus 26 3.47e-02 6.84e-02 0.2730 -0.232000 4.90e-02 -0.129000 -4.68e-02 4.09e-02 6.66e-01 2.57e-01 6.80e-01
Defective B3GALTL causes Peters-plus syndrome (PpS) 29 2.76e-02 5.71e-02 0.2730 -0.143000 3.74e-02 -0.224000 4.96e-02 1.82e-01 7.28e-01 3.70e-02 6.44e-01
ER Quality Control Compartment (ERQC) 18 4.35e-01 5.14e-01 0.2730 -0.098600 -2.12e-01 0.096900 1.03e-01 4.69e-01 1.20e-01 4.77e-01 4.51e-01
Negative regulators of DDX58/IFIH1 signaling 30 1.63e-01 2.36e-01 0.2730 0.126000 1.33e-01 -0.033500 -1.99e-01 2.31e-01 2.09e-01 7.51e-01 5.92e-02
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) 11 3.00e-01 3.83e-01 0.2720 -0.088000 2.13e-01 -0.038500 1.41e-01 6.13e-01 2.22e-01 8.25e-01 4.20e-01
COPI-mediated anterograde transport 77 8.29e-03 2.17e-02 0.2720 -0.118000 -1.63e-01 0.154000 9.87e-02 7.41e-02 1.36e-02 1.99e-02 1.35e-01
Disorders of transmembrane transporters 124 1.53e-06 7.51e-06 0.2710 0.062500 3.86e-02 0.261000 5.34e-03 2.31e-01 4.59e-01 5.29e-07 9.18e-01
MET receptor recycling 10 7.85e-01 8.22e-01 0.2710 -0.049800 -1.42e-01 -0.084100 -2.08e-01 7.85e-01 4.35e-01 6.45e-01 2.54e-01
Respiratory electron transport 97 2.69e-03 8.20e-03 0.2710 0.128000 1.85e-01 0.149000 2.29e-02 3.02e-02 1.71e-03 1.11e-02 6.97e-01
Lysosome Vesicle Biogenesis 30 2.34e-01 3.13e-01 0.2690 0.007810 8.27e-02 0.236000 9.89e-02 9.41e-01 4.33e-01 2.50e-02 3.49e-01
Mitochondrial calcium ion transport 20 2.53e-01 3.34e-01 0.2690 0.038100 -1.01e-01 0.235000 7.58e-02 7.68e-01 4.35e-01 6.94e-02 5.58e-01
Caspase activation via Death Receptors in the presence of ligand 15 1.59e-01 2.33e-01 0.2690 -0.085900 1.35e-01 -0.167000 1.37e-01 5.65e-01 3.65e-01 2.63e-01 3.59e-01
p38MAPK events 12 6.58e-01 7.05e-01 0.2690 0.162000 3.26e-02 -0.179000 -1.14e-01 3.31e-01 8.45e-01 2.82e-01 4.96e-01
Metabolism of steroids 109 9.76e-04 3.25e-03 0.2690 -0.046300 -1.75e-01 -0.160000 -1.18e-01 4.05e-01 1.62e-03 3.93e-03 3.39e-02
SUMOylation of intracellular receptors 25 2.95e-01 3.77e-01 0.2690 0.133000 -3.44e-03 -0.147000 -1.81e-01 2.49e-01 9.76e-01 2.05e-01 1.17e-01
WNT ligand biogenesis and trafficking 13 6.26e-01 6.79e-01 0.2670 -0.005590 -5.94e-02 0.113000 2.34e-01 9.72e-01 7.11e-01 4.80e-01 1.44e-01
TP53 Regulates Transcription of DNA Repair Genes 57 2.33e-04 8.72e-04 0.2670 0.016600 7.43e-02 0.212000 -1.42e-01 8.29e-01 3.32e-01 5.57e-03 6.35e-02
Beta-oxidation of very long chain fatty acids 10 6.37e-01 6.89e-01 0.2670 -0.076400 1.36e-01 0.119000 1.81e-01 6.76e-01 4.55e-01 5.15e-01 3.23e-01
COPI-independent Golgi-to-ER retrograde traffic 30 1.26e-01 1.92e-01 0.2670 -0.070000 -2.27e-01 0.115000 3.95e-02 5.07e-01 3.16e-02 2.77e-01 7.08e-01
MHC class II antigen presentation 90 8.43e-03 2.19e-02 0.2660 0.052000 4.14e-02 0.218000 1.38e-01 3.95e-01 4.98e-01 3.58e-04 2.37e-02
Defective B4GALT7 causes EDS, progeroid type 16 1.64e-01 2.37e-01 0.2660 -0.223000 5.44e-02 -0.134000 1.72e-02 1.23e-01 7.07e-01 3.52e-01 9.05e-01
TP53 Regulates Transcription of Cell Death Genes 36 1.51e-01 2.23e-01 0.2660 0.038300 9.47e-02 -0.214000 -1.20e-01 6.91e-01 3.26e-01 2.65e-02 2.13e-01
Signaling by MET 61 4.43e-02 8.34e-02 0.2650 0.026700 -6.90e-02 -0.200000 -1.57e-01 7.19e-01 3.52e-01 6.82e-03 3.37e-02
MAP kinase activation 60 1.15e-02 2.81e-02 0.2650 -0.020900 -2.07e-01 -0.085800 -1.41e-01 7.80e-01 5.62e-03 2.51e-01 5.95e-02
RNA Polymerase II Transcription Termination 61 1.10e-02 2.70e-02 0.2650 0.142000 1.74e-01 0.058900 -1.28e-01 5.58e-02 1.89e-02 4.27e-01 8.34e-02
Biological oxidations 130 2.62e-04 9.66e-04 0.2650 0.206000 9.58e-02 0.103000 8.84e-02 4.95e-05 6.00e-02 4.27e-02 8.26e-02
Other semaphorin interactions 19 1.43e-01 2.15e-01 0.2650 0.005150 1.06e-01 -0.210000 1.22e-01 9.69e-01 4.22e-01 1.13e-01 3.59e-01
Signaling by NOTCH1 66 4.94e-02 9.09e-02 0.2650 -0.117000 -7.49e-02 -0.186000 -1.27e-01 1.01e-01 2.93e-01 8.91e-03 7.41e-02
ERKs are inactivated 13 7.10e-01 7.52e-01 0.2650 0.034000 6.11e-02 0.232000 1.07e-01 8.32e-01 7.03e-01 1.48e-01 5.03e-01
Signaling by the B Cell Receptor (BCR) 104 1.81e-03 5.76e-03 0.2650 0.178000 1.61e-01 0.106000 -3.23e-02 1.70e-03 4.58e-03 6.26e-02 5.70e-01
Downregulation of ERBB2 signaling 23 4.46e-01 5.23e-01 0.2650 -0.204000 -1.51e-01 -0.034100 6.53e-02 9.03e-02 2.09e-01 7.77e-01 5.88e-01
Interleukin receptor SHC signaling 21 3.13e-01 3.93e-01 0.2650 0.066400 1.42e-01 -0.210000 -3.39e-02 5.98e-01 2.60e-01 9.52e-02 7.88e-01
NOTCH4 Intracellular Domain Regulates Transcription 18 4.65e-01 5.41e-01 0.2650 -0.120000 -4.84e-02 -0.223000 -5.97e-02 3.78e-01 7.22e-01 1.02e-01 6.61e-01
Oxidative Stress Induced Senescence 60 3.40e-02 6.73e-02 0.2640 -0.076200 -1.39e-01 -0.045700 -2.06e-01 3.08e-01 6.19e-02 5.41e-01 5.75e-03
O-glycosylation of TSR domain-containing proteins 30 3.12e-02 6.31e-02 0.2640 -0.152000 2.92e-02 -0.207000 5.45e-02 1.51e-01 7.82e-01 4.96e-02 6.06e-01
DARPP-32 events 21 3.27e-02 6.56e-02 0.2640 0.171000 -1.57e-01 0.118000 -4.02e-02 1.75e-01 2.12e-01 3.49e-01 7.50e-01
IGF1R signaling cascade 37 1.23e-01 1.90e-01 0.2630 0.011600 -1.40e-01 -0.101000 -1.99e-01 9.03e-01 1.40e-01 2.90e-01 3.66e-02
Interleukin-6 family signaling 18 2.61e-01 3.42e-01 0.2630 0.182000 5.69e-02 -0.090000 1.58e-01 1.81e-01 6.76e-01 5.09e-01 2.47e-01
Cell-extracellular matrix interactions 16 1.75e-01 2.49e-01 0.2630 -0.171000 5.44e-02 -0.103000 1.63e-01 2.38e-01 7.06e-01 4.77e-01 2.58e-01
FGFR1 mutant receptor activation 24 2.44e-01 3.23e-01 0.2630 0.035900 -1.56e-01 -0.172000 -1.20e-01 7.61e-01 1.87e-01 1.46e-01 3.11e-01
IKK complex recruitment mediated by RIP1 19 5.28e-01 5.95e-01 0.2630 -0.052700 -5.49e-02 -0.233000 -9.63e-02 6.91e-01 6.79e-01 7.94e-02 4.67e-01
Signaling by NOTCH2 27 9.52e-02 1.53e-01 0.2630 -0.080900 1.16e-01 -0.193000 -1.09e-01 4.67e-01 2.97e-01 8.32e-02 3.26e-01
Platelet degranulation 100 5.45e-05 2.21e-04 0.2620 -0.001070 8.84e-02 0.001700 2.46e-01 9.85e-01 1.27e-01 9.77e-01 2.16e-05
Post-translational protein phosphorylation 70 1.57e-03 5.08e-03 0.2610 -0.160000 -9.60e-02 -0.066200 1.70e-01 2.07e-02 1.65e-01 3.39e-01 1.39e-02
DNA Damage Recognition in GG-NER 35 7.88e-02 1.32e-01 0.2610 0.044000 -2.03e-02 0.254000 3.55e-02 6.53e-01 8.36e-01 9.32e-03 7.16e-01
Heparan sulfate/heparin (HS-GAG) metabolism 39 9.51e-02 1.53e-01 0.2610 -0.167000 -3.07e-02 0.086500 1.77e-01 7.06e-02 7.40e-01 3.50e-01 5.54e-02
DNA Double Strand Break Response 38 8.35e-03 2.17e-02 0.2600 0.107000 -6.95e-03 0.195000 -1.35e-01 2.55e-01 9.41e-01 3.80e-02 1.50e-01
Fatty acyl-CoA biosynthesis 23 3.68e-01 4.54e-01 0.2600 -0.128000 -7.02e-03 -0.161000 -1.59e-01 2.90e-01 9.54e-01 1.82e-01 1.86e-01
Anchoring of the basal body to the plasma membrane 92 1.13e-06 5.64e-06 0.2600 -0.006650 -2.19e-02 0.219000 -1.37e-01 9.12e-01 7.17e-01 2.81e-04 2.29e-02
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 103 3.48e-03 1.02e-02 0.2600 0.131000 1.82e-01 0.130000 1.36e-02 2.18e-02 1.43e-03 2.26e-02 8.12e-01
Signaling by RAF1 mutants 34 5.11e-02 9.36e-02 0.2600 0.011700 3.51e-02 -0.256000 2.19e-02 9.06e-01 7.23e-01 9.80e-03 8.26e-01
Chaperone Mediated Autophagy 15 4.81e-01 5.56e-01 0.2590 -0.076300 -1.06e-01 0.224000 2.14e-03 6.09e-01 4.79e-01 1.34e-01 9.89e-01
mRNA Splicing - Major Pathway 167 8.15e-09 5.91e-08 0.2590 0.120000 1.31e-01 0.137000 -1.28e-01 7.66e-03 3.46e-03 2.25e-03 4.30e-03
SLBP independent Processing of Histone Pre-mRNAs 10 6.92e-01 7.35e-01 0.2580 -0.069200 -4.57e-02 0.243000 2.77e-02 7.05e-01 8.02e-01 1.83e-01 8.79e-01
Response of Mtb to phagocytosis 20 2.31e-01 3.11e-01 0.2580 0.084600 5.14e-02 0.042200 -2.35e-01 5.12e-01 6.91e-01 7.44e-01 6.95e-02
Deadenylation-dependent mRNA decay 54 1.77e-02 3.99e-02 0.2580 0.140000 6.88e-02 -0.008040 -2.05e-01 7.64e-02 3.82e-01 9.19e-01 9.19e-03
Kinesins 35 8.00e-02 1.33e-01 0.2570 0.124000 1.22e-01 0.046000 -1.84e-01 2.06e-01 2.13e-01 6.38e-01 5.96e-02
Interleukin-2 family signaling 34 1.28e-01 1.96e-01 0.2570 0.133000 4.80e-02 -0.211000 -3.73e-02 1.79e-01 6.28e-01 3.33e-02 7.07e-01
p75NTR signals via NF-kB 14 6.48e-01 6.98e-01 0.2560 -0.229000 -1.00e-01 0.005220 -5.29e-02 1.37e-01 5.17e-01 9.73e-01 7.32e-01
Processing of Capped Intron-Containing Pre-mRNA 220 6.31e-13 8.80e-12 0.2550 0.105000 9.84e-02 0.145000 -1.53e-01 7.27e-03 1.22e-02 2.29e-04 1.00e-04
GAB1 signalosome 14 6.45e-01 6.96e-01 0.2550 -0.208000 -1.15e-01 -0.057700 7.06e-02 1.78e-01 4.56e-01 7.08e-01 6.47e-01
RHO GTPases activate IQGAPs 10 6.00e-01 6.56e-01 0.2540 0.222000 3.02e-02 0.105000 -5.84e-02 2.24e-01 8.69e-01 5.67e-01 7.49e-01
Chromatin modifying enzymes 185 2.59e-07 1.38e-06 0.2530 -0.019500 -8.04e-02 -0.035000 -2.37e-01 6.48e-01 5.99e-02 4.13e-01 3.04e-08
Chromatin organization 185 2.59e-07 1.38e-06 0.2530 -0.019500 -8.04e-02 -0.035000 -2.37e-01 6.48e-01 5.99e-02 4.13e-01 3.04e-08
HIV Life Cycle 132 1.72e-08 1.16e-07 0.2530 0.009970 -7.34e-02 0.227000 -8.40e-02 8.44e-01 1.46e-01 7.02e-06 9.64e-02
The canonical retinoid cycle in rods (twilight vision) 10 8.58e-01 8.84e-01 0.2530 -0.128000 -7.76e-02 -0.117000 -1.67e-01 4.84e-01 6.71e-01 5.21e-01 3.61e-01
Bile acid and bile salt metabolism 25 1.95e-01 2.72e-01 0.2520 0.039900 -9.88e-02 0.091300 2.10e-01 7.30e-01 3.93e-01 4.30e-01 6.94e-02
TBC/RABGAPs 40 6.23e-02 1.10e-01 0.2520 -0.065700 -1.61e-01 0.052100 -1.75e-01 4.73e-01 7.79e-02 5.69e-01 5.54e-02
Nuclear signaling by ERBB4 25 3.11e-01 3.92e-01 0.2520 -0.074800 -5.15e-02 0.059500 2.28e-01 5.17e-01 6.56e-01 6.07e-01 4.88e-02
CD28 dependent PI3K/Akt signaling 21 4.17e-01 5.00e-01 0.2520 0.146000 4.21e-02 -0.068000 -1.89e-01 2.46e-01 7.38e-01 5.90e-01 1.34e-01
HIV Transcription Initiation 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
RNA Polymerase II HIV Promoter Escape 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
RNA Polymerase II Promoter Escape 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
RNA Polymerase II Transcription Initiation 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
RNA Polymerase II Transcription Initiation And Promoter Clearance 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 45 7.24e-02 1.23e-01 0.2500 -0.028700 -9.83e-02 0.215000 7.37e-02 7.39e-01 2.54e-01 1.25e-02 3.93e-01
Complex I biogenesis 54 9.32e-02 1.52e-01 0.2490 0.061600 1.65e-01 0.158000 7.80e-02 4.34e-01 3.64e-02 4.46e-02 3.22e-01
TNFR1-induced proapoptotic signaling 13 3.79e-01 4.64e-01 0.2490 -0.043500 1.92e-01 -0.140000 -5.88e-02 7.86e-01 2.30e-01 3.82e-01 7.14e-01
Neuronal System 230 5.65e-07 2.91e-06 0.2480 -0.102000 -1.19e-01 -0.188000 -3.87e-02 7.94e-03 1.88e-03 9.28e-07 3.14e-01
Neurexins and neuroligins 35 1.22e-01 1.88e-01 0.2480 -0.137000 -8.34e-02 -0.187000 2.88e-02 1.60e-01 3.94e-01 5.57e-02 7.68e-01
Inositol phosphate metabolism 40 3.33e-01 4.17e-01 0.2480 -0.174000 -1.51e-01 -0.084100 -3.88e-02 5.67e-02 9.97e-02 3.58e-01 6.71e-01
Formation of HIV elongation complex in the absence of HIV Tat 40 2.20e-02 4.78e-02 0.2480 -0.077300 -4.22e-02 0.217000 -8.15e-02 3.98e-01 6.44e-01 1.76e-02 3.73e-01
Regulation of RUNX1 Expression and Activity 17 5.86e-01 6.45e-01 0.2480 -0.061900 1.82e-02 -0.208000 -1.18e-01 6.59e-01 8.96e-01 1.37e-01 4.01e-01
Transmission across Chemical Synapses 158 3.43e-04 1.24e-03 0.2480 -0.081500 -1.21e-01 -0.184000 -7.90e-02 7.80e-02 8.65e-03 6.96e-05 8.75e-02
mRNA Capping 28 3.11e-01 3.92e-01 0.2470 -0.124000 -1.12e-01 0.179000 2.67e-02 2.55e-01 3.03e-01 1.00e-01 8.07e-01
MyD88 cascade initiated on plasma membrane 77 3.36e-02 6.66e-02 0.2470 -0.096000 -2.03e-01 -0.057000 -8.34e-02 1.46e-01 2.05e-03 3.88e-01 2.07e-01
Toll Like Receptor 10 (TLR10) Cascade 77 3.36e-02 6.66e-02 0.2470 -0.096000 -2.03e-01 -0.057000 -8.34e-02 1.46e-01 2.05e-03 3.88e-01 2.07e-01
Toll Like Receptor 5 (TLR5) Cascade 77 3.36e-02 6.66e-02 0.2470 -0.096000 -2.03e-01 -0.057000 -8.34e-02 1.46e-01 2.05e-03 3.88e-01 2.07e-01
AKT phosphorylates targets in the cytosol 14 5.56e-01 6.21e-01 0.2460 -0.031000 -1.64e-01 0.014400 -1.80e-01 8.41e-01 2.88e-01 9.26e-01 2.43e-01
Cell-cell junction organization 26 2.76e-01 3.58e-01 0.2460 -0.060400 -1.28e-01 -0.201000 -1.91e-03 5.94e-01 2.60e-01 7.56e-02 9.87e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 76 1.49e-03 4.84e-03 0.2460 -0.145000 -8.42e-02 -0.070800 1.65e-01 2.87e-02 2.05e-01 2.86e-01 1.31e-02
RNA Pol II CTD phosphorylation and interaction with CE 26 3.75e-01 4.61e-01 0.2450 -0.098700 -6.21e-02 0.204000 7.20e-02 3.84e-01 5.84e-01 7.24e-02 5.25e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 26 3.75e-01 4.61e-01 0.2450 -0.098700 -6.21e-02 0.204000 7.20e-02 3.84e-01 5.84e-01 7.24e-02 5.25e-01
Sema4D induced cell migration and growth-cone collapse 20 1.60e-01 2.33e-01 0.2450 -0.233000 2.66e-02 -0.056800 4.56e-02 7.15e-02 8.37e-01 6.60e-01 7.24e-01
Formation of RNA Pol II elongation complex 53 8.49e-03 2.19e-02 0.2450 -0.081500 -1.09e-01 0.172000 -1.08e-01 3.05e-01 1.68e-01 3.02e-02 1.72e-01
RNA Polymerase II Transcription Elongation 53 8.49e-03 2.19e-02 0.2450 -0.081500 -1.09e-01 0.172000 -1.08e-01 3.05e-01 1.68e-01 3.02e-02 1.72e-01
Macroautophagy 102 1.61e-03 5.18e-03 0.2440 -0.109000 -1.88e-01 0.094100 -5.74e-02 5.66e-02 1.02e-03 1.01e-01 3.18e-01
Interleukin-6 signaling 10 4.56e-01 5.31e-01 0.2430 0.158000 -4.60e-02 -0.132000 1.22e-01 3.88e-01 8.01e-01 4.70e-01 5.05e-01
mRNA decay by 5' to 3' exoribonuclease 15 5.46e-01 6.13e-01 0.2430 0.078100 -4.47e-02 -0.047800 -2.21e-01 6.00e-01 7.64e-01 7.49e-01 1.39e-01
Autophagy 114 3.88e-04 1.39e-03 0.2430 -0.096400 -1.87e-01 0.117000 -3.35e-02 7.58e-02 5.80e-04 3.10e-02 5.38e-01
MET activates RAS signaling 10 8.06e-01 8.39e-01 0.2430 -0.010600 4.38e-03 -0.087100 -2.27e-01 9.54e-01 9.81e-01 6.33e-01 2.15e-01
RIP-mediated NFkB activation via ZBP1 17 5.68e-01 6.30e-01 0.2430 -0.228000 -8.28e-02 0.011900 -1.19e-02 1.04e-01 5.55e-01 9.32e-01 9.32e-01
Interleukin-1 signaling 89 8.35e-03 2.17e-02 0.2420 0.029000 4.41e-02 0.224000 7.48e-02 6.37e-01 4.73e-01 2.69e-04 2.23e-01
Signaling by Hedgehog 119 1.72e-03 5.50e-03 0.2420 -0.006930 -4.19e-02 0.206000 1.20e-01 8.96e-01 4.30e-01 1.09e-04 2.46e-02
Acyl chain remodelling of PC 18 6.66e-01 7.13e-01 0.2420 0.106000 1.08e-01 0.180000 5.73e-02 4.38e-01 4.28e-01 1.87e-01 6.74e-01
Endogenous sterols 17 2.69e-01 3.51e-01 0.2410 -0.065300 -3.93e-02 -0.143000 1.79e-01 6.41e-01 7.79e-01 3.06e-01 2.02e-01
mRNA Splicing - Minor Pathway 48 2.61e-02 5.49e-02 0.2410 -0.021100 -1.82e-02 0.239000 -1.02e-02 8.01e-01 8.27e-01 4.12e-03 9.03e-01
Oncogenic MAPK signaling 71 7.54e-02 1.27e-01 0.2410 -0.095800 -1.31e-01 -0.163000 -7.30e-02 1.63e-01 5.72e-02 1.76e-02 2.88e-01
Anti-inflammatory response favouring Leishmania parasite infection 88 3.87e-03 1.12e-02 0.2410 -0.001120 9.65e-02 0.047700 2.15e-01 9.86e-01 1.18e-01 4.40e-01 4.89e-04
Leishmania parasite growth and survival 88 3.87e-03 1.12e-02 0.2410 -0.001120 9.65e-02 0.047700 2.15e-01 9.86e-01 1.18e-01 4.40e-01 4.89e-04
Signaling by Retinoic Acid 32 3.10e-01 3.92e-01 0.2410 0.090600 -2.09e-02 -0.139000 -1.73e-01 3.76e-01 8.38e-01 1.74e-01 9.02e-02
Repression of WNT target genes 11 5.83e-01 6.43e-01 0.2400 -0.120000 2.57e-02 -0.014300 -2.06e-01 4.92e-01 8.83e-01 9.35e-01 2.37e-01
Synthesis of PIPs at the late endosome membrane 11 7.82e-01 8.21e-01 0.2390 0.088200 5.91e-02 -0.204000 -6.60e-02 6.13e-01 7.34e-01 2.41e-01 7.05e-01
Class I peroxisomal membrane protein import 19 5.26e-01 5.95e-01 0.2390 0.047500 6.80e-03 0.071100 2.23e-01 7.20e-01 9.59e-01 5.92e-01 9.19e-02
BBSome-mediated cargo-targeting to cilium 20 9.15e-02 1.50e-01 0.2390 0.218000 -8.93e-02 -0.000621 4.03e-02 9.15e-02 4.89e-01 9.96e-01 7.55e-01
G alpha (12/13) signalling events 70 1.06e-02 2.62e-02 0.2390 -0.181000 -9.24e-02 -0.088900 8.90e-02 8.95e-03 1.82e-01 1.99e-01 1.99e-01
Innate Immune System 746 2.00e-17 4.31e-16 0.2380 0.065100 1.34e-01 0.081900 1.66e-01 2.81e-03 6.57e-10 1.70e-04 2.26e-14
Diseases of metabolism 174 5.57e-05 2.25e-04 0.2380 -0.167000 -1.03e-01 0.038300 1.29e-01 1.51e-04 1.98e-02 3.84e-01 3.48e-03
Integrin signaling 24 2.85e-01 3.67e-01 0.2380 0.002660 1.42e-02 -0.237000 -8.95e-03 9.82e-01 9.04e-01 4.45e-02 9.40e-01
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 52 2.00e-01 2.76e-01 0.2370 -0.090300 -5.89e-02 -0.172000 -1.24e-01 2.60e-01 4.63e-01 3.24e-02 1.23e-01
Constitutive Signaling by NOTCH1 PEST Domain Mutants 52 2.00e-01 2.76e-01 0.2370 -0.090300 -5.89e-02 -0.172000 -1.24e-01 2.60e-01 4.63e-01 3.24e-02 1.23e-01
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 52 2.00e-01 2.76e-01 0.2370 -0.090300 -5.89e-02 -0.172000 -1.24e-01 2.60e-01 4.63e-01 3.24e-02 1.23e-01
Signaling by NOTCH1 PEST Domain Mutants in Cancer 52 2.00e-01 2.76e-01 0.2370 -0.090300 -5.89e-02 -0.172000 -1.24e-01 2.60e-01 4.63e-01 3.24e-02 1.23e-01
Signaling by NOTCH1 in Cancer 52 2.00e-01 2.76e-01 0.2370 -0.090300 -5.89e-02 -0.172000 -1.24e-01 2.60e-01 4.63e-01 3.24e-02 1.23e-01
Class A/1 (Rhodopsin-like receptors) 112 1.51e-05 6.65e-05 0.2370 0.065900 1.05e-01 -0.116000 1.66e-01 2.29e-01 5.60e-02 3.41e-02 2.49e-03
A tetrasaccharide linker sequence is required for GAG synthesis 20 1.68e-01 2.42e-01 0.2370 -0.207000 4.99e-02 -0.104000 -1.20e-02 1.09e-01 6.99e-01 4.23e-01 9.26e-01
Signalling to ERKs 30 1.60e-01 2.33e-01 0.2370 0.080500 -1.29e-01 -0.119000 -1.37e-01 4.46e-01 2.23e-01 2.59e-01 1.94e-01
MET promotes cell motility 28 1.63e-01 2.36e-01 0.2370 -0.006180 -4.38e-02 -0.231000 2.67e-02 9.55e-01 6.88e-01 3.45e-02 8.07e-01
Activation of GABAB receptors 30 1.02e-01 1.62e-01 0.2370 0.041400 2.21e-02 -0.060000 2.24e-01 6.95e-01 8.34e-01 5.70e-01 3.38e-02
GABA B receptor activation 30 1.02e-01 1.62e-01 0.2370 0.041400 2.21e-02 -0.060000 2.24e-01 6.95e-01 8.34e-01 5.70e-01 3.38e-02
NOTCH3 Activation and Transmission of Signal to the Nucleus 22 7.13e-02 1.22e-01 0.2360 -0.173000 1.34e-01 0.087800 1.65e-02 1.60e-01 2.77e-01 4.76e-01 8.94e-01
Glycosaminoglycan metabolism 93 5.98e-03 1.63e-02 0.2360 -0.107000 3.18e-03 0.102000 1.84e-01 7.38e-02 9.58e-01 8.93e-02 2.19e-03
mRNA Splicing 175 1.98e-07 1.07e-06 0.2360 0.116000 1.19e-01 0.128000 -1.09e-01 8.56e-03 6.62e-03 3.52e-03 1.35e-02
Response to elevated platelet cytosolic Ca2+ 105 6.38e-05 2.55e-04 0.2350 -0.008600 9.23e-02 -0.035000 2.14e-01 8.79e-01 1.03e-01 5.37e-01 1.59e-04
Signaling by FGFR1 36 1.03e-01 1.63e-01 0.2350 0.021200 -1.71e-01 -0.042900 -1.54e-01 8.26e-01 7.63e-02 6.56e-01 1.10e-01
Metabolism of RNA 598 5.00e-19 1.26e-17 0.2350 0.135000 1.32e-01 0.132000 -4.54e-02 2.24e-08 5.27e-08 4.69e-08 6.03e-02
Retrograde transport at the Trans-Golgi-Network 44 2.92e-01 3.75e-01 0.2350 -0.080400 -6.85e-02 -0.178000 -1.10e-01 3.57e-01 4.32e-01 4.06e-02 2.08e-01
eNOS activation 11 6.05e-01 6.61e-01 0.2340 0.114000 5.42e-02 -0.101000 1.69e-01 5.14e-01 7.56e-01 5.62e-01 3.31e-01
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 37 2.40e-02 5.13e-02 0.2340 0.082800 -3.11e-02 0.174000 -1.28e-01 3.84e-01 7.44e-01 6.73e-02 1.77e-01
Infection with Mycobacterium tuberculosis 23 3.30e-01 4.14e-01 0.2340 0.130000 1.05e-01 0.133000 -9.32e-02 2.79e-01 3.83e-01 2.69e-01 4.39e-01
Suppression of phagosomal maturation 11 8.16e-01 8.47e-01 0.2330 -0.077100 -9.46e-02 -0.035700 -1.95e-01 6.58e-01 5.87e-01 8.38e-01 2.63e-01
Signaling by TGF-beta Receptor Complex 67 2.14e-03 6.67e-03 0.2330 0.088800 -1.20e-01 -0.028800 -1.76e-01 2.09e-01 9.04e-02 6.84e-01 1.28e-02
Synthesis of bile acids and bile salts 22 1.74e-01 2.48e-01 0.2320 0.040600 -1.73e-01 0.052900 1.40e-01 7.42e-01 1.60e-01 6.68e-01 2.56e-01
Keratan sulfate/keratin metabolism 25 5.26e-01 5.95e-01 0.2320 -0.162000 -1.37e-01 0.001880 9.38e-02 1.62e-01 2.34e-01 9.87e-01 4.17e-01
Protein ubiquitination 56 1.77e-03 5.65e-03 0.2320 0.081900 -1.01e-01 0.086900 -1.71e-01 2.90e-01 1.90e-01 2.61e-01 2.67e-02
Mitochondrial Fatty Acid Beta-Oxidation 31 3.05e-01 3.87e-01 0.2320 0.093200 2.07e-01 0.021600 -4.23e-02 3.70e-01 4.61e-02 8.35e-01 6.84e-01
Apoptotic cleavage of cellular proteins 32 4.83e-01 5.56e-01 0.2310 -0.057200 -8.48e-02 -0.104000 -1.80e-01 5.75e-01 4.07e-01 3.11e-01 7.85e-02
HS-GAG biosynthesis 22 6.17e-01 6.72e-01 0.2310 -0.150000 -1.02e-01 0.091700 1.09e-01 2.24e-01 4.06e-01 4.57e-01 3.76e-01
Transport of vitamins, nucleosides, and related molecules 29 9.80e-02 1.57e-01 0.2300 -0.032000 1.94e-01 -0.021900 1.19e-01 7.66e-01 7.13e-02 8.38e-01 2.68e-01
Degradation of the extracellular matrix 70 4.26e-03 1.23e-02 0.2300 -0.174000 -4.83e-02 -0.107000 9.43e-02 1.20e-02 4.86e-01 1.21e-01 1.73e-01
SLC transporter disorders 64 4.92e-03 1.38e-02 0.2300 -0.018500 -1.03e-01 0.068500 -1.93e-01 7.98e-01 1.56e-01 3.44e-01 7.62e-03
Paradoxical activation of RAF signaling by kinase inactive BRAF 38 1.38e-01 2.08e-01 0.2300 -0.050400 1.05e-02 -0.221000 -3.30e-02 5.91e-01 9.11e-01 1.82e-02 7.25e-01
Signaling by RAS mutants 38 1.38e-01 2.08e-01 0.2300 -0.050400 1.05e-02 -0.221000 -3.30e-02 5.91e-01 9.11e-01 1.82e-02 7.25e-01
Signaling by moderate kinase activity BRAF mutants 38 1.38e-01 2.08e-01 0.2300 -0.050400 1.05e-02 -0.221000 -3.30e-02 5.91e-01 9.11e-01 1.82e-02 7.25e-01
Signaling downstream of RAS mutants 38 1.38e-01 2.08e-01 0.2300 -0.050400 1.05e-02 -0.221000 -3.30e-02 5.91e-01 9.11e-01 1.82e-02 7.25e-01
Synthesis of glycosylphosphatidylinositol (GPI) 18 5.88e-01 6.46e-01 0.2280 0.009320 -3.41e-02 0.076000 2.12e-01 9.45e-01 8.02e-01 5.77e-01 1.19e-01
Acyl chain remodelling of PE 16 7.41e-01 7.82e-01 0.2270 0.157000 6.89e-02 0.084400 1.22e-01 2.76e-01 6.33e-01 5.59e-01 3.97e-01
Infectious disease 563 2.76e-12 3.48e-11 0.2270 0.105000 8.87e-02 0.166000 7.09e-02 2.49e-05 3.63e-04 2.35e-11 4.42e-03
Glycerophospholipid biosynthesis 95 3.10e-02 6.28e-02 0.2260 -0.157000 -8.68e-02 -0.067400 -1.20e-01 8.48e-03 1.44e-01 2.57e-01 4.38e-02
NRIF signals cell death from the nucleus 14 7.77e-01 8.16e-01 0.2260 0.045700 -1.55e-02 0.135000 1.74e-01 7.67e-01 9.20e-01 3.82e-01 2.59e-01
Platelet Aggregation (Plug Formation) 25 2.95e-01 3.77e-01 0.2260 0.035000 5.10e-02 -0.217000 8.33e-03 7.62e-01 6.59e-01 6.06e-02 9.43e-01
Interleukin-3, Interleukin-5 and GM-CSF signaling 38 2.85e-01 3.67e-01 0.2250 -0.023800 -9.38e-03 -0.208000 -8.34e-02 8.00e-01 9.20e-01 2.68e-02 3.74e-01
Diseases associated with the TLR signaling cascade 22 5.11e-01 5.82e-01 0.2250 -0.178000 -8.68e-02 -0.015500 1.05e-01 1.49e-01 4.81e-01 9.00e-01 3.92e-01
Diseases of Immune System 22 5.11e-01 5.82e-01 0.2250 -0.178000 -8.68e-02 -0.015500 1.05e-01 1.49e-01 4.81e-01 9.00e-01 3.92e-01
Platelet sensitization by LDL 15 5.18e-01 5.88e-01 0.2240 -0.031900 -1.26e-01 0.178000 -4.35e-02 8.31e-01 3.99e-01 2.33e-01 7.71e-01
RHO GTPases activate CIT 19 4.55e-01 5.31e-01 0.2240 0.035400 1.79e-01 -0.057600 -1.17e-01 7.89e-01 1.77e-01 6.64e-01 3.76e-01
Prefoldin mediated transfer of substrate to CCT/TriC 24 1.82e-01 2.57e-01 0.2230 0.108000 2.35e-03 0.160000 -1.12e-01 3.59e-01 9.84e-01 1.75e-01 3.42e-01
RAB geranylgeranylation 46 4.73e-02 8.81e-02 0.2230 0.151000 2.65e-02 -0.025200 1.61e-01 7.69e-02 7.56e-01 7.68e-01 5.97e-02
RUNX2 regulates osteoblast differentiation 22 3.98e-01 4.82e-01 0.2230 -0.054400 -2.51e-02 0.005680 2.15e-01 6.59e-01 8.39e-01 9.63e-01 8.16e-02
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 47 3.29e-02 6.59e-02 0.2230 -0.103000 7.67e-02 -0.165000 -7.65e-02 2.20e-01 3.63e-01 5.11e-02 3.64e-01
Apoptotic execution phase 40 3.49e-01 4.35e-01 0.2220 -0.010800 -5.88e-02 -0.102000 -1.88e-01 9.06e-01 5.20e-01 2.67e-01 3.96e-02
RNA Polymerase II Pre-transcription Events 75 2.37e-03 7.33e-03 0.2220 -0.041500 -1.18e-01 0.163000 -8.45e-02 5.35e-01 7.78e-02 1.49e-02 2.06e-01
RHO GTPase Effectors 219 1.39e-07 7.70e-07 0.2220 0.125000 1.09e-01 0.070000 -1.30e-01 1.55e-03 5.48e-03 7.53e-02 9.75e-04
Platelet homeostasis 69 2.60e-03 7.96e-03 0.2220 -0.140000 -2.05e-02 -0.113000 1.28e-01 4.43e-02 7.69e-01 1.05e-01 6.68e-02
Intraflagellar transport 36 2.68e-01 3.50e-01 0.2220 0.064700 -3.40e-02 0.129000 1.65e-01 5.02e-01 7.24e-01 1.82e-01 8.70e-02
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 31 4.17e-01 5.00e-01 0.2210 -0.169000 -1.17e-01 -0.050000 6.58e-02 1.04e-01 2.61e-01 6.30e-01 5.26e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 26 1.36e-01 2.06e-01 0.2210 0.098200 -1.94e-02 0.144000 -1.34e-01 3.86e-01 8.64e-01 2.03e-01 2.38e-01
RMTs methylate histone arginines 29 1.71e-01 2.45e-01 0.2210 -0.058800 -9.22e-02 0.164000 -1.00e-01 5.84e-01 3.90e-01 1.28e-01 3.51e-01
SHC1 events in ERBB4 signaling 11 8.51e-01 8.78e-01 0.2200 -0.039900 -1.15e-01 -0.172000 -6.22e-02 8.19e-01 5.09e-01 3.23e-01 7.21e-01
Interleukin-15 signaling 14 4.01e-01 4.85e-01 0.2200 0.103000 -1.61e-01 -0.091500 -6.06e-02 5.06e-01 2.98e-01 5.54e-01 6.95e-01
Cell surface interactions at the vascular wall 95 1.16e-03 3.84e-03 0.2190 0.051200 1.59e-01 -0.099300 1.02e-01 3.90e-01 7.44e-03 9.49e-02 8.74e-02
Transcriptional Regulation by TP53 332 1.12e-16 2.23e-15 0.2190 0.046500 3.09e-02 0.108000 -1.82e-01 1.47e-01 3.35e-01 8.12e-04 1.30e-08
Toll Like Receptor 3 (TLR3) Cascade 86 5.60e-02 1.01e-01 0.2190 -0.039300 -1.40e-01 -0.111000 -1.20e-01 5.30e-01 2.46e-02 7.48e-02 5.54e-02
Leishmania infection 162 4.73e-05 1.95e-04 0.2190 0.024100 1.17e-01 0.009910 1.84e-01 5.97e-01 1.07e-02 8.28e-01 5.76e-05
Peroxisomal lipid metabolism 25 6.49e-01 6.99e-01 0.2190 0.169000 1.25e-01 -0.002610 6.01e-02 1.43e-01 2.80e-01 9.82e-01 6.03e-01
RNA Polymerase I Promoter Escape 30 4.95e-01 5.68e-01 0.2190 -0.044100 -7.12e-02 0.151000 1.34e-01 6.76e-01 5.00e-01 1.52e-01 2.05e-01
Signaling by NTRKs 121 9.31e-03 2.36e-02 0.2180 -0.106000 -1.90e-01 -0.015900 2.95e-04 4.37e-02 3.11e-04 7.63e-01 9.96e-01
VxPx cargo-targeting to cilium 18 4.55e-01 5.31e-01 0.2180 -0.018500 -1.69e-01 0.137000 1.10e-03 8.92e-01 2.16e-01 3.13e-01 9.94e-01
Diseases associated with O-glycosylation of proteins 41 2.82e-02 5.81e-02 0.2180 -0.109000 5.43e-02 -0.171000 5.78e-02 2.26e-01 5.48e-01 5.78e-02 5.22e-01
Diseases of glycosylation 107 1.33e-03 4.37e-03 0.2170 -0.150000 -4.02e-02 0.002160 1.52e-01 7.43e-03 4.73e-01 9.69e-01 6.62e-03
MyD88-independent TLR4 cascade 90 7.29e-02 1.23e-01 0.2160 -0.063800 -1.45e-01 -0.106000 -1.01e-01 2.96e-01 1.74e-02 8.17e-02 9.88e-02
TRIF(TICAM1)-mediated TLR4 signaling 90 7.29e-02 1.23e-01 0.2160 -0.063800 -1.45e-01 -0.106000 -1.01e-01 2.96e-01 1.74e-02 8.17e-02 9.88e-02
rRNA modification in the nucleus and cytosol 53 1.72e-01 2.46e-01 0.2160 0.088900 1.24e-01 -0.069600 -1.36e-01 2.63e-01 1.19e-01 3.81e-01 8.72e-02
Pre-NOTCH Expression and Processing 47 2.43e-01 3.22e-01 0.2160 -0.167000 -9.49e-02 -0.002380 -9.87e-02 4.83e-02 2.60e-01 9.77e-01 2.42e-01
RAF-independent MAPK1/3 activation 21 4.18e-01 5.00e-01 0.2150 0.016300 -1.79e-01 -0.084600 -8.31e-02 8.97e-01 1.56e-01 5.02e-01 5.10e-01
Neurotransmitter receptors and postsynaptic signal transmission 118 7.27e-03 1.94e-02 0.2150 -0.064300 -1.14e-01 -0.166000 -3.75e-02 2.29e-01 3.23e-02 1.87e-03 4.82e-01
Myogenesis 23 4.33e-01 5.13e-01 0.2150 -0.011200 -1.78e-01 -0.109000 -5.07e-02 9.26e-01 1.41e-01 3.65e-01 6.74e-01
Keratan sulfate biosynthesis 20 8.01e-01 8.35e-01 0.2150 -0.133000 -1.46e-01 -0.071000 -4.39e-02 3.02e-01 2.59e-01 5.83e-01 7.34e-01
Regulation of signaling by CBL 18 7.44e-01 7.84e-01 0.2150 0.113000 5.05e-02 -0.119000 -1.29e-01 4.08e-01 7.11e-01 3.81e-01 3.45e-01
Caspase activation via extrinsic apoptotic signalling pathway 24 1.32e-01 2.02e-01 0.2140 -0.170000 7.07e-02 -0.070500 8.33e-02 1.49e-01 5.49e-01 5.50e-01 4.80e-01
Signaling by FGFR2 55 9.36e-02 1.52e-01 0.2140 -0.052700 -1.76e-01 0.011100 -1.09e-01 5.00e-01 2.39e-02 8.87e-01 1.63e-01
Signaling by NTRK2 (TRKB) 22 5.67e-01 6.29e-01 0.2130 -0.022800 -1.29e-01 -0.160000 -5.08e-02 8.54e-01 2.94e-01 1.94e-01 6.80e-01
Intra-Golgi traffic 40 3.63e-01 4.49e-01 0.2130 -0.145000 -1.24e-01 0.009340 9.32e-02 1.13e-01 1.74e-01 9.19e-01 3.08e-01
Senescence-Associated Secretory Phenotype (SASP) 44 4.17e-02 7.96e-02 0.2130 -0.008640 -4.62e-03 0.198000 -7.74e-02 9.21e-01 9.58e-01 2.33e-02 3.75e-01
Nuclear Receptor transcription pathway 41 3.87e-01 4.73e-01 0.2120 -0.007720 -8.07e-02 -0.162000 -1.11e-01 9.32e-01 3.71e-01 7.24e-02 2.21e-01
Interleukin-20 family signaling 15 5.86e-01 6.45e-01 0.2120 -0.049500 -6.98e-03 -0.023100 2.05e-01 7.40e-01 9.63e-01 8.77e-01 1.69e-01
Sphingolipid metabolism 65 4.92e-02 9.09e-02 0.2120 -0.099500 -2.07e-02 0.035800 1.83e-01 1.66e-01 7.73e-01 6.18e-01 1.09e-02
Unfolded Protein Response (UPR) 84 6.65e-03 1.80e-02 0.2120 0.013500 -8.21e-02 0.192000 3.73e-02 8.31e-01 1.94e-01 2.43e-03 5.55e-01
Protein localization 144 2.29e-03 7.10e-03 0.2110 0.073600 7.63e-02 0.178000 4.16e-02 1.28e-01 1.15e-01 2.31e-04 3.89e-01
Nicotinate metabolism 24 3.76e-01 4.61e-01 0.2110 0.051400 1.49e-01 -0.127000 6.05e-02 6.63e-01 2.08e-01 2.82e-01 6.08e-01
GPCR ligand binding 157 1.05e-06 5.24e-06 0.2110 -0.012500 5.31e-02 -0.067900 1.92e-01 7.87e-01 2.52e-01 1.43e-01 3.43e-05
TRAF6 mediated NF-kB activation 21 4.04e-01 4.87e-01 0.2110 -0.166000 1.11e-02 -0.068200 -1.10e-01 1.88e-01 9.30e-01 5.89e-01 3.84e-01
Potassium Channels 49 2.50e-02 5.31e-02 0.2110 -0.083300 -1.02e-02 -0.164000 1.02e-01 3.14e-01 9.02e-01 4.72e-02 2.16e-01
MAP2K and MAPK activation 33 1.40e-01 2.10e-01 0.2110 -0.003330 1.38e-01 -0.157000 2.30e-02 9.74e-01 1.70e-01 1.18e-01 8.20e-01
Defective B3GAT3 causes JDSSDHD 16 3.99e-01 4.83e-01 0.2110 -0.191000 3.86e-02 -0.080400 -2.92e-03 1.87e-01 7.89e-01 5.78e-01 9.84e-01
N-glycan antennae elongation in the medial/trans-Golgi 20 4.35e-01 5.14e-01 0.2100 0.035900 -8.03e-02 0.039500 1.87e-01 7.81e-01 5.34e-01 7.60e-01 1.48e-01
Cellular Senescence 118 2.45e-04 9.08e-04 0.2100 -0.043100 -7.11e-02 0.053400 -1.85e-01 4.20e-01 1.83e-01 3.17e-01 5.16e-04
ZBP1(DAI) mediated induction of type I IFNs 20 5.64e-01 6.27e-01 0.2100 -0.200000 -5.05e-02 -0.034900 -2.17e-02 1.23e-01 6.96e-01 7.87e-01 8.67e-01
Signaling by BRAF and RAF fusions 55 1.09e-01 1.71e-01 0.2090 -0.094600 -8.97e-02 -0.163000 1.28e-02 2.25e-01 2.50e-01 3.62e-02 8.70e-01
G alpha (q) signalling events 120 6.88e-05 2.74e-04 0.2090 -0.057400 3.33e-02 -0.196000 2.99e-02 2.79e-01 5.30e-01 2.10e-04 5.72e-01
Peptide hormone metabolism 48 1.09e-01 1.71e-01 0.2090 -0.113000 -9.23e-02 -0.134000 6.75e-02 1.74e-01 2.69e-01 1.10e-01 4.19e-01
Nuclear Events (kinase and transcription factor activation) 56 1.90e-01 2.66e-01 0.2090 -0.090300 -1.87e-01 -0.024800 -8.09e-03 2.43e-01 1.57e-02 7.49e-01 9.17e-01
GABA receptor activation 35 8.04e-02 1.34e-01 0.2090 0.044700 -3.88e-02 -0.072400 1.87e-01 6.48e-01 6.92e-01 4.59e-01 5.62e-02
EPH-Ephrin signaling 81 1.25e-02 3.01e-02 0.2080 -0.011500 1.23e-01 0.020500 1.66e-01 8.59e-01 5.59e-02 7.50e-01 9.84e-03
FGFR2 alternative splicing 23 4.34e-01 5.14e-01 0.2080 -0.086100 -9.16e-02 0.157000 -5.34e-02 4.75e-01 4.47e-01 1.93e-01 6.58e-01
RHO GTPases activate PKNs 32 3.14e-01 3.95e-01 0.2080 -0.021600 9.05e-02 -0.160000 -9.36e-02 8.33e-01 3.76e-01 1.16e-01 3.59e-01
Role of LAT2/NTAL/LAB on calcium mobilization 14 8.41e-01 8.68e-01 0.2060 0.160000 1.09e-01 0.001100 -7.03e-02 2.99e-01 4.79e-01 9.94e-01 6.49e-01
Cargo trafficking to the periciliary membrane 45 3.24e-02 6.51e-02 0.2060 0.112000 -9.49e-02 0.131000 6.06e-02 1.92e-01 2.71e-01 1.28e-01 4.82e-01
Negative epigenetic regulation of rRNA expression 48 3.04e-01 3.87e-01 0.2060 0.093000 6.73e-02 0.161000 5.61e-02 2.65e-01 4.20e-01 5.33e-02 5.02e-01
Signaling by high-kinase activity BRAF mutants 29 2.91e-01 3.74e-01 0.2060 0.029400 1.23e-01 -0.162000 1.61e-02 7.84e-01 2.52e-01 1.32e-01 8.81e-01
Signaling by FGFR in disease 50 1.59e-01 2.33e-01 0.2040 -0.018000 -1.63e-01 -0.051200 -1.11e-01 8.26e-01 4.69e-02 5.31e-01 1.76e-01
Transcription of the HIV genome 64 1.22e-02 2.95e-02 0.2040 -0.022200 -7.84e-02 0.169000 -7.94e-02 7.59e-01 2.78e-01 1.94e-02 2.73e-01
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 26 1.87e-01 2.63e-01 0.2030 -0.053300 1.12e-01 0.006700 -1.61e-01 6.38e-01 3.21e-01 9.53e-01 1.56e-01
Sema4D in semaphorin signaling 24 2.33e-01 3.13e-01 0.2030 -0.148000 7.83e-02 0.025100 1.13e-01 2.10e-01 5.07e-01 8.32e-01 3.40e-01
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 84 9.97e-02 1.59e-01 0.2030 -0.089300 -1.72e-01 -0.020500 -5.52e-02 1.58e-01 6.41e-03 7.45e-01 3.82e-01
RNA polymerase II transcribes snRNA genes 70 1.53e-02 3.55e-02 0.2020 -0.054200 -9.49e-02 0.090400 -1.44e-01 4.33e-01 1.70e-01 1.92e-01 3.69e-02
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 18 5.89e-01 6.47e-01 0.2020 0.031900 1.29e-01 0.151000 -1.78e-02 8.15e-01 3.43e-01 2.66e-01 8.96e-01
Cellular responses to external stimuli 426 1.56e-12 2.01e-11 0.2020 0.070200 4.78e-02 0.183000 -1.17e-02 1.36e-02 9.32e-02 1.17e-10 6.81e-01
Signaling by TGFB family members 84 2.88e-03 8.67e-03 0.2020 0.038400 -1.66e-01 -0.043000 -9.93e-02 5.43e-01 8.50e-03 4.96e-01 1.16e-01
RNA Polymerase I Transcription Termination 30 5.89e-01 6.47e-01 0.2020 -0.056900 -3.56e-02 0.110000 1.55e-01 5.90e-01 7.36e-01 2.98e-01 1.41e-01
Potential therapeutics for SARS 34 5.10e-01 5.82e-01 0.2020 0.135000 1.32e-01 0.025200 -6.57e-02 1.73e-01 1.82e-01 7.99e-01 5.07e-01
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 13 8.87e-01 9.05e-01 0.2000 0.119000 1.44e-01 -0.039100 -6.11e-02 4.59e-01 3.69e-01 8.07e-01 7.03e-01
Rho GTPase cycle 128 3.33e-04 1.21e-03 0.2000 -0.135000 7.82e-03 -0.144000 -3.04e-02 8.45e-03 8.79e-01 4.97e-03 5.54e-01
Neurotransmitter release cycle 27 4.36e-01 5.14e-01 0.2000 -0.019700 -1.03e-01 -0.170000 -9.57e-03 8.59e-01 3.53e-01 1.27e-01 9.31e-01
Synthesis of PIPs at the Golgi membrane 15 8.38e-01 8.67e-01 0.1980 -0.026600 -2.35e-02 -0.080400 -1.77e-01 8.58e-01 8.75e-01 5.90e-01 2.35e-01
SUMOylation of DNA methylation proteins 16 7.77e-01 8.16e-01 0.1970 -0.062900 -1.51e-01 -0.110000 -9.25e-03 6.63e-01 2.97e-01 4.45e-01 9.49e-01
HDACs deacetylate histones 30 2.16e-01 2.94e-01 0.1970 0.105000 5.61e-03 0.080000 -1.46e-01 3.19e-01 9.58e-01 4.49e-01 1.66e-01
Cellular responses to stress 422 1.24e-11 1.47e-10 0.1970 0.067200 4.38e-02 0.179000 -7.97e-03 1.86e-02 1.25e-01 3.36e-10 7.80e-01
RA biosynthesis pathway 13 7.08e-01 7.50e-01 0.1960 0.191000 1.67e-02 0.016100 -3.44e-02 2.32e-01 9.17e-01 9.20e-01 8.30e-01
Semaphorin interactions 63 4.56e-03 1.30e-02 0.1950 -0.083400 9.26e-02 -0.111000 1.02e-01 2.53e-01 2.04e-01 1.29e-01 1.62e-01
Interaction between L1 and Ankyrins 21 6.90e-01 7.34e-01 0.1950 -0.167000 -7.97e-02 -0.051800 3.39e-02 1.84e-01 5.27e-01 6.81e-01 7.88e-01
MAPK targets/ Nuclear events mediated by MAP kinases 31 1.76e-01 2.50e-01 0.1950 0.052300 -1.63e-01 -0.025900 -8.91e-02 6.14e-01 1.16e-01 8.03e-01 3.91e-01
Transcriptional Regulation by VENTX 35 4.97e-01 5.70e-01 0.1950 -0.129000 -1.15e-01 0.084400 -2.88e-02 1.87e-01 2.38e-01 3.88e-01 7.68e-01
Metabolism of fat-soluble vitamins 30 5.90e-01 6.47e-01 0.1940 -0.056500 3.07e-02 0.123000 1.36e-01 5.93e-01 7.71e-01 2.45e-01 1.97e-01
Glutathione synthesis and recycling 10 8.25e-01 8.56e-01 0.1940 0.091600 -3.86e-02 0.157000 5.63e-02 6.16e-01 8.33e-01 3.90e-01 7.58e-01
NoRC negatively regulates rRNA expression 45 4.30e-01 5.11e-01 0.1940 0.056700 3.84e-02 0.161000 8.43e-02 5.11e-01 6.56e-01 6.20e-02 3.28e-01
Mitophagy 25 5.33e-01 6.00e-01 0.1940 -0.072200 -1.42e-01 0.100000 -4.86e-02 5.32e-01 2.20e-01 3.87e-01 6.74e-01
Cell death signalling via NRAGE, NRIF and NADE 68 1.20e-01 1.86e-01 0.1940 -0.156000 -7.50e-02 -0.086000 1.71e-02 2.63e-02 2.86e-01 2.21e-01 8.07e-01
Signaling by PDGFR in disease 20 6.30e-01 6.82e-01 0.1920 0.039800 -1.02e-01 -0.063700 -1.45e-01 7.58e-01 4.32e-01 6.22e-01 2.61e-01
Cell-Cell communication 80 6.26e-03 1.70e-02 0.1920 -0.085000 3.61e-02 -0.167000 2.02e-02 1.89e-01 5.77e-01 9.92e-03 7.55e-01
Visual phototransduction 54 2.69e-01 3.51e-01 0.1920 -0.162000 -8.71e-02 -0.037400 3.88e-02 3.95e-02 2.68e-01 6.35e-01 6.23e-01
Signalling to RAS 17 7.89e-01 8.26e-01 0.1920 0.100000 1.95e-03 -0.120000 -1.11e-01 4.75e-01 9.89e-01 3.91e-01 4.30e-01
CLEC7A (Dectin-1) signaling 89 4.09e-02 7.81e-02 0.1920 0.074800 5.86e-02 0.166000 1.21e-02 2.23e-01 3.40e-01 6.89e-03 8.44e-01
NOTCH3 Intracellular Domain Regulates Transcription 22 7.16e-01 7.57e-01 0.1910 -0.111000 -6.25e-02 -0.139000 -2.97e-02 3.68e-01 6.12e-01 2.61e-01 8.09e-01
SHC1 events in EGFR signaling 11 9.46e-01 9.57e-01 0.1900 -0.143000 -1.23e-01 -0.016200 -1.90e-02 4.10e-01 4.81e-01 9.26e-01 9.13e-01
ABC transporters in lipid homeostasis 14 5.05e-01 5.78e-01 0.1900 0.064100 -1.71e-01 0.021700 -4.73e-02 6.78e-01 2.67e-01 8.88e-01 7.59e-01
Translocation of SLC2A4 (GLUT4) to the plasma membrane 50 2.13e-01 2.91e-01 0.1890 0.018900 -1.22e-01 -0.107000 -9.50e-02 8.17e-01 1.34e-01 1.91e-01 2.45e-01
Estrogen-dependent gene expression 81 6.78e-02 1.17e-01 0.1890 -0.057300 -7.97e-02 -0.002770 -1.61e-01 3.74e-01 2.16e-01 9.66e-01 1.23e-02
Signaling by NTRK1 (TRKA) 105 5.86e-02 1.05e-01 0.1880 -0.074000 -1.65e-01 -0.019300 -4.91e-02 1.91e-01 3.52e-03 7.33e-01 3.86e-01
Synthesis of PIPs at the plasma membrane 51 2.20e-01 3.00e-01 0.1880 0.062000 -2.77e-02 -0.166000 -5.86e-02 4.44e-01 7.33e-01 4.09e-02 4.70e-01
CTLA4 inhibitory signaling 21 5.99e-01 6.56e-01 0.1880 0.112000 -8.79e-03 0.142000 5.16e-02 3.75e-01 9.44e-01 2.60e-01 6.83e-01
The citric acid (TCA) cycle and respiratory electron transport 149 2.55e-04 9.43e-04 0.1870 0.114000 4.71e-02 0.062200 -1.26e-01 1.61e-02 3.23e-01 1.91e-01 8.09e-03
N-Glycan antennae elongation 13 7.59e-01 8.00e-01 0.1870 0.060100 -5.81e-02 0.061300 1.56e-01 7.07e-01 7.17e-01 7.02e-01 3.31e-01
Signaling by SCF-KIT 42 2.79e-01 3.61e-01 0.1870 0.016600 3.31e-02 -0.182000 -2.04e-02 8.52e-01 7.11e-01 4.12e-02 8.19e-01
Metabolism of carbohydrates 227 5.12e-04 1.79e-03 0.1860 -0.124000 -9.40e-02 0.101000 4.43e-03 1.30e-03 1.50e-02 8.78e-03 9.09e-01
Pre-NOTCH Transcription and Translation 32 5.41e-01 6.07e-01 0.1860 -0.119000 -3.33e-02 -0.063800 -1.24e-01 2.46e-01 7.44e-01 5.33e-01 2.26e-01
Growth hormone receptor signaling 19 8.12e-01 8.45e-01 0.1860 -0.068100 -1.52e-01 -0.074100 -3.48e-02 6.08e-01 2.51e-01 5.76e-01 7.93e-01
Regulation of lipid metabolism by PPARalpha 109 5.91e-03 1.62e-02 0.1860 0.011600 -1.14e-02 0.003720 -1.85e-01 8.35e-01 8.37e-01 9.47e-01 8.71e-04
Sema3A PAK dependent Axon repulsion 16 6.26e-01 6.79e-01 0.1860 -0.129000 -1.26e-02 -0.067900 1.14e-01 3.73e-01 9.31e-01 6.38e-01 4.28e-01
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 13 8.95e-01 9.13e-01 0.1840 -0.129000 -1.12e-01 -0.042900 5.39e-02 4.20e-01 4.85e-01 7.89e-01 7.36e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta 55 2.28e-01 3.09e-01 0.1840 -0.028200 4.45e-02 -0.091400 -1.51e-01 7.17e-01 5.69e-01 2.42e-01 5.32e-02
TCF dependent signaling in response to WNT 143 3.94e-04 1.40e-03 0.1840 -0.064900 -8.15e-02 0.118000 -9.41e-02 1.81e-01 9.34e-02 1.49e-02 5.27e-02
Retinoid metabolism and transport 27 5.05e-01 5.78e-01 0.1830 -0.110000 2.74e-02 0.063100 1.30e-01 3.25e-01 8.05e-01 5.71e-01 2.42e-01
Signaling by ERBB2 42 6.46e-01 6.96e-01 0.1830 -0.107000 -1.01e-01 -0.088200 -6.42e-02 2.32e-01 2.56e-01 3.23e-01 4.72e-01
CD209 (DC-SIGN) signaling 19 7.99e-01 8.34e-01 0.1830 -0.033300 2.67e-02 -0.133000 -1.18e-01 8.02e-01 8.40e-01 3.15e-01 3.73e-01
RNA Polymerase III Transcription Initiation From Type 1 Promoter 28 6.87e-01 7.31e-01 0.1830 0.044000 1.26e-02 0.156000 8.37e-02 6.87e-01 9.08e-01 1.53e-01 4.44e-01
MyD88 dependent cascade initiated on endosome 85 1.53e-01 2.26e-01 0.1820 -0.078500 -1.59e-01 -0.008710 -4.29e-02 2.12e-01 1.16e-02 8.90e-01 4.95e-01
Toll Like Receptor 7/8 (TLR7/8) Cascade 85 1.53e-01 2.26e-01 0.1820 -0.078500 -1.59e-01 -0.008710 -4.29e-02 2.12e-01 1.16e-02 8.90e-01 4.95e-01
G alpha (z) signalling events 36 1.85e-01 2.61e-01 0.1820 -0.079400 -7.62e-03 -0.099100 1.30e-01 4.10e-01 9.37e-01 3.04e-01 1.77e-01
Beta-catenin independent WNT signaling 128 1.82e-02 4.10e-02 0.1820 -0.061600 2.90e-02 0.146000 8.50e-02 2.30e-01 5.72e-01 4.51e-03 9.74e-02
Platelet activation, signaling and aggregation 208 5.97e-07 3.06e-06 0.1810 -0.022800 8.87e-02 -0.064700 1.42e-01 5.73e-01 2.79e-02 1.09e-01 4.15e-04
Ephrin signaling 19 4.85e-01 5.58e-01 0.1810 -0.125000 3.46e-02 -0.121000 3.54e-02 3.46e-01 7.94e-01 3.61e-01 7.89e-01
Cilium Assembly 171 3.62e-05 1.52e-04 0.1800 0.026200 -4.91e-02 0.169000 -2.72e-02 5.56e-01 2.69e-01 1.41e-04 5.40e-01
Golgi-to-ER retrograde transport 103 1.43e-02 3.35e-02 0.1800 0.008290 -8.73e-02 0.151000 4.50e-02 8.85e-01 1.26e-01 8.40e-03 4.31e-01
PPARA activates gene expression 107 7.75e-03 2.04e-02 0.1800 0.012800 -2.04e-02 0.012400 -1.78e-01 8.19e-01 7.16e-01 8.24e-01 1.52e-03
Metalloprotease DUBs 18 8.82e-01 9.03e-01 0.1790 0.142000 9.86e-02 0.045300 1.56e-02 2.97e-01 4.69e-01 7.40e-01 9.09e-01
Programmed Cell Death 151 6.36e-03 1.72e-02 0.1790 0.023600 7.22e-02 0.159000 3.06e-02 6.18e-01 1.27e-01 7.60e-04 5.17e-01
Apoptosis 148 5.35e-03 1.49e-02 0.1790 0.023900 6.84e-02 0.162000 2.24e-02 6.17e-01 1.52e-01 6.97e-04 6.39e-01
COPI-dependent Golgi-to-ER retrograde traffic 73 9.73e-02 1.56e-01 0.1780 0.040500 -2.94e-02 0.165000 4.70e-02 5.50e-01 6.65e-01 1.52e-02 4.88e-01
Interleukin-4 and Interleukin-13 signaling 85 1.18e-02 2.87e-02 0.1780 -0.009210 2.89e-02 -0.056700 1.66e-01 8.83e-01 6.46e-01 3.67e-01 8.32e-03
Adrenaline,noradrenaline inhibits insulin secretion 21 5.79e-01 6.39e-01 0.1770 -0.007520 2.91e-02 -0.030500 1.72e-01 9.52e-01 8.18e-01 8.09e-01 1.72e-01
VEGFA-VEGFR2 Pathway 90 1.22e-01 1.88e-01 0.1770 0.047000 6.34e-02 -0.143000 -6.83e-02 4.42e-01 2.99e-01 1.91e-02 2.63e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 16 8.85e-01 9.04e-01 0.1760 -0.025200 1.00e-02 -0.113000 -1.32e-01 8.62e-01 9.45e-01 4.35e-01 3.60e-01
Interleukin-37 signaling 18 5.50e-01 6.16e-01 0.1750 -0.101000 2.45e-02 -0.125000 6.54e-02 4.60e-01 8.57e-01 3.57e-01 6.31e-01
Positive epigenetic regulation of rRNA expression 45 1.49e-01 2.22e-01 0.1750 0.082600 2.61e-02 0.092800 -1.21e-01 3.38e-01 7.62e-01 2.82e-01 1.61e-01
Keratinization 20 6.96e-01 7.39e-01 0.1750 -0.023500 -1.09e-01 -0.134000 5.18e-04 8.56e-01 3.98e-01 2.98e-01 9.97e-01
C-type lectin receptors (CLRs) 109 6.45e-02 1.13e-01 0.1750 0.081500 8.63e-02 0.128000 7.46e-03 1.42e-01 1.20e-01 2.12e-02 8.93e-01
Aggrephagy 17 8.39e-01 8.67e-01 0.1740 -0.101000 -1.10e-01 0.081600 -3.86e-02 4.72e-01 4.33e-01 5.60e-01 7.83e-01
Cargo recognition for clathrin-mediated endocytosis 85 6.38e-02 1.12e-01 0.1740 -0.048200 -1.48e-01 0.077500 -1.10e-02 4.44e-01 1.86e-02 2.18e-01 8.61e-01
Toll Like Receptor 9 (TLR9) Cascade 88 1.68e-01 2.42e-01 0.1730 -0.072300 -1.52e-01 -0.007390 -3.96e-02 2.42e-01 1.36e-02 9.05e-01 5.22e-01
ADORA2B mediated anti-inflammatory cytokines production 54 1.37e-01 2.08e-01 0.1730 0.013100 3.39e-03 -0.022400 1.71e-01 8.68e-01 9.66e-01 7.76e-01 2.95e-02
Sphingolipid de novo biosynthesis 32 3.98e-01 4.82e-01 0.1720 -0.056400 -9.89e-02 -0.073500 1.06e-01 5.81e-01 3.33e-01 4.72e-01 3.01e-01
Transcriptional regulation by RUNX3 88 8.35e-02 1.38e-01 0.1710 0.041200 1.14e-01 0.121000 2.20e-03 5.04e-01 6.60e-02 5.02e-02 9.72e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1 16 6.12e-01 6.67e-01 0.1700 -0.146000 2.98e-02 -0.060100 5.69e-02 3.13e-01 8.36e-01 6.78e-01 6.94e-01
RUNX2 regulates bone development 28 5.58e-01 6.24e-01 0.1690 -0.069900 -9.32e-02 -0.034300 1.18e-01 5.23e-01 3.94e-01 7.54e-01 2.80e-01
FCERI mediated MAPK activation 30 6.58e-01 7.05e-01 0.1690 0.063200 3.12e-02 -0.147000 -4.66e-02 5.50e-01 7.68e-01 1.65e-01 6.59e-01
p75NTR recruits signalling complexes 11 8.69e-01 8.93e-01 0.1690 -0.159000 -1.92e-02 -0.052300 -1.49e-02 3.62e-01 9.12e-01 7.64e-01 9.32e-01
trans-Golgi Network Vesicle Budding 65 3.80e-01 4.65e-01 0.1690 -0.030200 -4.01e-02 0.120000 1.08e-01 6.74e-01 5.77e-01 9.46e-02 1.34e-01
PTEN Regulation 131 2.80e-03 8.52e-03 0.1690 0.017500 -2.89e-03 0.166000 -2.66e-02 7.30e-01 9.55e-01 1.08e-03 5.99e-01
Intrinsic Pathway for Apoptosis 44 4.24e-01 5.05e-01 0.1680 0.013000 8.02e-02 0.144000 2.95e-02 8.82e-01 3.58e-01 9.86e-02 7.35e-01
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 88 2.39e-01 3.19e-01 0.1670 -0.072100 -1.40e-01 -0.045900 -3.06e-02 2.43e-01 2.30e-02 4.58e-01 6.20e-01
Toll Like Receptor 2 (TLR2) Cascade 88 2.39e-01 3.19e-01 0.1670 -0.072100 -1.40e-01 -0.045900 -3.06e-02 2.43e-01 2.30e-02 4.58e-01 6.20e-01
Toll Like Receptor TLR1:TLR2 Cascade 88 2.39e-01 3.19e-01 0.1670 -0.072100 -1.40e-01 -0.045900 -3.06e-02 2.43e-01 2.30e-02 4.58e-01 6.20e-01
Toll Like Receptor TLR6:TLR2 Cascade 88 2.39e-01 3.19e-01 0.1670 -0.072100 -1.40e-01 -0.045900 -3.06e-02 2.43e-01 2.30e-02 4.58e-01 6.20e-01
Fc epsilon receptor (FCERI) signaling 121 5.63e-02 1.02e-01 0.1670 0.110000 9.11e-02 0.079100 -3.43e-02 3.71e-02 8.40e-02 1.34e-01 5.15e-01
Adaptive Immune System 577 5.91e-06 2.72e-05 0.1660 0.129000 9.00e-02 0.038900 3.53e-02 1.59e-07 2.55e-04 1.14e-01 1.51e-01
SARS-CoV Infections 75 1.17e-01 1.82e-01 0.1650 0.037400 -1.32e-02 0.159000 1.94e-02 5.76e-01 8.44e-01 1.74e-02 7.71e-01
RNA Polymerase I Promoter Clearance 48 3.40e-01 4.25e-01 0.1630 -0.006470 -2.26e-02 0.160000 1.40e-02 9.38e-01 7.87e-01 5.48e-02 8.67e-01
Gamma carboxylation, hypusine formation and arylsulfatase activation 30 6.78e-01 7.23e-01 0.1620 -0.101000 -1.10e-02 0.104000 7.17e-02 3.38e-01 9.17e-01 3.26e-01 4.97e-01
Opioid Signalling 74 7.30e-02 1.23e-01 0.1620 -0.011200 -1.29e-01 -0.093700 2.22e-02 8.68e-01 5.47e-02 1.64e-01 7.41e-01
Golgi Associated Vesicle Biogenesis 51 4.75e-01 5.51e-01 0.1590 -0.054900 -1.12e-01 0.070700 6.96e-02 4.98e-01 1.69e-01 3.83e-01 3.90e-01
Signaling by VEGF 98 1.21e-01 1.86e-01 0.1590 0.014800 6.06e-02 -0.135000 -5.60e-02 8.00e-01 3.01e-01 2.12e-02 3.39e-01
Phospholipid metabolism 173 6.42e-02 1.12e-01 0.1590 -0.070900 -3.84e-02 -0.097000 -9.65e-02 1.09e-01 3.85e-01 2.81e-02 2.90e-02
E3 ubiquitin ligases ubiquitinate target proteins 39 2.63e-01 3.45e-01 0.1590 0.080900 -7.33e-02 0.002320 -1.15e-01 3.82e-01 4.28e-01 9.80e-01 2.14e-01
Transcriptional regulation of white adipocyte differentiation 75 5.83e-02 1.05e-01 0.1580 0.028100 -1.39e-02 0.049400 -1.47e-01 6.74e-01 8.36e-01 4.60e-01 2.78e-02
Immune System 1518 7.59e-15 1.36e-13 0.1580 0.060600 9.05e-02 0.035100 1.09e-01 1.26e-04 9.91e-09 2.61e-02 4.60e-12
Carboxyterminal post-translational modifications of tubulin 26 6.82e-01 7.27e-01 0.1570 -0.085900 2.13e-05 0.128000 2.92e-02 4.48e-01 1.00e+00 2.57e-01 7.96e-01
Interleukin-1 family signaling 114 1.92e-01 2.67e-01 0.1570 0.002900 2.91e-02 0.130000 8.31e-02 9.57e-01 5.92e-01 1.65e-02 1.26e-01
Signaling by Insulin receptor 56 4.44e-01 5.21e-01 0.1560 -0.045500 -1.30e-01 -0.012700 -7.29e-02 5.57e-01 9.32e-02 8.70e-01 3.46e-01
Caspase-mediated cleavage of cytoskeletal proteins 12 8.87e-01 9.05e-01 0.1550 -0.146000 -2.48e-02 0.007460 -4.65e-02 3.81e-01 8.82e-01 9.64e-01 7.80e-01
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 21 6.69e-01 7.15e-01 0.1550 0.038400 -1.17e-01 -0.079400 -5.08e-02 7.61e-01 3.52e-01 5.29e-01 6.87e-01
Signaling by FGFR 63 1.77e-01 2.51e-01 0.1550 -0.008010 -1.29e-01 0.018900 -8.29e-02 9.13e-01 7.59e-02 7.95e-01 2.56e-01
Basigin interactions 20 5.81e-01 6.41e-01 0.1550 -0.022400 1.50e-01 0.014000 -2.98e-02 8.62e-01 2.47e-01 9.14e-01 8.18e-01
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon 14 8.59e-01 8.85e-01 0.1550 -0.152000 -2.39e-02 -0.011100 -7.91e-03 3.24e-01 8.77e-01 9.43e-01 9.59e-01
Signaling by NOTCH3 43 2.03e-01 2.79e-01 0.1540 -0.140000 3.29e-02 -0.047900 -2.75e-02 1.11e-01 7.09e-01 5.87e-01 7.55e-01
GPCR downstream signalling 381 1.23e-07 6.89e-07 0.1540 -0.064100 -1.34e-02 -0.137000 2.68e-02 3.29e-02 6.57e-01 4.93e-06 3.73e-01
RNA Polymerase III Transcription Initiation From Type 2 Promoter 27 7.89e-01 8.26e-01 0.1530 0.015100 -1.95e-02 0.136000 6.62e-02 8.92e-01 8.61e-01 2.22e-01 5.52e-01
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 10 8.98e-01 9.14e-01 0.1530 -0.087600 -9.48e-05 0.015500 -1.24e-01 6.32e-01 1.00e+00 9.32e-01 4.97e-01
alpha-linolenic acid (ALA) metabolism 10 8.98e-01 9.14e-01 0.1530 -0.087600 -9.48e-05 0.015500 -1.24e-01 6.32e-01 1.00e+00 9.32e-01 4.97e-01
PI Metabolism 79 3.63e-01 4.49e-01 0.1510 0.043200 2.83e-02 -0.124000 -6.89e-02 5.08e-01 6.64e-01 5.71e-02 2.91e-01
TICAM1-dependent activation of IRF3/IRF7 10 9.34e-01 9.46e-01 0.1500 0.021900 6.44e-02 -0.016200 -1.32e-01 9.04e-01 7.24e-01 9.29e-01 4.69e-01
Factors involved in megakaryocyte development and platelet production 101 4.26e-02 8.08e-02 0.1490 0.011700 3.96e-02 0.016600 -1.43e-01 8.39e-01 4.93e-01 7.74e-01 1.34e-02
Gene expression (Transcription) 1084 8.65e-20 2.47e-18 0.1490 0.044100 1.16e-03 0.021100 -1.41e-01 1.62e-02 9.50e-01 2.51e-01 1.44e-14
Peroxisomal protein import 54 6.26e-01 6.79e-01 0.1490 0.125000 7.85e-02 -0.012600 1.86e-03 1.11e-01 3.19e-01 8.72e-01 9.81e-01
Signaling by GPCR 411 3.17e-07 1.67e-06 0.1480 -0.080600 -3.50e-02 -0.112000 4.08e-02 5.36e-03 2.27e-01 1.08e-04 1.59e-01
Phase I - Functionalization of compounds 60 3.75e-01 4.61e-01 0.1480 0.133000 3.65e-02 0.050600 1.62e-02 7.44e-02 6.25e-01 4.99e-01 8.28e-01
Death Receptor Signalling 122 3.56e-02 6.97e-02 0.1480 -0.043500 3.18e-02 -0.135000 -2.54e-02 4.08e-01 5.46e-01 1.02e-02 6.29e-01
B-WICH complex positively regulates rRNA expression 32 5.27e-01 5.95e-01 0.1470 0.099300 1.58e-02 0.052900 -9.40e-02 3.31e-01 8.77e-01 6.05e-01 3.57e-01
RNA Polymerase II Transcription 968 1.32e-16 2.51e-15 0.1470 0.050100 6.56e-03 0.015800 -1.37e-01 9.52e-03 7.34e-01 4.13e-01 1.34e-12
Neddylation 205 5.55e-04 1.93e-03 0.1460 0.112000 -7.26e-03 0.092100 4.22e-03 5.71e-03 8.58e-01 2.34e-02 9.17e-01
HATs acetylate histones 74 1.11e-01 1.74e-01 0.1450 -0.004540 -1.75e-02 0.047900 -1.36e-01 9.46e-01 7.94e-01 4.76e-01 4.35e-02
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 30 8.37e-01 8.67e-01 0.1450 -0.092800 -9.34e-02 0.060900 5.49e-03 3.79e-01 3.76e-01 5.64e-01 9.58e-01
Organelle biogenesis and maintenance 240 1.46e-05 6.46e-05 0.1450 0.021900 -7.33e-02 0.079100 -9.47e-02 5.61e-01 5.15e-02 3.56e-02 1.18e-02
Signal transduction by L1 21 7.32e-01 7.73e-01 0.1450 0.051000 1.36e-02 -0.035600 1.30e-01 6.86e-01 9.14e-01 7.78e-01 3.02e-01
RNA Polymerase I Transcription 49 4.48e-01 5.25e-01 0.1450 -0.014000 -8.92e-03 0.143000 8.16e-03 8.66e-01 9.14e-01 8.27e-02 9.21e-01
Activation of HOX genes during differentiation 54 2.29e-01 3.09e-01 0.1440 0.000317 -6.03e-02 0.121000 -5.00e-02 9.97e-01 4.44e-01 1.23e-01 5.25e-01
Activation of anterior HOX genes in hindbrain development during early embryogenesis 54 2.29e-01 3.09e-01 0.1440 0.000317 -6.03e-02 0.121000 -5.00e-02 9.97e-01 4.44e-01 1.23e-01 5.25e-01
Protein folding 84 4.13e-01 4.96e-01 0.1440 0.019900 -6.31e-03 0.106000 9.58e-02 7.53e-01 9.21e-01 9.46e-02 1.30e-01
G alpha (s) signalling events 76 1.08e-01 1.70e-01 0.1440 -0.030700 -1.18e-02 -0.045800 1.33e-01 6.44e-01 8.59e-01 4.91e-01 4.59e-02
p75 NTR receptor-mediated signalling 84 1.46e-01 2.18e-01 0.1440 -0.115000 -2.89e-02 -0.073600 3.57e-02 6.94e-02 6.48e-01 2.44e-01 5.73e-01
Fatty acid metabolism 129 5.42e-02 9.84e-02 0.1440 0.036700 1.30e-01 -0.049400 3.44e-03 4.72e-01 1.12e-02 3.33e-01 9.46e-01
Regulation of PTEN gene transcription 58 4.74e-01 5.50e-01 0.1430 -0.053900 -8.38e-02 0.013500 -1.02e-01 4.78e-01 2.70e-01 8.59e-01 1.79e-01
mTORC1-mediated signalling 23 7.98e-01 8.34e-01 0.1430 0.026500 -3.37e-02 0.132000 3.62e-02 8.26e-01 7.79e-01 2.74e-01 7.64e-01
Diseases associated with glycosaminoglycan metabolism 33 5.50e-01 6.16e-01 0.1430 -0.125000 -1.11e-02 -0.055500 4.12e-02 2.15e-01 9.12e-01 5.81e-01 6.82e-01
RHO GTPases Activate ROCKs 19 6.55e-01 7.05e-01 0.1430 -0.064600 6.51e-02 -0.077900 7.72e-02 6.26e-01 6.23e-01 5.57e-01 5.60e-01
Class I MHC mediated antigen processing & presentation 318 1.76e-04 6.74e-04 0.1430 0.119000 1.91e-02 0.069000 3.11e-02 2.72e-04 5.61e-01 3.53e-02 3.42e-01
RAS processing 19 7.19e-01 7.60e-01 0.1420 0.089000 -1.67e-02 0.096800 -5.15e-02 5.02e-01 9.00e-01 4.65e-01 6.98e-01
Generic Transcription Pathway 854 1.98e-13 2.99e-12 0.1410 0.050600 7.17e-03 0.012300 -1.31e-01 1.34e-02 7.26e-01 5.48e-01 1.34e-10
TP53 Regulates Metabolic Genes 82 3.33e-01 4.17e-01 0.1390 -0.071200 -7.41e-02 0.021200 -9.10e-02 2.66e-01 2.47e-01 7.41e-01 1.55e-01
PINK1-PRKN Mediated Mitophagy 18 8.78e-01 8.99e-01 0.1390 -0.061800 -7.74e-02 0.090900 -3.47e-02 6.50e-01 5.70e-01 5.05e-01 7.99e-01
Formation of Incision Complex in GG-NER 40 4.42e-01 5.19e-01 0.1380 0.109000 -9.39e-03 0.083900 -7.94e-03 2.32e-01 9.18e-01 3.59e-01 9.31e-01
SUMOylation of immune response proteins 11 9.80e-01 9.84e-01 0.1380 -0.020300 -1.68e-02 -0.085500 -1.05e-01 9.07e-01 9.23e-01 6.24e-01 5.47e-01
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 16 8.66e-01 8.90e-01 0.1380 0.066800 -3.39e-02 0.053800 1.02e-01 6.44e-01 8.14e-01 7.10e-01 4.79e-01
Amyloid fiber formation 35 8.71e-01 8.94e-01 0.1370 0.029800 5.69e-02 0.089700 8.15e-02 7.60e-01 5.60e-01 3.58e-01 4.04e-01
RNA Polymerase I Transcription Initiation 45 6.34e-01 6.86e-01 0.1360 -0.024400 -3.22e-02 0.126000 2.79e-02 7.77e-01 7.08e-01 1.43e-01 7.46e-01
Vitamin B5 (pantothenate) metabolism 15 9.13e-01 9.28e-01 0.1360 0.097500 5.84e-03 -0.087400 -3.45e-02 5.13e-01 9.69e-01 5.58e-01 8.17e-01
Acyl chain remodelling of PG 11 8.85e-01 9.04e-01 0.1340 -0.106000 3.80e-02 -0.071900 -9.26e-03 5.42e-01 8.27e-01 6.80e-01 9.58e-01
O-linked glycosylation 66 3.61e-01 4.48e-01 0.1330 -0.095500 -4.36e-02 -0.052100 6.38e-02 1.80e-01 5.40e-01 4.65e-01 3.70e-01
Signaling by Receptor Tyrosine Kinases 412 9.58e-04 3.20e-03 0.1320 -0.080600 -7.22e-02 -0.075300 1.24e-02 5.29e-03 1.25e-02 9.21e-03 6.68e-01
Metabolism of proteins 1541 9.03e-18 2.11e-16 0.1320 0.051400 -1.91e-02 0.114000 3.57e-02 1.05e-03 2.23e-01 2.83e-13 2.30e-02
NR1H2 and NR1H3-mediated signaling 37 6.85e-01 7.29e-01 0.1320 -0.125000 -2.81e-02 -0.028600 -1.31e-03 1.87e-01 7.68e-01 7.64e-01 9.89e-01
G alpha (i) signalling events 196 2.76e-03 8.40e-03 0.1300 -0.038900 -2.26e-02 -0.107000 5.98e-02 3.50e-01 5.86e-01 1.02e-02 1.50e-01
Amino acids regulate mTORC1 48 7.36e-01 7.77e-01 0.1290 -0.067100 -7.73e-02 0.029600 7.35e-02 4.22e-01 3.55e-01 7.23e-01 3.79e-01
Signaling by Rho GTPases 337 8.17e-04 2.78e-03 0.1290 0.033500 6.77e-02 -0.015500 -1.04e-01 2.93e-01 3.37e-02 6.26e-01 1.16e-03
Toll Like Receptor 4 (TLR4) Cascade 116 3.01e-01 3.83e-01 0.1290 -0.056300 -7.46e-02 -0.088200 -8.44e-03 2.96e-01 1.66e-01 1.01e-01 8.75e-01
Transcriptional regulation by RUNX1 154 4.46e-02 8.39e-02 0.1280 0.052700 5.07e-02 0.099600 -3.47e-02 2.60e-01 2.79e-01 3.33e-02 4.59e-01
O-linked glycosylation of mucins 31 8.62e-01 8.87e-01 0.1250 -0.043000 -6.11e-02 0.044700 9.01e-02 6.79e-01 5.56e-01 6.67e-01 3.86e-01
Association of TriC/CCT with target proteins during biosynthesis 36 5.99e-01 6.56e-01 0.1250 0.072900 -2.13e-02 0.099500 -3.18e-03 4.50e-01 8.25e-01 3.02e-01 9.74e-01
Post-translational modification: synthesis of GPI-anchored proteins 54 5.62e-01 6.27e-01 0.1250 -0.040500 -3.86e-02 0.004400 1.12e-01 6.07e-01 6.24e-01 9.55e-01 1.57e-01
SLC-mediated transmembrane transport 150 1.56e-01 2.30e-01 0.1240 0.017700 2.37e-02 -0.115000 -3.48e-02 7.09e-01 6.17e-01 1.51e-02 4.63e-01
tRNA processing 106 6.04e-02 1.07e-01 0.1240 -0.002160 3.49e-03 0.088500 -8.66e-02 9.69e-01 9.51e-01 1.16e-01 1.24e-01
Activation of BH3-only proteins 27 9.06e-01 9.21e-01 0.1240 0.073900 7.77e-02 -0.009540 -6.10e-02 5.06e-01 4.85e-01 9.32e-01 5.84e-01
Signaling by Interleukins 347 1.47e-02 3.44e-02 0.1230 0.059400 6.15e-02 0.010300 8.74e-02 5.87e-02 5.04e-02 7.42e-01 5.43e-03
Acyl chain remodelling of PS 14 8.72e-01 8.94e-01 0.1220 0.018300 -3.14e-02 -0.077000 8.78e-02 9.06e-01 8.39e-01 6.18e-01 5.69e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 32 6.30e-01 6.82e-01 0.1210 0.071600 -1.31e-02 -0.032200 9.10e-02 4.84e-01 8.98e-01 7.53e-01 3.73e-01
Metabolism of water-soluble vitamins and cofactors 101 5.28e-01 5.95e-01 0.1210 -0.081100 -7.96e-02 0.040000 -2.49e-03 1.60e-01 1.67e-01 4.88e-01 9.66e-01
Hemostasis 444 5.08e-07 2.64e-06 0.1200 -0.017600 7.06e-02 -0.065000 7.07e-02 5.28e-01 1.14e-02 1.98e-02 1.13e-02
Vesicle-mediated transport 557 3.60e-04 1.30e-03 0.1190 -0.047800 -9.89e-02 0.036600 2.60e-02 5.61e-02 7.67e-05 1.44e-01 2.99e-01
Antigen processing: Ubiquitination & Proteasome degradation 268 6.55e-04 2.26e-03 0.1180 0.098500 -9.58e-03 0.054100 -3.40e-02 5.74e-03 7.88e-01 1.29e-01 3.41e-01
Membrane Trafficking 528 2.38e-04 8.85e-04 0.1170 -0.039000 -1.05e-01 0.032400 1.37e-02 1.29e-01 4.49e-05 2.07e-01 5.93e-01
Rab regulation of trafficking 113 3.08e-01 3.90e-01 0.1170 -0.020100 -9.18e-02 -0.008320 -6.85e-02 7.13e-01 9.23e-02 8.79e-01 2.09e-01
Signaling by WNT 221 6.54e-02 1.14e-01 0.1150 -0.066700 -6.51e-02 0.056900 -3.63e-02 8.86e-02 9.65e-02 1.46e-01 3.54e-01
Axon guidance 426 5.62e-03 1.56e-02 0.1130 0.016200 7.33e-02 0.024400 8.12e-02 5.68e-01 1.00e-02 3.92e-01 4.32e-03
Cytochrome P450 - arranged by substrate type 30 8.07e-01 8.39e-01 0.1130 0.038300 2.86e-02 -0.029900 9.78e-02 7.16e-01 7.87e-01 7.77e-01 3.54e-01
Recycling pathway of L1 27 8.46e-01 8.73e-01 0.1130 -0.035000 -3.45e-02 0.027900 -9.74e-02 7.53e-01 7.56e-01 8.02e-01 3.81e-01
Adenylate cyclase inhibitory pathway 12 9.25e-01 9.39e-01 0.1120 0.014300 -1.05e-01 -0.008840 3.52e-02 9.32e-01 5.28e-01 9.58e-01 8.33e-01
ESR-mediated signaling 140 4.08e-01 4.92e-01 0.1120 -0.021100 -3.83e-02 -0.040600 -9.49e-02 6.67e-01 4.35e-01 4.08e-01 5.32e-02
Extra-nuclear estrogen signaling 63 6.58e-01 7.05e-01 0.1110 0.032000 3.12e-02 -0.100000 -1.69e-02 6.60e-01 6.69e-01 1.69e-01 8.16e-01
Epigenetic regulation of gene expression 84 3.34e-01 4.18e-01 0.1090 0.060100 1.20e-02 0.034900 -8.34e-02 3.42e-01 8.50e-01 5.81e-01 1.87e-01
Metabolism of vitamins and cofactors 148 4.37e-01 5.15e-01 0.1090 -0.069800 -6.06e-02 0.047800 3.15e-02 1.43e-01 2.04e-01 3.17e-01 5.09e-01
Signaling by NOTCH 159 4.60e-02 8.62e-02 0.1080 -0.042700 3.82e-02 0.091300 -1.21e-02 3.54e-01 4.07e-01 4.76e-02 7.93e-01
ERK/MAPK targets 22 7.95e-01 8.31e-01 0.1070 0.042900 -8.17e-02 0.035500 -4.06e-02 7.28e-01 5.07e-01 7.73e-01 7.42e-01
Constitutive Signaling by Aberrant PI3K in Cancer 53 5.09e-01 5.82e-01 0.1070 -0.019200 7.65e-03 -0.085000 6.13e-02 8.09e-01 9.23e-01 2.85e-01 4.41e-01
Chaperonin-mediated protein folding 78 6.30e-01 6.82e-01 0.1050 0.037400 -1.46e-02 0.071700 6.59e-02 5.68e-01 8.24e-01 2.74e-01 3.15e-01
PI3K/AKT Signaling in Cancer 79 7.81e-01 8.20e-01 0.1050 -0.016100 -4.84e-02 -0.069200 -6.04e-02 8.05e-01 4.57e-01 2.88e-01 3.54e-01
Cytokine Signaling in Immune system 647 3.82e-03 1.11e-02 0.1050 0.048100 6.46e-02 0.008360 6.67e-02 3.92e-02 5.58e-03 7.20e-01 4.22e-03
Intra-Golgi and retrograde Golgi-to-ER traffic 165 1.81e-01 2.56e-01 0.1040 -0.011900 -7.44e-02 0.058100 4.18e-02 7.93e-01 1.00e-01 1.99e-01 3.55e-01
Downregulation of ERBB2:ERBB3 signaling 11 9.95e-01 9.96e-01 0.1030 -0.060200 -7.63e-02 -0.024100 -2.24e-02 7.30e-01 6.62e-01 8.90e-01 8.98e-01
Transport of small molecules 477 2.29e-02 4.93e-02 0.1020 -0.042300 -5.41e-02 0.053400 5.41e-02 1.17e-01 4.47e-02 4.76e-02 4.48e-02
Diseases of signal transduction by growth factor receptors and second messengers 330 1.45e-01 2.18e-01 0.1020 -0.047200 -7.26e-02 -0.017400 -5.19e-02 1.43e-01 2.43e-02 5.90e-01 1.07e-01
Signaling by ERBB4 43 8.06e-01 8.39e-01 0.1020 -0.034300 -7.82e-02 -0.047600 2.96e-02 6.98e-01 3.75e-01 5.89e-01 7.37e-01
Intracellular signaling by second messengers 269 3.52e-02 6.93e-02 0.1010 -0.029100 -5.88e-02 0.034500 -6.88e-02 4.14e-01 9.83e-02 3.33e-01 5.32e-02
PIP3 activates AKT signaling 232 1.85e-02 4.16e-02 0.0995 -0.000397 -2.54e-02 0.083200 -4.83e-02 9.92e-01 5.07e-01 2.97e-02 2.07e-01
Metabolic disorders of biological oxidation enzymes 19 9.69e-01 9.77e-01 0.0995 -0.027100 -9.01e-02 -0.013500 -2.91e-02 8.38e-01 4.97e-01 9.19e-01 8.26e-01
Signal Transduction 1705 9.55e-06 4.32e-05 0.0960 -0.053500 -3.53e-02 -0.062500 -3.48e-02 3.73e-04 1.90e-02 3.19e-05 2.08e-02
L1CAM interactions 84 6.10e-01 6.65e-01 0.0957 -0.065400 -2.13e-02 -0.066400 5.58e-03 3.01e-01 7.36e-01 2.94e-01 9.30e-01
Metabolism of cofactors 18 9.30e-01 9.43e-01 0.0940 0.007290 -8.38e-02 0.010400 4.06e-02 9.57e-01 5.38e-01 9.39e-01 7.65e-01
Metabolism of lipids 566 3.55e-02 6.97e-02 0.0937 -0.028900 -1.09e-02 -0.067700 -5.69e-02 2.44e-01 6.59e-01 6.39e-03 2.19e-02
Toll-like Receptor Cascades 132 3.23e-01 4.06e-01 0.0925 -0.031600 -5.67e-02 -0.043000 5.00e-02 5.32e-01 2.61e-01 3.94e-01 3.23e-01
Cytosolic sensors of pathogen-associated DNA 57 5.65e-01 6.28e-01 0.0924 -0.034000 7.72e-02 0.033500 1.70e-02 6.57e-01 3.14e-01 6.62e-01 8.24e-01
Metabolism 1569 5.59e-08 3.32e-07 0.0902 0.024400 1.89e-02 0.084700 3.50e-04 1.17e-01 2.25e-01 5.18e-08 9.82e-01
Signaling by Nuclear Receptors 195 4.67e-01 5.43e-01 0.0884 0.000120 -9.06e-03 -0.039600 -7.85e-02 9.98e-01 8.28e-01 3.42e-01 5.97e-02
tRNA modification in the nucleus and cytosol 38 9.34e-01 9.46e-01 0.0877 0.015700 4.03e-02 0.012200 7.54e-02 8.67e-01 6.67e-01 8.97e-01 4.22e-01
Clathrin-mediated endocytosis 122 4.82e-01 5.56e-01 0.0869 -0.014100 -7.00e-02 0.048600 1.02e-02 7.89e-01 1.83e-01 3.55e-01 8.46e-01
VEGFR2 mediated vascular permeability 27 9.27e-01 9.41e-01 0.0862 -0.001510 -7.88e-02 0.004130 -3.48e-02 9.89e-01 4.79e-01 9.70e-01 7.55e-01
Nervous system development 444 3.22e-02 6.49e-02 0.0846 0.003590 5.68e-02 0.008110 6.21e-02 8.98e-01 4.16e-02 7.71e-01 2.61e-02
Disease 1107 2.10e-03 6.56e-03 0.0802 0.007730 -7.40e-04 0.073000 3.23e-02 6.71e-01 9.68e-01 5.88e-05 7.53e-02
RNA Polymerase III Abortive And Retractive Initiation 41 9.75e-01 9.81e-01 0.0783 0.021300 3.49e-02 0.054200 3.91e-02 8.14e-01 6.99e-01 5.48e-01 6.65e-01
RNA Polymerase III Transcription 41 9.75e-01 9.81e-01 0.0783 0.021300 3.49e-02 0.054200 3.91e-02 8.14e-01 6.99e-01 5.48e-01 6.65e-01
Post-translational protein modification 1100 5.24e-08 3.13e-07 0.0768 0.038200 -4.36e-02 0.041600 -2.84e-02 3.61e-02 1.67e-02 2.23e-02 1.19e-01
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 16 9.63e-01 9.73e-01 0.0768 0.061500 -2.10e-02 -0.007720 4.02e-02 6.70e-01 8.85e-01 9.57e-01 7.81e-01
RAB GEFs exchange GTP for GDP on RABs 83 7.05e-01 7.48e-01 0.0751 0.016400 -5.97e-02 -0.021000 -3.69e-02 7.97e-01 3.48e-01 7.41e-01 5.62e-01
RNA Polymerase III Transcription Initiation From Type 3 Promoter 28 9.82e-01 9.86e-01 0.0741 -0.009120 2.60e-02 0.032300 6.08e-02 9.33e-01 8.12e-01 7.68e-01 5.78e-01
Signaling by Non-Receptor Tyrosine Kinases 48 9.69e-01 9.77e-01 0.0623 -0.045400 -3.00e-02 -0.013900 2.69e-02 5.86e-01 7.19e-01 8.68e-01 7.47e-01
Signaling by PTK6 48 9.69e-01 9.77e-01 0.0623 -0.045400 -3.00e-02 -0.013900 2.69e-02 5.86e-01 7.19e-01 8.68e-01 7.47e-01
RNA Polymerase III Transcription Initiation 36 9.87e-01 9.90e-01 0.0620 -0.011400 3.12e-03 0.053500 2.89e-02 9.06e-01 9.74e-01 5.79e-01 7.64e-01
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 80 9.56e-01 9.67e-01 0.0561 -0.027700 -4.38e-02 0.002630 2.12e-02 6.68e-01 4.99e-01 9.68e-01 7.43e-01
MAPK family signaling cascades 261 8.77e-01 8.98e-01 0.0444 -0.035500 -1.64e-02 -0.013900 -1.60e-02 3.26e-01 6.51e-01 7.00e-01 6.58e-01
Negative regulation of the PI3K/AKT network 87 9.92e-01 9.94e-01 0.0326 -0.009560 -2.97e-02 -0.007010 -6.62e-03 8.78e-01 6.33e-01 9.10e-01 9.15e-01
FLT3 Signaling 237 9.78e-01 9.84e-01 0.0309 -0.024800 -1.77e-02 -0.000691 -4.97e-03 5.12e-01 6.41e-01 9.85e-01 8.96e-01
Developmental Biology 665 8.15e-01 8.46e-01 0.0293 -0.003530 1.45e-02 0.012900 2.16e-02 8.78e-01 5.27e-01 5.74e-01 3.48e-01
RAF/MAP kinase cascade 223 9.93e-01 9.95e-01 0.0166 -0.014400 -8.62e-04 0.001380 8.14e-03 7.13e-01 9.82e-01 9.72e-01 8.35e-01
MAPK1/MAPK3 signaling 228 9.96e-01 9.96e-01 0.0131 -0.009940 2.14e-03 0.000839 8.28e-03 7.97e-01 9.56e-01 9.83e-01 8.30e-01


Detailed Gene set reports


Classical antibody-mediated complement activation

Classical antibody-mediated complement activation
metric value
setSize 10
pMANOVA 6.32e-09
p.adjustMANOVA 4.74e-08
s.dist 1.5
s.heart_ctrl_vs_acetate 0.256
s.heart_ctrl_vs_hifibre 0.684
s.spleen_ctrl_vs_acetate 0.896
s.spleen_ctrl_vs_hifibre 0.948
p.heart_ctrl_vs_acetate 0.161
p.heart_ctrl_vs_hifibre 0.000178
p.spleen_ctrl_vs_acetate 9.16e-07
p.spleen_ctrl_vs_hifibre 2.05e-07




Top 20 genes
Gene spleen_ctrl_vs_hifibre spleen_ctrl_vs_acetate
C1QA 5529.0 6718.0
IGHG1 5439.5 6828.5
IGHG2 5439.5 6828.5
IGHG3 5439.5 6828.5
IGHG4 5439.5 6828.5
C1QB 5474.0 6768.0
C1QC 5471.0 6725.0
IGKC 5401.0 6413.0
C1R 5561.0 4906.0
C1S 5522.0 2996.0

Click HERE to show all gene set members

All member genes
heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate spleen_ctrl_vs_hifibre
C1QA 5552.0 6352.0 6718.0 5529.0
C1QB 2397.0 5852.0 6768.0 5474.0
C1QC 1827.0 5700.0 6725.0 5471.0
C1R -599.0 5446.0 4906.0 5561.0
C1S -3242.0 -911.0 2996.0 5522.0
IGHG1 1522.5 4829.5 6828.5 5439.5
IGHG2 1522.5 4829.5 6828.5 5439.5
IGHG3 1522.5 4829.5 6828.5 5439.5
IGHG4 1522.5 4829.5 6828.5 5439.5
IGKC 5754.0 3132.0 6413.0 5401.0



Unwinding of DNA

Unwinding of DNA
metric value
setSize 12
pMANOVA 1.21e-13
p.adjustMANOVA 1.89e-12
s.dist 1.34
s.heart_ctrl_vs_acetate 0.705
s.heart_ctrl_vs_hifibre 0.705
s.spleen_ctrl_vs_acetate 0.864
s.spleen_ctrl_vs_hifibre -0.231
p.heart_ctrl_vs_acetate 2.32e-05
p.heart_ctrl_vs_hifibre 2.32e-05
p.spleen_ctrl_vs_acetate 2.19e-07
p.spleen_ctrl_vs_hifibre 0.166




Top 20 genes
Gene spleen_ctrl_vs_acetate heart_ctrl_vs_acetate
MCM6 5952 6208
CDC45 6388 5622
MCM5 6405 5469
MCM4 5931 5542
GINS4 5503 5839
MCM7 6212 4960
GINS1 5387 5291
MCM2 6383 4410
MCM3 6061 3878
GINS2 6307 3700
MCM8 6611 2589
GINS3 4591 1957

Click HERE to show all gene set members

All member genes
heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate spleen_ctrl_vs_hifibre
CDC45 5622 2870 6388 -751
GINS1 5291 5451 5387 -3714
GINS2 3700 4767 6307 -3352
GINS3 1957 415 4591 -2614
GINS4 5839 3985 5503 -1900
MCM2 4410 5869 6383 -3749
MCM3 3878 5525 6061 -2721
MCM4 5542 6361 5931 -3055
MCM5 5469 6300 6405 -2703
MCM6 6208 6082 5952 -1760
MCM7 4960 5693 6212 -2230
MCM8 2589 2131 6611 4651



Creation of C4 and C2 activators

Creation of C4 and C2 activators
metric value
setSize 11
pMANOVA 7.68e-08
p.adjustMANOVA 4.5e-07
s.dist 1.32
s.heart_ctrl_vs_acetate 0.265
s.heart_ctrl_vs_hifibre 0.71
s.spleen_ctrl_vs_acetate 0.742
s.spleen_ctrl_vs_hifibre 0.794
p.heart_ctrl_vs_acetate 0.128
p.heart_ctrl_vs_hifibre 4.55e-05
p.spleen_ctrl_vs_acetate 2.02e-05
p.spleen_ctrl_vs_hifibre 5.13e-06




Top 20 genes
Gene spleen_ctrl_vs_hifibre spleen_ctrl_vs_acetate
C1QA 5529.0 6718.0
IGHG1 5439.5 6828.5
IGHG2 5439.5 6828.5
IGHG3 5439.5 6828.5
IGHG4 5439.5 6828.5
C1QB 5474.0 6768.0
C1QC 5471.0 6725.0
IGKC 5401.0 6413.0
C1R 5561.0 4906.0
C1S 5522.0 2996.0

Click HERE to show all gene set members

All member genes
heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate spleen_ctrl_vs_hifibre
C1QA 5552.0 6352.0 6718.0 5529.0
C1QB 2397.0 5852.0 6768.0 5474.0
C1QC 1827.0 5700.0 6725.0 5471.0
C1R -599.0 5446.0 4906.0 5561.0
C1S -3242.0 -911.0 2996.0 5522.0
COLEC11 2402.0 6262.0 -4551.0 -5290.0
IGHG1 1522.5 4829.5 6828.5 5439.5
IGHG2 1522.5 4829.5 6828.5 5439.5
IGHG3 1522.5 4829.5 6828.5 5439.5
IGHG4 1522.5 4829.5 6828.5 5439.5
IGKC 5754.0 3132.0 6413.0 5401.0



Initial triggering of complement

Initial triggering of complement
metric value
setSize 18
pMANOVA 3.07e-11
p.adjustMANOVA 3.35e-10
s.dist 1.27
s.heart_ctrl_vs_acetate 0.349
s.heart_ctrl_vs_hifibre 0.692
s.spleen_ctrl_vs_acetate 0.673
s.spleen_ctrl_vs_hifibre 0.747
p.heart_ctrl_vs_acetate 0.0103
p.heart_ctrl_vs_hifibre 3.71e-07
p.spleen_ctrl_vs_acetate 7.58e-07
p.spleen_ctrl_vs_hifibre 4.01e-08